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Despite 35 years of clinical trials, there has been little improvement in one-year 
survival rates with any chemotherapeutic regimen for the treatment of metastatic 
melanoma due to resistance to all known agents. Regardless of advances in detection 
and prevention, diagnosis of metastatic disease remains a death sentence. Resistance 
mechanisms, including aberrant kinase signaling and drug transport pumps, indicate a 
need for identification of other therapeutic targets that impinge upon multiple signaling 
pathways. The Abl family of non-receptor tyrosine kinases (c-Abl, Arg) has been indicted 
as a causative force in leukemia for more than three decades; however, their role in solid 
tumors has only recently been described. We first demonstrated that activated Abl family 
kinases promote breast cancer development and progression, and recently identified 
them to be novel therapeutic targets in metastatic melanoma cells by demonstrating that 
they promote proliferation, survival, invasion, and metastasis. We now present evidence 
that inhibitors of Abl family kinases abrogate resistance to a number of commonly used 
chemotherapeutics (i.e., 5-fluorouracil, cisplatin, paclitaxel, camptothecin) in a panel of 
breast cancer cells.  We proceed to show that inhibitors of Abl family kinases, likewise, 
sensitize both breast cancer and melanoma cells to doxorubicin by blocking cell 
proliferation and dramatically inducing apoptosis. These findings were extended to 
advanced multi-drug resistant melanoma cells, in which we show for the first time that c-
Abl promotes expression of the drug transporter, ABCB1, during acquired resistance, 
and drugs that inhibit c-Abl/Arg prevent ABCB1 expression and function. Moreover, c-
Abl/Arg also promote acquired chemoresistance independent of ABCB1 by modulating 
multiple survival pathways. We demonstrate that c-Abl/Arg promote chemoresistance by 
upregulating STAT3, preventing doxorubicin-mediated conversion of NF-κB into a 
transcriptional repressor, activating an HSP27/p38/Akt survival pathway, and modulating 
ERK signaling. Therefore, c-Abl/Arg promote chemoresistance in highly resistant 
melanoma cells by impinging on drug transporter and cell survival pathways. Taken 
together, these data indicate that c-Abl/Arg inhibitors are likely to reverse acquired 
resistance in metastatic melanomas harboring activated c-Abl/Arg, and thus, may be 
effective in a combination regimen. 
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 1 
CHAPTER ONE 
INTRODUCTION 
1.1 Abelson family kinases  
1.1.1 Regulation 
The Abelson family of non-receptor tyrosine kinases (Abl family kinases) includes 
two proteins, c-Abl and Arg (Abl-Related-Gene), which are encoded by Abl1 and Abl2 
genes, respectively (Figure 1.1A) [1]. Both genes can give rise to one of two alternatively 
spliced isoforms (i.e., 1a or 1b), with the 1a isoforms lacking a myristic acid residue at 
their N(amino)-termini [2]. c-Abl and Arg are highly homologous in their N-termini, where 
they contain SH3, SH2, and kinase domains, but are more divergent in their C(carboxy)-
termini (Figure 1.1A) [1]. Abl family kinases are activated via phosphorylation of tyrosine 
residue Y245, Y89, and Y276, which are located in the SH2/kinase domain interlinker 
region, and Y412, located in the activation loop [3-5].  
c-Abl and Arg are ubiquitously expressed in all tissues, but these two proteins 
vary in their subcellular localization [4]. Whereas most tyrosine kinases are 
predominantly localized near the plasma membrane, c-Abl uniquely possesses three 
nuclear localization signals in its C-terminus, allowing it to also shuttle between the 
cytoplasm and nucleus (Figure 1.1A) [6-8]. Cytoplasmic and membrane-localized c-Abl 
and Arg respond to growth factor signals, promoting cell proliferation and motility [3, 9]. 
Upon activation in the nucleus, c-Abl can promote genotoxic stress-induced apoptosis 
[10]. Another unique property of Abl family kinases, relative to most other tyrosine 
kinases, is the ability to directly bind cytoskeletal components and influence and respond 
to changes in cell movement and shape [11].  
Autoinhibition of c-Abl/Arg prevents aberrant activation of these kinases, and is 
regulated via intramolecular interactions between myristic acid residues on the N-termini 
and the kinase domains of c-Abl and Arg, as well as the interaction of SH3 domains and 
proline residues within the interlinker region [1, 12, 13]. In addition to autoinhibition, 
several molecules have been discovered to act as inhibitors of Abl family kinases, 
including RB, PRDX1, PIP2, AAP1, Fus1, and PCNA. RB (retinoblastoma protein) binds 
and prevents c-Abl-mediated cell cycle regulation and activation of transcription [14]. 
PRDX1 (Peroxiredoxin 1) inhibits c-Abl kinase activity via interaction with its SH3 domain 
[15]. Autoinhibition of membrane-bound c-Abl/Arg is disrupted due to insertion of the 
myristic acid tail into the phospholipid bilayer, and in these instances, PIP2 prevents 
 2 
 
Figure 1.1. c-Abl and Arg structure and function. (A) c-Abl and Arg possess very 
high homology in their N-terminal region, due to highly conserved SH3, SH2, and kinase 
domains. The C-terminal region is variable since c-Abl, but not Arg, possesses a DNA 
binding domain (DBD) and three nuclear localization signals (NLS). Both contain an F-
actin binding domain (FBD) and G-actin binding domain (GBD). Figure provided by Dr. 
Plattner. Adapted from Pendergast, Adv Cancer Research (2002);85:51-100. (B) Protein 
crystallography demonstrating the interaction of STI571 with the kinase domain of c-Abl. 
STI571 binds the kinase domain of Abl family kinases and stabilizes the inactive 
confirmation. Figure adapted from Nagar, et al, Cancer Research (2002) Aug 
1;62(15):4236-43. (C) STI571 (imatinib) binds the kinase domain of Abl family kinases 
(BCR-Abl is shown), preventing substrate binding and subsequent phosphorylation. 
Figure attributed to Sodium at the English language Wikipedia. 
 3 
kinase activity by directly binding to the kinase domain [16, 17]. AAP1 (Abl-associated 
protein 1) binds the SH3 domain of c-Abl, preventing substrate phosphorylation, and, 
importantly, loss of AAP1 correlates with increased expression of oncogenic forms of c-
Abl [18]. Fus1 is a negative regulator of Abl family kinases, preventing their full activation 
and subsequent tumorigenic signaling [19]. PCNA (proliferating cell nuclear antigen) 
promotes the degradation of c-Abl in response to genotoxic stress, thereby attenuating 
the pro-apoptotic function of nuclear c-Abl [20]. Importantly, the loss of regulation of Abl 
family kinase activity, either by disruption of autoinhibition or disruption of inhibitory 
interactions with other proteins, is directly correlated with disease progression, both in 
hematopoietic cancer and solid tumors.  
 
1.1.2 Role in hematopoietic cancer 
Abl family kinases (c-Abl, Arg) were first characterized for their involvement in 
human leukemia, where a chromosomal translocation event causes the translocation of 
the Abl1 gene next to the BCR gene [21]. This results in a constitutively active BCR-Abl 
fusion protein that drives the development of chronic myelogenous leukemia (CML) [21]. 
BCR-Abl+ CML cells possess an increased capability to survive, proliferate, migrate, and 
invade [22, 23]. This chromosomal abnormality was identified to be a reciprocal 
translocation between chromosomes 9 and 22, resulting in an elongated chromosome 9 
and a severely truncated chromosome 22 [24]. 95% of CML patients were found to 
harbor this abnormality in chromosome 22, which was referred to as the Philadelphia 
chromosome due to the discovery of the phenotype by scientists at the University of 
Pennsylvania and Fox Chase Cancer Center (Philadelphia, PA) [24]. Depending on the 
specific site where the chromosomal fusion occurs, three variants of the BCR-Abl fusion 
protein have been shown to be of clinical importance. These variants, p190, p210, and 
p230, have been shown to promote specific forms of hematopoietic disease: acute 
lymphoblastic leukemia (ALL), CML, and chronic neutrophilic leukemia (CNL), 
respectively [25]. In addition, novel FOXP1-Abl1, SNX2-Abl1, and NUP214-Abl1 fusion 
genes have recently been observed in a small cohort of ALL patients [5, 26]. Other 
leukemogenic c-Abl and Arg fusion genes arise due to translocations with the ETV6, 
EML1, RCSD1, and Tel genes in a number of leukemias [5, 27-29]. In summary, 
constitutively active, mutant forms of Abl family kinases, arising from chromosomal 
translocations, drive malignant transformation in a variety of leukemias. 
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STI571 (Gleevec; imatinib) was developed to specifically inhibit BCR-Abl, and is 
FDA-approved to treat CML [30]. STI571 competitively binds the kinase domain of active 
Abl family kinases, preventing subsequent phosphorylation of target substrates (Figure 
1.1B, C) [30]. Nilotinib, a second-generation c-Abl/Arg inhibitor, has shown effectiveness 
in CML patients that develop resistance to STI571 [31]. In addition to inhibiting 
constitutively active Abl family kinases (i.e., BCR-Abl), accumulating evidence has 
revealed other cellular targets for nilotinib and STI571, including c-Abl/Arg, DDR1 
(Discoidin domain receptor 1), c-Kit, PDGFR, and CSF1R (colony stimulating factor 1 
receptor) [32-36].  
 
1.1.3 Role in solid tumors 
We showed that endogenous Abl family kinases are activated by growth factors 
(PDGF, platelet-derived growth factor; EGF, epidermal growth factor receptor), and 
promote proliferation, membrane ruffling, and migration in fibroblasts [16, 37]. 
Significantly, our lab recently demonstrated that Abl family kinases are also activated 
downstream of deregulated growth factor receptors (PDGFR, EGFR, IGF-1R, 
ErbB2/Her2) and Src family kinases in invasive breast cancer cells, and promote 
invasion, survival in response to nutrient deprivation, and proliferation [38, 39]. We 
demonstrated that PDGFR-mediated activation of Abl family kinases requires both PLC-
γ1 and Src, and that Src can independently activate c-Abl/Arg [37, 40]. Our lab was first 
to demonstrate that activated Abl family kinases drive the proliferation, invasion, cell 
survival, and anchorage-independent growth of aggressive breast cancer cells [38, 39]; 
however, others have demonstrated a role for activated Abl family kinases in breast 
cancer cells as well, implicating c-Abl/Arg in Src-mediated transformation and 
invadopodia formation [41-43]. 
We also demonstrated that activation of Abl family kinases in glioblastoma 
occurs in a PDGFR-dependent manner [44]. Activated c-Abl and Arg have also been 
implicated in non-small cell lung cancer cells, and drive progression of gastric carcinoma 
cells in response to c-Met [19, 45]. c-Abl is strongly expressed in chondrosarcoma and 
liposarcoma, and is coexpressed with EGFR in colon cancer specimens, but kinase 
activity has not been measured in these cancer types [46, 47]. Recent work has also 
demonstrated a potential role of Abl family kinases in prostate cancer cell motility [48, 
49]. We also were the first to demonstrate that c-Abl and Arg are highly activated in 
invasive melanoma cells (Figure 1.2), and promote proliferation, invasion, and 
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Figure 1.2. c-Abl and Arg are highly activated in melanoma cells. Melanoma cells 
were serum-starved, lysed, and c-Abl and Arg were immunoprecipitated. Kinase 
activities were determined by in vitro kinase assay using GST-Crk as the substrate. 
Lysates were also blotted with indicated antibodies. Figure adapted from Ganguly, et al, 
Oncogene (2011) Sep 5. doi: 10.1038/onc.2011.361.    
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metastasis of melanoma cells [50]. Taken together, these data explicitly demonstrate the 
integral role of Abl family kinases in many facets of cancer progression to metastasis.  
 
1.2 Deregulated proliferation and survival pathways in cancer 
1.2.1  STAT3 pathway 
The STAT (signal transducer and activator of transcription) family of transcription 
factors is composed of seven members that possess a DNA binding domain, SH2 
domain, and a C-terminal transactivation domain [51]. The transcription factor, STAT3, is 
primarily activated via phosphorylation downstream of cytokines and receptor and non-
receptor tyrosine kinases, and is responsible for transferring signals from the plasma 
membrane to the nucleus [52]. Upon phosphorylation on tyrosine residue Y705, STAT3 
dimerizes, translocates to the nucleus, binds specific sites in a gene’s promoter region, 
and induces transcription of genes that control cell development, survival, and 
proliferation (Figure 1.3) [51, 53].  
STAT3 activation has been observed in numerous human cancers, including 
breast cancer and melanoma, and promotes cellular transformation in vitro [51]. STAT3 
mediates survival by increasing expression of anti-apoptotic proteins (i.e., Bcl-2 family 
members), and is crucial for G1S cell cycle transition via activation of cyclin D1/cyclin-
dependent kinase 4 (cdk4) complexes, and inactivation of p27 [54-56]. Non-receptor 
tyrosine kinases, such as Src and constitutively active Abl family kinases, have been 
shown to promote STAT3 phosphorylation [53]. Importantly, we observed that Abl family 
kinases promote STAT3 phosphorylation in breast cancer and melanoma cells, and 
promote melanoma invasion in a STAT3-dependent manner [39, 50]. STAT3 has been 
linked to chemoresistance of tumor cells, and downregulation of this transcription factor 
sensitizes cells to undergo chemotherapy-induced apoptosis [51]. 
 
1.2.2  PI3K/Akt pathway 
The PI3K (phosphoinositide 3-kinase)/Akt pathway is commonly activated in an 
abundance of tumor types [57]. PI3K/Akt signaling is activated by growth factor 
receptors and G protein-coupled receptors (GPCR) and promotes cell proliferation and 
survival [58]. After receptor-mediated activation, PI3K phosphorylates the membrane 
phospholipid PIP2 (phosphatidylinositol (3,4)-bisphosphate), generating PIP3 
(phosphatidylinositol (3,4,5)-triphosphate), and PTEN negatively regulates this process 
by dephosphorylating PIP3 [59, 60]. PDK1 localizes to the membrane, where upon  
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Figure 1.3. STAT3 signaling in cancer cells. STAT3 is activated by growth factor 
receptors (e.g., EGFR) or cytokines (e.g., IL-6R) in response to a wide array of stimuli. 
Phosphorylated STAT3 localizes to the nucleus and binds in a site-specific manner to 
the promoter regions of genes responsible for promoting many processes involved in 
cancer progression. Figure adapted from Aggarwal, et al., Ann NY Acad Sci (2009) 
Aug;1171:59-76. 
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activation by PIP3, it phosphorylates Akt on its T308 residue [61]. In order to fully activate 
Akt, phosphorylation on a second residue, S473, is also required. Akt is activated by a 
diverse number of stimuli leading to enhanced cell growth (Figure 1.4) [58, 62]. In 
response to growth factors, Akt is activated by PDK1, leading to phosphorylation of 
T308, and mTORC2, which acts as a PDK2 and phosphorylates S473. In response to 
DNA damage, DNA-PK acts as a PDK2 and activates Akt signaling, and, in certain cell 
types, in response to cell stress, such as DNA damage and reactive oxygen species, Akt 
is activated by phosphorylation of S473 via a complex comprised of HSP27, p38, and 
MK2 [62-68]. HSP27 expression is induced by cell stress and it regulates cell survival in 
response to cell stress, resulting in cancer cell progression. HSP27 is upregulated 
transcriptionally by STAT3 in response to stress, and further regulated by p38 [69]. 
HSP27 expression is crucial for Akt activation in response to stress due to its scaffolding 
function, and disruption of HSP27/Akt interaction induces apoptosis in neutrophils [64]. 
Activation of the PI3K/Akt pathway promotes cell proliferation and survival by driving cell 
cycle progression via cyclin D1 and c-Myc, and upregulating a variety of anti-apoptotic 
proteins [60, 70-72]. 
 
1.2.3  NF-κB pathway 
The NF-κB pathway is known to promote cancer progression, and various 
components of this pathway are overexpressed in advanced cancer types [73, 74]. The 
NF-κB pathway consists of numerous binding partners (i.e., p65/RelA, RelB, c-Rel, p50, 
p52) that share a common Rel homology domain, with p65/RelA as the major 
component of most NF-κB-mediated signaling events [75]. Canonical NF-κB activation 
occurs in response to growth factors and cytokine stimulation, and this results in IKKβ 
phosphorylation of the NF-κB inhibitor, IκBα (Figure 1.5) [76]. This promotes IκB 
degredation, allowing p65/RelA to localize to the nucleus, and allows translocation of the 
NF-κB dimer (i.e., p65-p50) to the nucleus [76]. NF-κB dimers are phosphorylated on 
two serine residues (S536 and S276) by IKK1/2 and PKA, respectively [77], and can be 
further modified via acetylation by histone acetyltransferases (HATs) such as p300, to 
promote interaction with various coactivators [76, 78]. Once in the nucleus, NF-κB binds 
DNA binding sites and promotes transcription of target genes, many of which are 
responsible for cancer cell survival [77]. Non-canonical activation of NF-κB signaling  
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Figure 1.4. Akt promotes cell survival following activation by diverse stimuli. 
Activation of Akt signaling is dependent on PI3K/PDK1-dependent phosphorylation of 
T308, as well as phosphorylation of S473. The protein responsible for phosphorylating 
S473 varies depending on the stimulus (i.e., growth factor stimulation, DNA damage, or 
cell stress resulting from deleterious cellular insults, such as reactive oxygen species 
(ROS)). Figure references data from: Rane, et al, J Biol Chem (2001) Feb 
2;276(5):3517-23; Rane, et al, J Biol Chem (2003) Jul 25;278(30):27828-35; Zheng, et 
al, J Biol Chem (2006) Dec 1;281(48):37215-26; Wu, et al, J Biol Chem (2007) Jul 
27;282(30):21598-608; Shi, et al, Mol Cell Biol (2011) May;31(10):1938-48; Dowling, et 
al, Biochim Biophys Acta (2010) Mar;1804(3):433-9; Bozulic, et al, Mol Cell (2008) Apr 
25;30(2):203-13. 
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Figure 1.5. Mechanisms of NF-κB activation in cancer cells. NF-κB signaling occurs 
via a canonical or non-canonical pathway. In the canonical pathway, IKKβ 
phosphorylates IκB, targeting it for degradation. The p65/RelA-p50 dimer is released, 
further modified via phosphorylation and acetylation, and translocates to the nucleus 
where it binds in a site-specific manner to the promoter regions of genes, inducing 
transcription. In the non-canonical pathway, IKKα phosphorylates p100, inducing 
processing of p100 to p52. The RelB-p52 dimer translocates to the nucleus and induces 
gene transcription. Figure adapted from Gilmore, Oncogene (2006) Oct 30;25(51):6887-
99.  
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involves IKKα-mediated phosphorylation of the inhibitory protein, p100 (Figure 1.5) [76]. 
Unlike IκB, which is degraded, p100 is processed to p52 and the resulting RelB-p52 
dimer then translocates to the nucleus to promote transcription of target genes [76].  
NF-κB signaling is activated by STAT3 and PI3K/Akt and promotes cancer cell 
progression and survival in the presence of chemotherapeutic agents [79-81]. 
Specifically, STAT3 has been shown to promote phosphorylation and acetylation of 
p65/RelA, increasing the duration of transactivation [78]. The NF-κB pathway is a master 
regulator of anti-apoptotic IAP (inhibitor of apoptosis protein) expression [82]. The IAP 
family inhibits caspases-3, -7, and -9, and are inhibited themselves by Smac/DIABLO 
(Figure 1.6), and this balance critically determines cellular response to therapy in 
numerous cancer types [83, 84]. There is some controversy regarding the role of NF-κB 
in response to chemotherapeutics such as doxorubicin. Some reports indicate that NF-
κB activity is induced in response to doxorubicin, while others show that NF-κB 
promotes doxorubicin-induced death via transcriptional repression of anti-apoptotic 
genes [85-87]. This is likely to be tightly governed by cell type-specific responses to 
various stimuli, and determining how cellular milieu regulates NF-κB activation in 
response to therapy will be critical for designing future therapeutic agents. 
 
1.3 Breast Cancer 
1.3.1 Clinical stages and progression 
Breast cancer is one of the most commonly diagnosed diseases in U.S. women 
[88]. As with other epithelial-derived malignancies, progression to metastasis is 
responsible for 90% of cancer-related deaths [89]. Cells progress to an invasive, 
metastatic state via a process defined as epithelial-to-mesenchymal transition (EMT) 
[90]. During this process, cells undergo remodeling of their actin cytoskeleton, lose 
apical-basal polarity and adhesion, and gain the ability to migrate and infiltrate the 
extracellular matrix [90]. Epithelial cancers of glandular origin arise due to enhanced 
localized cell proliferation, giving rise to a benign tumor called an adenoma [90]. As the 
disease progresses towards malignancy, this cell mass, now defined as an 
adenocarcinoma, acquires the ability to invade surrounding tissues and potentially 
intravasate into the bloodstream, extravasate to secondary sites, and establish colonies 
in distant organs to form metastases (Figure 1.7) [90].  
Proliferation is a strong prognostic index for response to breast cancer therapy, 
since enhanced proliferation drives tumor development and increases the likelihood of  
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Figure 1.6. Inhibitors of Apoptosis Proteins (IAPs) inhibit caspase activation. 
Apoptosis can be induced by either an intrinsic or extrinsic pathway. In the extrinsic 
pathway, death receptors activate caspase-8, leading to caspase-3/7 activation. In the 
intrinsic pathway, cell stress/damage leads to cytochrome c release from the 
mitochondria and formation of the apoptosome, which is composed of cytochrome c, 
APAF-1, and caspase-9, and this leads to caspase-3/7 activation. IAPs inhibit caspases-
3, -7, and -9, and are inhibited by Smac/DIABLO. Adapted from: Arnt, et al., J Biol Chem 
(2002) Nov 15;277(46):44236-43; Abe, et al, Exp Mol Path (2007) Dec;83(3):405-12; 
Lopes, et al., Int J Cancer (2007) Jun 1;120(11):2344-52; Wright, et al, J Clin Invest 
(2005) Oct;115(10):2673-8. 
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Figure 1.7. The stages of epithelial cancer progression. Cellular dysplasia and 
unchecked proliferation results in the formation of an adenoma. As cells develop into a 
carcinoma and become more malignant, they undergo epithelial-to-mesenchymal 
transition (EMT) and acquire the ability to invade surrounding tissues, intravasate into 
the bloodstream, and extravasate out at secondary sites to form metastases. Figure 
adapted from Thiery, JP, Nat Rev Cancer (2002) Jun;2(6):442-54. 
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metastasis, resulting in a poor prognosis for the patient [91, 92]. MAPK, PI3K/Akt, & 
STAT have all been shown to drive breast cancer proliferation and progression [93-95]. 
Akt signaling promotes breast cancer cell survival in the presence of chemotherapeutic 
agents, with Akt2 having specifically been shown to promote chemoresistance [71]. 
Moreover, primary breast tumor samples possess elevated levels of pAkt [57]. The NF-
κB pathway is known to promote breast cancer progression, and various components of 
this pathway are significantly overexpressed in breast cancer cells [73, 74]. Tyrosine 
kinases have a pivotal role in breast cancer progression, including the ErbB family (i.e., 
EGFR, Her2), IGFR, PDGFR, Src, and Abl family kinases [38, 39, 96]. Previously, we 
showed that Abl family kinases promote STAT3 activation in breast cancer cells [39], 
and elevated STAT3 activity promotes proliferation, survival, and chemoresistance of 
invasive breast cancer cells [97-99]. 
 
1.3.2 Current breast cancer treatment options 
Invasive, aggressively growing breast tumors are less amenable to currently 
used treatments; therefore, new therapeutic targets are required to specifically combat 
highly aggressive breast cancer [92, 100, 101]. Doxorubicin is one of the most 
successful chemotherapeutic agents for treating epithelial cancers [101, 102]. 
Doxorubicin-induced DNA damage stalls the progression of cells through the cell cycle 
[103]. Doxorubicin has many different mechanisms of action, including inhibition of 
topoisomerase II, DNA intercalation, and free radical generation [104, 105]. 
Chemotherapy, such as doxorubicin, improves survival, but causes harmful side effects 
due to a lack of target specificity; therefore targeted agents are routinely used in 
combination regimens to increase antitumor effects without increasing systemic toxicity 
[101, 106, 107]. Targeted therapies, focused on inhibition of specific deregulated 
signaling pathways, as in the case of trastuzumab or erlotinib for treatment of Her2+ or 
ER+ breast cancers, respectively, have generated some exciting clinical data both as 
single agents and in combination regimens [108]. However, these therapies are not 
effective in Her2- or ER- tumors, and advanced metastatic disease has proven refractory 
to these targeted therapies as well [108]. Patient-specific, diagnostic therapies must be 
developed to eradicate this difficult to treat disease.  
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1.4  Melanoma 
1.4.1 Clinical stages and progression 
Melanoma, the most frequently diagnosed skin cancer type, can arise from 
exposure to the sun that is both chronic and intermittent; however, cases are diagnosed 
in mucosal/unexposed areas as well [109, 110].  Half of all cases arise from dysplastic 
nevi (i.e., atypical moles) [111, 112]. Though melanoma represents a small proportion of 
all diagnosed skin malignancies (~7%), it is responsible for the majority of skin cancer-
related deaths (~75%) [109].  
Melanoma spreads by first exhibiting the ability to grow within the epidermal layer 
in a process known as radial growth phase (RGP) (Figure 1.8). This is followed by 
transition into vertical growth phase (VGP), where cells invade the dermal layer, and 
finally metastasis to distant organs (Figure 1.8) [111].	   Akt is activated in primary 
melanoma samples, and activated Akt converts RGPVGP melanoma [113]. 
Progression from RGP to VGP to metastasis also requires activation of various 
transcription factors (i.e., STAT3 & NF-κB) [111, 114]. A majority of the critical markers 
of melanoma progression and invasion are direct transcriptional targets of these factors 
[114, 115]. Importantly, we showed in melanoma cells that c-Abl-mediated invasion 
occurs in a STAT3-dependent manner, whereas Arg-mediated invasion is STAT3-
independent [50]. Therefore, we propose that Abl family kinases could represent novel 
therapeutic targets in melanoma, allowing for direct inhibition of signaling mechanisms 
that are critical for chemoresistance.	  
 
1.4.2 Current melanoma treatment options 
Only 5% of patients with advanced disease survive longer than one year and 
melanoma diagnoses are more common than any other cancer [116]. Currently 
metastatic melanoma essentially represents an untreatable disease, with little to no 
improvement having been observed in one-year survival rates. Due to resistance to 
currently used chemotherapeutics, surgery is the only viable therapeutic option [88, 116]. 
Past clinical trials for melanoma have tested a gamut of chemotherapeutic options: 
Alkylating agents, nitroureas, vinca alkaloids, platinums, taxanes, topoisomerase 
inhibitors, and anthracyclines.  These all had little impact on patient survival [116]. One 
such chemotherapeutic drug, doxorubicin, is currently the focus of six clinical trials 
based on data obtained from the ClinicalTrials.gov database. 
One of the more common genetic phenotypes associated with malignant,  
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Figure 1.8. Proposed molecular changes for the initiation and progression of 
metastatic melanoma. Abnormal cells within the epidermal layer arise from either 
heritable mutations or from cellular insults such as sun exposure. These cells form a 
nevus, and, via additional DNA mutations and epigenetic modifications, eventually 
expand within the epidermal layer to form a RGP (radial growth phase) melanoma. 
Tumors with the acquired ability to invade the dermal layer are known as VGP (vertical 
growth phase) melanomas. The progression from RGP to VGP to metastasis requires 
gain of function of various transcription factors (i.e., STAT3 and NF-kB). Figure adapted 
from: Zaidi, et al., J Invest Dermatol (2008) Oct;128(10):2381-91. 
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chemoresistant melanoma is oncogenic mutation of B-Raf [117, 118]. Although B-Raf 
mutations are rare across all cancers (~7%), they are present in nearly 60-70% of 
malignant melanomas [119]. B-Raf inhibitors show promise for treating metastatic 
melanoma; however, some melanomas do not contain B-Raf mutations, others acquire 
resistance by activating receptor tyrosine kinase signaling pathways [120, 121], and still 
others (10%) are intrinsically resistant [122]. c-Kit mutations are more commonly 
observed in melanomas from mucosal and minimal exposure areas (i.e. hands and feet) 
[110, 123]. Some melanomas containing activated c-Kit respond to STI571; however, 
there are other cases in which they do not [110, 123, 124]. 
Treatment regimens are limited, in part, because approximately 80% of 
melanomas express an ABC transporter [125].  Studies indicate that ABCC1 and ABCB1 
are commonly expressed in melanoma, positively correlating with progression to 
metastasis, and contribute to the invasive potential of melanoma cells [125, 126]. 
Studies have shown promising data in regards to malignant melanoma therapy with 
drugs that target c-Kit or B-Raf [122, 124], although no therapy to date has extended 
survival longer than 10 months [127]. 
 
1.5  Drug Resistance 
1.5.1 Types of resistance mechanisms 
Resistance to chemotherapy is a constant obstacle in treating cancer patients, 
which highlights the need to understand mechanisms that drive resistance. Multidrug 
resistance occurs via three primary mechanisms: 1) decreased influx of water soluble 
compounds that require transport mechanisms to enter cells; 2) increased efflux of 
hydrophobic drugs that diffuse through cell membranes; and 3) upregulation of DNA 
repair processes, anti-apoptotic and proliferative factors, or metabolic enzymes [128]. 
Overexpression of anti-apoptotic proteins (e.g., Bcl-2, Bcl-XL) and induction of 
transcription factors (e.g., STAT3, NF-κB) have a definitive role in chemotherapeutic 
resistance. 
Doxorubicin activates pro-apoptotic proteins (i.e. Bak, Bax), and this process is 
counteracted by anti-apoptotic proteins (i.e. Bcl-2, Bcl-XL) that prevent Bak/Bax from 
triggering cytochrome c release and the mitochondrial cell death pathway [129]. STAT3 
signaling induces expression of anti-apoptotic proteins (i.e., Survivin, Bcl-2, and Mcl-1), 
and XIAP/cIAP1 are upregulated transcriptionally by NF-κB [130, 131]. IAP expression 
correlates with resistance to doxorubicin and chemo-resistant cells potentially lack 
 18 
mechanisms for down-regulating IAPs & up-regulating Smac/DIABLO [83, 130, 132]. 
However, although a plethora of intrinsic resistance mechanisms exist, the most 
common mechanism of resistance is via increased efflux mediated by ATP Binding 
Cassette (ABC) transporter family members [128, 133]. 
 
1.5.2 ATP Binding Cassette (ABC) transporters 
The ATP Binding Cassette (ABC) transporter family consists of a multitude of 
membrane spanning proteins responsible for ATP-dependent transport of substances 
across both intra- and extracellular membranes [134]. Members of this superfamily 
possess two highly conserved nucleotide (ATP) binding domains and two 
transmembrane domains (Figure 1.9) [135]. Although substrate specificities vary 
between members, transporter activity is dependent on ATP [135]. Researchers have 
identified approximately fifty human ABC transporters in a variety of tissue types [136]. 
Three ABC transporters (i.e., ABCB1, ABCC1, and ABCG2) account for an 
overwhelming majority of the multidrug resistance observed in mammalian cells in vitro 
[137].   
ABCB1, or P-glycoprotein, is highly elevated within many cancer types and 
possesses the broadest substrate specificity of all known transporters [128]. It transports 
hydrophobic compounds that are neutral to slightly positive in charge; therefore, 
encapsulating most commonly used chemotherapeutic drugs [138]. It is widely 
associated with resistance to anthracyclines, taxanes, and vinca alkaloids, among many 
other classes of chemotherapeutics across a multitude of cell types [135].   
ABCG2 was originally named BCRP (breast cancer resistance protein), due to 
the fact that it was cloned from a doxorubicin-resistant breast cancer cell line [139]. This 
transporter recognizes both positively and negatively charged molecules, organic 
anions, and substrates possessing sulfate conjugates. There is a great deal of similarity 
in tissue distribution and substrate specificity between ABCG2 and ABCB1 [137]. 
ABCG2 differs from other members of the ABC transporter family in that it only contains 
one ATP-binding domain, one transmembrane domain, and typically functions as either 
a homodimer or a tetramer [137, 140]. It primarily confers resistance to anthracyclines, 
mitoxantrone, and topotecan [135].   
ABCC1, also called MRP1, is expressed ubiquitously as well, and primarily 
effluxes negatively charged molecules and compounds that have undergone phase II 
metabolism [134, 141]. It shares substrate specificity with ABCB1 for a number of  
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Figure 1.9. Basic structure of ABC transporters. Family members of the ATP binding 
cassette (ABC) transporter family contain transmembrane domains (TMD) and 
nucleotide binding domains (NBD). The NBDs of ABC transporters bind ATP, resulting in 
active transport of substrates across cellular membranes. Figure adapted from: 
http://www-dsv.cea.fr/art/images/devm_lems/abc3d.gif 
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hydrophobic compounds and primarily confers resistance to doxorubicin, etoposide, 
vincristine, and methotrexate [128, 135]. 
  
1.5.3 Role of ABC transporters in disease 
Studies have shown that ABCB5 and ABCB8, structural paralogs of ABCB1, 
promote melanoma resistance to doxorubicin [142, 143], and ABCB1 expression and 
function is induced in melanoma cells following drug treatment [144]. Breast cancer stem 
cells bypass chemotherapy-induced cell death, in part, by upregulating the drug 
transporter, ABCG2, a stem cell marker [145]. Interestingly, BCR-Abl increases ABCG2 
expression in hematopoietic cells [146]. ABCB1 has been shown to induce efflux of 
doxorubicin in BCR-Abl+ hematopoietic cells [147], and STI571 and nilotinib have been 
shown to interact with both ABCB1 and ABCG2 [148].  
 
1.5.4 Use of ABC transporter inhibitors for cancer treatment 
While a number of inhibitors are well suited for laboratory-based pharmacological 
studies, there are abundant limitations preventing the clinical usefulness of these 
compounds. Fumitremorgin C (FTC), a mycotoxin derived from A. fumigatus, and its 
many analogs, reverses ABCG2-mediated drug resistance, but is highly neurotoxic in 
vivo [137, 149].  Ko143, another potent BCRP inhibitor, is currently undergoing analysis, 
and has produced a promisingly low degree of in vivo toxicity in preliminary tests [150]. 
ABCB1 inhibitors, such as cyclosporine A and verapamil, increase intracellular drug 
accumulation and cytotoxic effects; however, it appears that the effectiveness of these 
inhibitors varies across different cell types [151]. Despite three decades of study, all 
attempts to therapeutically target ABCB1 have failed due to systemic toxicity [135]. 
Targeting resistant cancers has proved difficult due to intrinsic (anti-apoptotic signaling) 
and acquired (ABC transporter) resistance mechanisms. Current treatment options have 
not provided the necessary therapeutic value required to adequately combat 
chemoresistant tumors; therefore, novel druggable targets which influence multiple 
mechanisms of resistance must be identified in order to make headway against these 
most difficult to treat forms of disease.  
 
1.6  Project Objectives 
Our previous observations have indicted Abl family kinases as causative agents 
in melanoma and breast cancer cell proliferation, invasion, survival to nutrient 
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deprivation, and metastasis [38, 39, 50]. As cancer cells progress, they notoriously 
become more resistant to therapy that may have effectively killed cells at an earlier 
stage of the disease. Due to the critical nature of Abl family kinases in promotion of 
melanoma and breast cancer cell progression, we hypothesize that c-Abl/Arg may be 
critical mediators of the resistant phenotype required for survival of advanced disease. 
The goal of this work is to identify whether c-Abl and Arg promote chemoresistance of 
invasive/metastatic cancer cells, and identify the mechanisms by which this occurs.  
We will determine whether c-Abl/Arg promote viability, proliferation and prevent 
apoptosis in response to various chemotherapeutics used in the treatment of breast 
cancer and melanoma cells (chapters 2 and 3). Furthermore, we will identify 
mechanisms by which c-Abl/Arg inhibitors sensitize highly resistant melanoma cells to 
doxorubicin (chapter 4). Finally, we will ascertain the mechanism by which c-Abl/Arg 
promote resistance to doxorubicin-induced apoptosis (chapter 5), and postulate a 
mechanism by which c-Abl/Arg promote proliferation in the presence of doxorubicin 
(chapter 6).  
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CHAPTER TWO 
ABL FAMILY KINASES PROMOTE BREAST CANCER CHEMORESISTANCE 
2.1 Introduction 
Breast cancer is the second leading cause of cancer-related deaths in U.S. 
women, and accounts for a quarter of new cancer diagnoses each year [152]. Her2-
positive breast cancers are treated with Herceptin; however, many tumors develop 
resistance and others are Her2-negative. Taxanes (e.g. paclitaxel; taxol), 5-fluorouracil 
(5-FU), camptothecins, and cyclophosphamide, which metabolizes to 
mechloroethamine, are currently used for treatment of patients with ER− (estrogen 
receptor-negative), PR− (progesterone receptor-negative) tumors, and platinum (e.g. 
cisplatin) regimens are in preclinical trials [153-156]. Conventional chemotherapeutic 
approaches for treating patients with hormone-negative, Her2-negative tumors are far 
from optimal, as the treatments often are not effective due to resistance, and the drugs 
have significant side effects. Thus, the development of new combinations to treat this 
class of patients is critical. The use of targeted agents together with conventional 
chemotherapeutic drugs may increase the effectiveness of the drugs, allowing doses to 
be decreased, thereby decreasing toxicity.  
We showed that Abl family kinases have dramatically increased activities in 
invasive breast cancer cells as compared to non-invasive MCF-7 breast cancer cells 
[38]. Interestingly, the mechanism of c-Abl/Arg activation in breast cancer cells is unique 
from their activation in leukemia. In leukemia, chromosomal translocation activates the 
Abl family kinases, whereas in ER−, PR− breast cancer cells, Abl family kinases are 
activated downstream of deregulated growth factor receptors such as EGFR, 
ErbB2/Her2, and IGF-1R, as well as by activated Src family kinases [38, 39]. Using 
STI571 and siRNA approaches, we showed that activation of c-Abl/Arg in breast cancer 
cells has dramatic consequences as they promote proliferation, G1S transition in 
response to IGF-1, survival in response to nutrient deprivation, and invasion [38, 39]. In 
this chapter, we demonstrate that STI571 synergizes with conventional 
chemotherapeutic agents to inhibit proliferation and increase apoptosis of breast cancer 
cells. Interestingly, the effects of the drug combinations are cell type-specific, as STI571 
synergizes with cisplatin in BT-549 cells, camptothecin in MDA-MB-231 cells, and 5-FU 
in MDA-MB-468 cells, whereas mechloroethamine has antagonistic effects with STI571 
in all cell lines. Therefore, although all the cell lines are equally sensitive to the effects of 
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STI571 alone [39], there are cell type-specific differences, which affect the ability of 
STI571 to synergize with conventional chemotherapeutic agents. 
 
2.2 Materials and Methods 
2.2.1 Cell Lines and Reagents 
Cell lines were purchased from the University of North Carolina Tissue Culture 
Facility. BT-549 cells were grown in RPMI/10% FBS (fetal bovine serum), and MDA-MB-
231 and MDA-MB-468 cells were cultured in MEM/10% FBS/1mM sodium pyruvate. 
STI571, kindly provided by Novartis (Basel, Switzerland), was dissolved in water at a 
concentration of 10mM and stored at −80°C. Doxorubicin, paclitaxel, cisplatin, 
camptothecin, 5-fluorouracil, and mechlorethamine were purchased from Sigma (St. 
Louis, MO). Antibodies to PARP (Poly (ADP-ribose) polymerase; sc-8007), pan-ERK1/2 
(sc-94), IκB (sc-371), and α-tubulin were obtained from Santa Cruz Biotechnologies 
(Santa Cruz Biotechnology; Santa Cruz, CA), Lamin A/C was obtained from Milllipore 
(Temecula, CA), GAPDH, c-Abl (8E9), and STAT3 antibodies were obtained from BD 
Biosciences (Chicago, IL), phospho-Akt, Akt, and phospho-STAT3 (Y705) antibodies 
were from Cell Signaling Technology (Danvers, MA), and phospho-ERK1/2 antibody was 
from Promega (Madison, WI). Western blots were performed according to 
manufacturers' protocols. 
 
2.2.2 Viability Assays 
CellTiter-Glo Assay (Promega; Madison, WI). Cells were plated in triplicate in 96-
well dishes such that the vehicle-treated population was subconfluent at the end of the 
assay. The day after plating, the media was replaced with media containing drugs, and 
viability was assessed 72 hours later using the CellTiter-Glo Assay. For 5-FU 
experiments, viability was assessed after 96 hours. An equal volume of CellTiter-Glo 
reagent (at room temperature) was added to each well, the plate was rocked, incubated 
at room temperature for 10 minutes, half of the mixture from each well was transferred to 
an opaque 96-well plate, and luminescence (all wavelengths of light emitted for 10 
seconds) was measured on a Synergy 2 plate reader (Biotek; Winooski, VT). MTT Assay 
(Sigma; St. Louis, MO). Cells were plated in triplicate in 96-well plates at a density of 
2500 cells/well, and the next day the media was replaced with media containing STI571. 
After 72 hours, the media was replaced with 3-(4, 5-methylthiazol-2-yl)-2, 5-diphenyl-
tetrazolium bromide (MTT)-containing media (0.5mg/ml), incubated at 37°C for 4 hours, 
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an equal volume of solubilization solution (10% SDS, 0.01M HCl) was added, and the 
plate was incubated at 37°C overnight to solubilize formazon crystals. Absorbance was 
measured at 570nm in a Biotek Synergy 2 plate reader (Biotek; Winooski, VT). 
 
2.2.3 Proliferation Assays 
Cells were plated in triplicate in 24-well dishes so that vehicle-treated cells were 
subconfluent on the day of harvest. The day after plating, the media was replaced with 
media containing drugs, and 72 hours later (96 hours for low dose 5-FU experiments) 
tritiated thymidine was added (2.5µCi) for 2 hours. Cells were harvested by washing with 
PBS, 10% trichloroacetic acid (TCA), incubating in 10% TCA for 45 minutes, solubilizing 
radioactivity in 0.2N NaOH, and reading on a scintillation counter. 
 
2.2.4 Apoptosis Assays 
PARP Assay. Cells were plated in 60mm dishes, the media was replaced with 
media containing drugs the next day, and 40 hours later, detached and attached cells 
were lysed in RIPA buffer (50mM Tris pH 7.5, 150mM NaCl, 1% triton-X 100, 0.1% SDS, 
1% sodium deoxycholate, 1mM PMSF, 1mM sodium orthovanadate, 25mM sodium 
fluoride, 10µg/ml leupeptin, aprotinin, pepstatin). Total protein was quantitated with a 
Lowry DC kit (BioRad; Hercules, CA), equal protein was loaded on SDS-PAGE gels, and 
blots were incubated with antibodies to PARP and GAPDH. Caspase-Glo-3/7 Assay 
(Promega; Madison, WI). Cells were plated as described above, lysed in caspase lysis 
buffer (50mM HEPES pH 7.4, 5mM CHAPS, 5mM DTT), clarified by centrifugation, 15µl 
of the supernatant or buffer (blank) and 35µl of buffer were added to wells in an opaque 
96-well plate, and an equal volume (50µl) of room temperature Caspase-Glo substrate 
was added to each well. The plate was rocked, and luminescence (all wavelengths of 
light emitted) from each well was read 40–60 minutes after addition of Caspase-Glo 
using the Synergy 2 plate reader. Luminescent values were normalized to protein 
concentration using the Bradford protein assay (BioRad; Hercules, CA). Fluorescent 
Caspase-3/7 Assay (Sigma; St. Louis, MO). Cells were plated in 6-well dishes (60,000 
cells/well), treated for 40hours with STI571, and lysed in 1X lysis buffer. Lysate (5µl) was 
added to an opaque 96-well plate, incubated with 200µl of substrate (diluted 1:3), and 
fluorescence was assessed at 360nm (excitation)/460nm (emission) using a Biotek 
Synergy 2 plate reader. Relative Fluorescence Units (RFUs) were divided by the protein 
concentration of each sample as determined by Bradford assay (Biorad; Hercules, CA). 
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2.2.5 Subcellular Fractionation 
Cells were plated in 60mm dishes, and cytoplasmic/membrane and nuclear 
fractions were isolated using the NE-PER kit (Pierce; Rockford, IL) according to the 
manufacturer's protocol. 
 
2.2.6 Statistics/Determination of Combination Indices 
Statistics were performed using SigmaStat for Windows (Systat Software, Inc.; 
San Jose, CA). Combination Index (CI) values were determined using CalcuSyn 
software (Biosoft; Cambridge, UK) utilizing STI571 and chemotherapeutic drug dose 
response curves. 
 
2.3 Results 
2.3.1 MTT viability assays cannot be utilized to study effects of STI571 on solid 
tumor cell lines.   
We previously showed that STI571 inhibits many cellular processes associated 
with cancer progression in a variety of breast cancer and melanoma cell lines [39, 50].  
For instance, we demonstrated that treatment of breast cancer and 435s/M14 melanoma 
cells, which possess active Abl family kinases, with the c-Abl/Arg inhibitor, STI571 
(Gleevec), dramatically inhibits cell growth [39]. MDA-MB-435s cells were originally 
believed to be of breast cancer origin, but, in fact, are identical to M14 melanoma cells 
and will be referred to as 435s/M14 [50, 157]. To determine if the aforementioned 
decrease in growth in these cells was due to proliferation, we performed tritiated 
thymidine assays and observed a dose-dependent decrease in cell proliferation (Figure 
2.1A). To determine whether STI571 induces apoptosis of solid tumor cells grown in 
serum conditions, we performed fluorescent caspase-3/7 assays. Significantly, treatment 
of 435s/M14 and MDA-MB-468 cells with STI571 increased caspase activity (Figure 
2.1B). Therefore, STI571 reduces the growth of cells in serum by inhibiting proliferation 
and inducing apoptosis. A dose of 10µM STI571 was used for these assays because we 
previously showed that 10µM was required to effectively (65–75%) reduce 
phosphorylation/activities of active endogenous c-Abl and/or Arg [38]. Since our studies 
are focused on chemotherapeutic resistance, we decided to focus primarily on STI571’s 
overall effect on cell viability.  
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Figure 2.1. STI571 inhibits proliferation and induces apoptosis of cells containing 
highly active Abl family kinases. (A) Cell lines were plated in triplicate in 12-well 
dishes, the media was replaced the next day with media containing STI571, and tritiated 
thymidine incorporation was measured 72h later. Experiments shown are mean±SEM of 
three independent experiments. (B) Cells were plated in 6-well dishes, the media was 
replaced with media containing STI571 the next day, and caspase-3/7 activity was 
detected 40h after treatment in detached and attached cells by fluorescent caspase 
assay. Mean±SEM of three independent experiments. Values were normalized to values 
obtained in untreated wells and expressed as a percentage of untreated. *p<0.05, 
***p<0.001 using a Student t-test. 
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Since both proliferation and apoptosis are affected by STI571, viability assays 
should demonstrate a decrease in viability in the presence of STI571. To test this 
hypothesis, we utilized the MTT assay (Sigma; St. Louis, MO). 435s/M14 and MDA-MB-
468 cells were grown in the absence or presence of STI571 in serum, and MTT was 
added 72 hours later (the same timepoint used for tritiated thymidine assays). 
Surprisingly, although there was a noticeable decrease in cell number in wells treated 
with STI571, there was increased rather than decreased MTT reduction to formazan in 
STI571-treated 435s/M14 and MDA-MB-468 cells, and the increase in formazan 
formation was dependent on the STI571 dose, which was observed with as little as 1µM 
STI571 (Figure 2.2A, data not shown). These data were clearly inconsistent with growth 
kinetics, tritiated thymidine, and caspase assays, and also were inconsistent with what 
was observed by eye (Figure 2.1, data not shown) [39]. To be certain that the MTT 
assay was working in our hands, we treated 435s/M14 cells with increasing doses of 
doxorubicin, a drug known to inhibit cell viability, and observed that doxorubicin induced 
decreased MTT reduction, demonstrating that the MTT assay accurately assesses the 
ability of doxorubicin to inhibit viability (Figure 2.2B).  
To determine whether the effect of STI571 on viability was specific to the 
tetrazolium-based assay, we assessed the effect of STI571 treatment on the viability of 
435s/M14 and MDA-MB-468 cells using a different assay, CellTiter-Glo (CTG; Promega; 
Fitchburg, WI). CellTiter-Glo is a luminescent assay that quantitates the amount of 
cellular ATP present, which reflects the number of metabolically active, viable cells. 
Luciferase enzymatic activity requires ATP; therefore, the amount of luminescent signal 
is proportional to the amount of ATP present in the lysate. Treatment of 435s/M14 and 
MDA-MB-468 cells with STI571 resulted in a decrease in CellTiter-Glo luminescence 
(Figure 2.2C) consistent with tritiated thymidine and caspase assays (Figure 2.1), 
although the decrease in luminescence was not as great as one would expect given the 
large effect of STI571 on proliferation and apoptosis. However, the CellTiter-Glo assay 
did detect a decrease in viability that was not observed with the MTT assay. 
 
 2.3.2 STI571 sensitizes MDA-MB-468 cells to paclitaxel. 
We previously showed that a variety of breast cancer cell lines containing highly 
active Abl family kinases are sensitive to STI571, which inhibits cell proliferation in 
serum and serum-free conditions [39]. In this chapter, we utilized three of the cell lines 
that we previously characterized: BT-549, which has highly active c-Abl and Arg, MDA- 
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Fig. 2.2. STI571 interferes with the ability of the MTT assay to measure cell 
viability. 435s/M14 melanoma cells and MDA-MB-468 breast cancer cells were plated 
in 96-well dishes in triplicate, the media was replaced the next day with media containing 
STI571 (A,C) or doxorubicin (B), and 72h later the cells were used either in MTT (A,B) 
or CellTiter-Glo (C) viability assays. Experiments shown are mean±SEM for three 
independent experiments. Some error bars are too small to be visualized. *p<0.05, 
**p<0.005, ***p<0.001 using Student t-tests. 
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MB-231, which has highly active c-Abl, and MDA-MB-468, which has highly active Arg 
and also expresses another STI571 target, c-Kit [38]. To determine whether STI571 
sensitizes breast cancer cells to conventional chemotherapeutic agents, we treated the 
above cell lines with vehicle, STI571, chemotherapeutic drug, or 
STI571+chemotherapeutic drug, and assessed the effect on viability, proliferation, and 
apoptosis. First, we tested the taxane, paclitaxel, a frequently used breast cancer drug, 
which promotes assembly of microtubules from tubulin dimers, leading to 
hyperstabilization and decreased depolymerization, thereby preventing microtubule 
reorganization, which is essential for interphase and mitotic cellular functions [153]. 
Breast cancer cells were treated with STI571 and paclitaxel alone or in combination, and 
viability was assessed using the CellTiter-Glo assay, which quantitates ATP, a measure 
of metabolically active cells. Combination indices (CI), a measure of how well the drugs 
act together, were determined with CalcuSyn software, using STI571 and paclitaxel dose 
response curves (Table 2.1; data not shown). CI values that are greater than one 
indicate drug antagonism, values equal to one indicate that the drugs act in an additive 
fashion, and values that are less than one indicate drug synergism.  
In MDA-MB-231 and BT-549 cells, treatment with STI571 antagonized the effects 
of paclitaxel on viability (Figure 2.3A, B; Table 2.1), whereas in MDA-MB-468 cells, 
STI571 slightly sensitized the cells to paclitaxel in an additivesynergistic manner 
(Figure 2.3C; Table 2.1). To determine whether STI571 sensitized MDA-MB-468 cells to 
paclitaxel by inhibiting proliferation, we performed tritiated thymidine assays. Since 
tritiated thymidine assays are extremely sensitive, low doses of the drugs have a very 
dramatic effect, and thus low doses were utilized in order to accurately assess IC50 
values. We observed a dose-dependent decrease in proliferation mediated by STI571 
and paclitaxel alone in MDA-MB-468 cells, and the combination of the two drugs 
produced additive effects (Figure 2.3D; Table 2.1). To determine whether apoptosis 
contributed to the additivesynergistic effects on viability, we measured two outcomes 
indicative of apoptosis: cleavage of PARP, a nuclear polymerase that is cleaved from 
115 kDa to 89 kDa during apoptosis [158]; and quantitation of caspase-3/7 activities 
using a luminescent caspase assay, Caspase-Glo (Promega; Madison, WI). The 
caspase-3/7 proluminescent substrate contains the signature DEVD peptide sequence. 
Lysed cells release active caspase-3 or -7, which cleaves the DEVD substrate from 
aminoluciferin, and the oxidation of luciferin by luciferase produces light. The amount of 
light produced is proportional to the amount of caspase activity. STI571 had no effect on  
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Table 2.1. Combination indices for STI571/chemotherapeutic combinations. 
Combination indices were determined using CalcuSyn software and dose response 
curves for STI571 and chemotherapeutic drugs (data not shown). Values shown are 
representative of three independent experiments. Values greater than one indicate 
antagonism; values equal to one indicate additivity; and values less than one indicate 
synergism. MCE=mechlorethamine. 
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Figure 2.3. Paclitaxel has additive or antagonistic effects with STI571 in breast 
cancer cells. (A-C) Cells were plated in triplicate in 96-well dishes, the media was 
replaced the next day with media containing drugs, and three days later viability was 
assessed by CellTiter-Glo Assay. Experiments were performed three times in triplicate, 
and representative experiments are shown. Data are expressed as a percentage of 
values obtained from vehicle-treated cells. Mean±SEM. Some error bars are too small to 
be visualized. IC50 values are mean±SEM for three independent experiments. (D) MDA-
MB-468 cells were plated in 24-well dishes in triplicate, drug treated the next day, and 
proliferation was assessed 72h later by tritiated thymidine assay. Experiments were 
performed in triplicate three times, and a representative experiment is shown. 
Mean±SEM. Some error bars are too small to be visualized. IC50 values are mean±SEM 
for three independent experiments. *p<0.05, **p<0.005 using Student's t-tests. 
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the ability of paclitaxel to induce PARP cleavage or activate caspase-3/7 (Figure 2.4A, 
B). Taken together, these data indicate that STI571 produces additivesynergistic 
effects with paclitaxel in MDA-MB-468 cells by decreasing proliferation, whereas STI571 
antagonizes the effects of paclitaxel in BT-549 and MDA-MB-231 cells. To identify the 
mechanism by which STI571 reduces proliferation of MDA-MB-468 cells treated with 
paclitaxel, we blotted lysates with antibodies to Akt, ERK1/2 (Extracellular Signal-
Regulated Kinase 1, 2), STAT3, and IκB, in order to assess whether activation of 
PI3K/Akt, Ras/ERK, STAT3, or NF-κB signaling pathways, which are involved in breast 
cancer cell proliferation and survival [93-95, 159, 160], are altered in the presence of 
STI571. IκB stability was not altered by STI571 and/or paclitaxel treatment (Figure 2.4B). 
Moreover, Akt phosphorylation was increased by paclitaxel treatment, which may be a 
mechanism by which cells resist the effects of paclitaxel; however STI571 had no effect 
on this upregulation (Figure 2.4B). Interestingly, STI571 induced phosphorylation of 
ERK1/2 and STAT3 (Figure 2.4B), which may be a mechanism by which cells resist 
STI571. Interestingly, treatment of cells with paclitaxel reduced the STI571-dependent 
induction of STAT3 and ERK1/2 phosphorylation (Figure 2.4B), indicating that paclitaxel 
may sensitize cells to STI571 by inhibiting STI571-dependent activation of STAT3 and 
ERK1/2. 
 
2.3.3 STI571 acts synergistically with cisplatin in BT-549 and MDA-MB-468 breast 
cancer cells to inhibit viability, proliferation, and survival. 
Cisplatin is not commonly used to treat breast cancer; however, there are a 
number of preclinical and clinical studies underway to test whether cisplatin may be 
efficacious [156]. Cisplatin, a DNA damaging agent, crosslinks guanine bases in DNA 
strands, which inhibits the ability of the strands to uncoil and separate, thereby blocking 
cell division [156]. DNA damaging agents such MMS (methyl methanesulfonate), 
mitomycin C, and cisplatin induce apoptosis of non-transformed fibroblasts by activating 
the nuclear pool of c-Abl [161]. Since cisplatin induces apoptosis by activating nuclear c-
Abl in fibroblasts, we hypothesized that STI571 treatment will inhibit cisplatin-induced 
activation of nuclear c-Abl, thereby antagonizing the effects of cisplatin. To our surprise, 
STI571 treatment of MDA-MB-468 cells reduced the cisplatin viability IC50 nearly 3-fold, 
and STI571 demonstrated synergism with cisplatin at multiple doses (Figure 2.5A; Table 
2.1; data not shown). STI571 sensitized BT-549 to cisplatin and moderately lowered the 
 33 
 
Figure 2.4. Paclitaxel inhibits STI571-induced phosphorylation of STAT3 and 
ERK1/2 in MDA-MB-468 cells. MDA-MB-468 cells were plated in 60mm dishes, treated 
with STI571 and/or paclitaxel the next day, and 40h later, detached and attached cells 
were lysed and apoptosis assessed by Caspase-Glo assay (A), or by Western blot with 
PARP and GAPDH antibodies (B). Mean±SEM from three independent experiments. 
Some error bars are too small to be visualized (A). PARP and GAPDH blots were 
stripped and probed with other antibodies (B). (A) Done in collaboration with S. Ganguly. 
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Figure 2.5. STI571 synergistically sensitizes MDA-MB-468 and BT-549 breast 
cancer cells to cisplatin. (A-C) Cells were plated, treated, and viability assessed as in 
Fig. 2.3A–C. Experiments were performed in triplicate 3 times, and representative 
experiments are shown. Mean±SEM. IC50 values are mean±SEM for 3 independent 
experiments. (D, E) Proliferation was assessed by tritiated thymidine assay as in Fig. 
2.3D. Graphs shown are representative of 3 experiments. Mean±SEM. IC50 values are 
mean±SEM for 3 independent experiments. (A-E) Done in collaboration with L. Fiore. 
*p<0.05, **p<0.005, ***p<0.001 using Student's t-tests. 
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IC50; however, at certain cisplatin doses (10µM, 15µM), strong synergy was observed 
(Figure 2.5B; Table 2.1). In contrast to BT-549 and MDA-MB-468 cells, STI571 slightly 
antagonized cisplatin in MDA-MB-231 cells (Figure 2.5C; Table 2.1).  
To determine the mechanism by which STI571 sensitizes BT-549 and MDA-MB-
468 cells to cisplatin, we assessed the effect of combination treatment on proliferation 
and apoptosis. In both BT-549 and MDA-MB-468 cells, STI571 synergized with cisplatin 
to inhibit proliferation (Figure 2.5D, E). In BT-549 cells, STI571 also dramatically 
sensitized cisplatin-treated cells to apoptosis, as seen by increased PARP cleavage and 
caspase-3/7 activity (Figure 2.6A, B), whereas in MDA-MB-468 cells, STI571 treatment 
did not increase cisplatin-mediated PARP cleavage or caspase-3/7 activity (Figure 2.6C, 
D). Taken together, these data indicate that although cisplatin induces apoptosis by 
activating nuclear c-Abl in non-transformed cells, inhibition of Abl family kinases using 
STI571 in BT-549 and MDA-MB-468 breast cancer cells does not prevent cisplatin from 
inhibiting viability, but rather sensitizes cells to cisplatin. In BT-549 cells, STI571 
synergizes with cisplatin to inhibit cell viability by affecting both proliferation and 
apoptosis, whereas in MDA-MB-468 cells, the synergistic effect of STI571+cisplatin on 
viability is due to decreased proliferation. In contrast, in MDA-MB-231 cells, STI571 
antagonized the effects of cisplatin (Figure 2.5C; Table 2.1), which suggests that there is 
something intrinsically different about the MDA-MB-231 cell line, which prevents STI571 
from sensitizing the cells to cisplatin.  
To determine the mechanism by which STI571 synergistically inhibits 
proliferation and induces apoptosis in cisplatin-treated BT-549 cells, we analyzed 
PI3K/Akt, ERK1/2, STAT3, and NF-κB signaling pathways. Interestingly, STI571 and 
cisplatin independently increased the stability of IκB (Figure 2.6A), which negatively 
regulates NF-κB signaling. However, STI571+cisplatin combination treatment did 
increase IκB stabilization (Figure 2.6A), suggesting that inhibition of NF-κB signaling is 
not a likely mechanism by which STI571 sensitizes BT-549 cells to cisplatin. Similarly, 
cisplatin treatment resulted in a significant reduction in STAT3 phosphorylation; 
however, addition of STI571 had no additional effect (Figure 2.6A). Significantly, STI571 
increased the ability of cisplatin to inhibit constitutive Akt phosphorylation (Figure 2.6A), 
which indicates that STI571 is likely to increase apoptosis by inhibiting activation of the 
PI3K/Akt pathway. STI571 treatment also increased phosphorylation of ERK2, and 
cotreatment with cisplatin further increased ERK2 phosphorylation (Figure 2.6A). 
Activation of ERK2 by STI571 and cisplatin could be a mechanism by which BT-549  
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Figure 2.6. Cisplatin and STI571 synergize to induce apoptosis in BT-549 cells. BT-
549 and MDA-MB-468 cells were plated in 60mm dishes, treated with STI571 and/or 
cisplatin the next day, and 40h later, detached and attached cells were lysed and blotted 
with antibodies to PARP and GAPDH (A, C) or caspase-3/7 activity was assessed by 
Caspase-Glo assay from duplicate samples (B, D). PARP and GAPDH blots were 
stripped and reprobed with other antibodies (A, C). Experiments shown are 
representative of three independent experiments. Mean±SEM. (B-left, D). Mean±SEM of 
three independent experiments where STI571 alone is normalized to untreated, and 
Cis+STI571 is normalized to cisplatin alone (B-right). Some error bars are too small to 
be seen. (A, C, D) Done in collaboration with S. Ganguly. **p<0.01, ***p<0.001 using a 
Student's t-test. 
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cells resist the effects of STI571 and cisplatin. However, it is also possible that ERK2 
upregulation is a mechanism by which both drugs inhibit proliferation and induce 
apoptosis, since STI571 treatment of BCR-Abl+ CML cells increases ERK1/2 activity, 
and treatment with a MEK1/2 inhibitor increases suppression of CML progenitors, and 
sensitizes cells to STI571-dependent apoptosis [162, 163]. Interestingly, in MDA-MB-468 
cells, STI571 and cisplatin had no effect on IκB stability or Akt phosphorylation, and 
similar to BT-549 cells, STI571 increased ERK2 activation in a synergistic manner with 
cisplatin (Figure 2.6C). In addition, STI571 increased STAT3 phosphorylation, and 
cisplatin treatment decreased the STI571-dependent effect (Figure 2.6C). Therefore, 
cisplatin may synergize with STI571 in MDA-MB-468 cells by inhibiting the STI571-
dependent increase in STAT3 phosphorylation and/or by increasing ERK2 
phosphorylation. 
 
2.3.4 STI571 chemosensitizes MDA-MB-231 cells to camptothecin. 
Camptothecin binds topisomerase I, and prevents it from religating DNA, which 
results in single strand breaks in DNA, and camptothecin also stabilizes the 
topoisomerase I/DNA complex so that single strand nicks result in double strand breaks 
[154]. STI571 sensitized MDA-MB-468 and BT-549 cells to camptothecin in an additive 
fashion, and there was a 2-fold reduction in the IC50 in the presence of STI571 (Figure 
2.7A, B; Table 2.1). In MDA-MB-231 cells, STI571 had an additiveantagonistic effect 
with camptothecin, when camptothecin was added at the same time as STI571 (Figure 
2.7C; Table 2.1). However, when MDA-MB-231 cells were treated with camptothecin 24 
hours prior to addition of STI571 (alternate dosing), STI571 synergistically sensitized 
cells to camptothecin, reducing the camptothecin IC50 5-fold (Figure 2.7D; Table 2.1). An 
alternate dosing regimen also was tested with STI571 and other chemotherapeutic 
agents in MDA-MB-231 cells, and a similar response was not noted (data not shown), 
indicating that the effect of alternate dosing is specific for the STI571+camptothecin 
combination. Similarly, synergistic effects of STI571 and camptothecin were observed on 
the proliferation of MDA-MB-231 cells, using an alternate dosing regimen (Figure 2.7E; 
Table 2.1). In MDA-MB-468 cells, STI571 also sensitized the cells to the anti-proliferative 
effects of camptothecin, and synergized with camptothecin at higher doses (0.035µM) 
(Figure 2.7F; Table 2.1).  
To determine whether STI571 increases the ability of camptothecin to induce 
apoptosis, PARP and caspase-3/7 assays were performed. In MDA-MB-231 cells, 
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Figure 2.7. STI571 and camptothecin synergize to inhibit the viability and 
proliferation of MDA-MB-231 cells when utilizing an alternate dosing schedule. (A-
D) MDA-MB-468, BT-549, and MDA-MB-231 cells were plated, treated as described in 
Fig. 2.3A–C, and viability assessed. For alternate dosing experiments, MDA-MB-231 
cells were plated in triplicate in 96-well dishes, camptothecin was added the next day, 
and the following day, the media was changed and camptothecin and STI571 were 
added. Cells were harvested for the CellTiter-Glo assay 72h later (D). Experiments were 
repeated three times, and representative experiments are shown. Mean±SEM IC50 
values are mean±SEM for three independent experiments. (E) MDA-MB-231 cells were 
plated in 24-well dishes, and treated for 24h with camptothecin alone, followed by 72h of 
STI571+camptothecin, and tritiated thymidine incorporation was measured. (F) MDA-
MB-468 cells were set-up and treated as described in Fig. 2.3D, and tritiated thymidine 
incorporation assessed. Experiments were repeated three times, and representative 
experiments are shown. Mean±SEM. IC50 values are mean±SEM for three independent 
experiments. *p<0.05, **p<0.01 using Student's t-tests. 
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STI571 had no effect on the ability of camptothecin to induce apoptosis (Figure 2.8A, B), 
whereas in MDA-MB-468 cells, STI571 antagonized the apoptotic effects of 
camptothecin (Figure 2.8C, D). Thus, in MDA-MB-468 cells, STI571 synergistically 
increases the ability of camptothecin to inhibit proliferation, while it only has additive 
effects on viability. This is likely due to the fact that STI571 antagonizes the ability of 
camptothecin to induce apoptosis, resulting in a decreased overall effect on viability. In 
MDA-MB-231 cells, synergistic effects of STI571 and camptothecin were observed both 
in proliferation and viability assays, whereas STI571 had no effect on apoptosis, 
indicating that camptothecin inhibits the viability of MDA-MB-231 cells solely by affecting 
cell proliferation.  
In MDA-MB-231 cells, STI571 and camptothecin had little effect on STAT3 
phosphorylation, Akt was not constitutively phosphorylated in this cell type, as a band 
the correct size was not detected, and ERK1/2 phosphorylation was decreased by 
camptothecin treatment, but this inhibition was not enhanced by STI571 (Figure 2.8A). 
Conversely, the stability of IκB was enhanced in MDA-MB-231 cells treated with STI571 
or camptothecin, and the combination regimen further increased IκB stability (Figure 
2.8A). These data indicate that inhibition of NF-κB signaling is a likely mechanism by 
which STI571 sensitizes MDA-MB-231 cells to the anti-proliferative effects of 
camptothecin. In MDA-MB-468 cells, STI571 induced a modest decrease in Akt 
phosphorylation; however, this inhibition was not reproducible and camptothecin had no 
additional effect on Akt phosphorylation (Figure 2.8C). Interestingly, STAT3 
phosphorylation was induced by STI571, and treatment with camptothecin prevented 
this upregulation (Figure 2.8C), similar to what was observed in MDA-MB-468 cells 
treated with paclitaxel (Figure 2.4B). These data indicate that camptothecin may 
synergize with STI571 to inhibit proliferation in MDA-MB-468 cells by preventing STI571-
dependent upregulation of STAT3. ERK1/2 also was upregulated by STI571 treatment 
and addition of camptothecin increased this upregulation (Figure 2.8C), similar to what 
was observed in BT-549 cells treated with STI571 and cisplatin (Figure 2.6A). 
 
2.3.5 STI571 synergistically sensitizes MDA-MB-468 cells to 5-fluorouracil. 
5-fluorouracil (5-FU) is an anti-metabolite; FUTP incorporates into RNA, FdUTP 
incorporates into DNA, and FdUMP forms a complex with thymidylate synthase [155]. 5-
FU is incorporated in the place of purines or pyrimidines, and prevents purine/pyrimidine 
incorporation into DNA during S-phase, inhibiting cell division [155]. 5-FU also inhibits  
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Figure 2.8. STI571 synergizes with camptothecin to increase the stability of IκB in 
MDA-MB-231 cells, but STI571 has no effect on the ability of camptothecin to 
induce apoptosis. Cells were plated in 60mm dishes, treated with STI571 and/or 
camptothecin the next day, and 40h later, detached and attached cells were lysed and 
blotted with antibodies to PARP and GAPDH (A, C) or caspase-3/7 activity was 
assessed by Caspase-Glo assay (B, D). Mean±SEM for three independent experiments. 
(D) Done in collaboration with S. Ganguly. 
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thymidine incorporation into DNA, which inhibits DNA/RNA synthesis [155]. STI571 
sensitized MDA-MB-468 cells to 5-FU in a synergistic manner only at higher doses of 5-
FU (100–500µM), but had additive/antagonistic effects at lower doses (Figure 2.9A; 
Table 2.1). These data indicate that STI571 may kill or prevent the proliferation of a 
small population of MDA-MB-468 cells that are intrinsically resistant to 5-FU and survive 
high doses of the drug. In contrast, in BT-549 and MDA-MB-231 cells, STI571 
antagonized the effects of 5-FU on cell viability (Figure 2.9B, C; Table 2.1). Interestingly, 
although STI571 reduced the viability of 5-FU-treated MDA-MB-468 cells in a synergistic 
manner, synergism was not observed in proliferation assays, and in fact STI571 actually 
antagonized the effect of 5-FU on proliferation at several 5-FU doses (e.g. 1.25µM, 
3.5µM; Figure 2.9D; Table 2.1). This may be due to the fact that lower doses of 5-FU 
were utilized in proliferation assays. To test this hypothesis, we repeated the proliferation 
assays using high doses of 5-FU, and indeed, STI571 synergized with high doses of 5-
FU to inhibit proliferation (Figure 2.9E; Table 2.1). These data confirm that STI571 
induces synergism by preventing the proliferation of cells that survive high doses of 5-
FU. We performed PARP and caspase-3/7 assays to determine whether STI571 also 
reduces the viability of MDA-MB-468 cells by increasing apoptosis. Significantly, STI571 
dramatically sensitized MDA-MB-468 cells to apoptotic death induced by high doses of 
5-FU (Figure 2.10A, B). Thus, STI571 sensitizes MDA-MB-468 cells to 5-FU by 
increasing its ability to induce apoptosis as well as by inhibiting proliferation, and STI571 
may specifically target residual cells that are resistant to 5-FU.  
STI571 did not increase IκB stability in MDA-MB-468 cells treated with 5-FU 
(Figure 2.10A) nor did STI571 alter Akt phosphorylation, indicating that STI571 does not 
increase apoptosis or reduce proliferation by inhibiting NF-κB or PI3K/Akt signaling. 
However, as was observed in MDA-MB-468 cells treated with cisplatin (Figure 2.6C), 
STI571 increased STAT3 phosphorylation (Figure 2.10A), and addition of 5-FU 
prevented STI571-dependent STAT3 upregulation (Figure 2.10A), indicating that this 
may be a mechanism by which the combination treatment inhibits proliferation. In 
addition, ERK1/2 phosphorylation was dramatically increased in the combination 
treatment regimen, which indicates that the Ras/ERK signaling may also be involved in 
the antiproliferative response (Figure 2.10A). 
  
 43 
 
Figure 2.9. STI571 synergizes with high doses of 5-fluorouracil in MDA-MB-468 
cells, while STI571 antagonizes the effects of 5-fluorouracil in BT-549 and MDA-
MB-231 cells. (A-C) Cells were plated, treated with STI571 and/or 5-fluorouracil for 96h, 
and viability assessed as in Fig. 2.3A. Experiments were repeated three times, and 
representative experiments are shown. Mean±SEM. IC50 values are mean±SEM for 
three independent experiments. (D,E) MDA-MB-468 cells were set-up and treated with 
STI571 and/or 5-FU for 72 (E) or 96h (D), and tritiated thymidine incorporation assessed. 
Experiments were repeated three times, and representative experiments are shown. 
Mean±SEM. IC50 values are mean±SEM for three independent experiments. (A) Done in 
collaboration with C. Holler and L. Fiore. (C) Done in collaboration with E. Park. (D) 
Done in collaboration with S. Ganguly. *p<0.05 using a Student's t-test.  
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Figure 2.10. STI571 increases the ability of 5-FU to induce apoptosis. (A) PARP 
cleavage, western blots, and (B) caspase-3/7 activity were assessed as described in 
Fig. 2.4. Mean±SEM for three independent experiments. (B-left). Mean of three 
independent experiments where STI571 alone is normalized to untreated, and 5-
FU+STI571 is normalized to 5-FU alone (B-right). Some error bars are too small to be 
seen. (A, B) Done in collaboration with S. Ganguly. *p<0.05, **p<0.01 using a Student's 
t-test. 
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2.3.6 STI571 strongly antagonizes the effects of mechloroethamine in all breast 
cancer cell lines. 
Mechlorethamine, a metabolite of cyclophosphamide, is an alkylating agent that: 
1) attaches alkyl groups to DNA bases, which results in DNA fragmentation; 2) induces 
DNA damage by forming crosslinks that prevent DNA strands from separating; and 3) 
induces mispairing of nucleotides, which leads to mutations [164]. Interestingly, STI571 
strongly antagonized the effects of mechloroethamine on viability in all breast cancer cell 
lines examined (Figure 2.11; Table 2.1), which indicates that Abl family kinases or 
another STI571 target is likely to be required for the action of mechloroethamine in 
breast cancer cells. 
 
2.3.7 MDA-MB-468 and MDA-MB-231 cells have similar levels of nuclear and 
cytoplasmic c-Abl. 
In MDA-MB-231 cells, STI571 had antagonistic effects with all chemotherapeutic 
agents examined except for camptothecin. In contrast, in MDA-MB-468 cells, STI571 
had either additive or synergistic effects with all the chemotherapeutic agents examined, 
except for mechloroethamine. DNA damaging agents induce apoptosis in non-
transformed fibroblasts by activating the nuclear pool of c-Abl [161]. Thus, STI571, which 
is likely to inhibit nuclear c-Abl, could antagonize the effects of chemotherapeutic agents 
if there is large pool of c-Abl localized in the nucleus. To determine whether MDA-MB-
231 cells have higher levels of nuclear c-Abl than MDA-MB-468 cells, we performed 
subcellular fractionation. Both cell lines contained high levels of c-Abl in the cytoplasm, 
and lower levels of c-Abl in the nucleus (Figure 2.12A). These data indicate that 
increased expression of nuclear c-Abl is not likely to be the reason that MDA-MB-231 
cells are more resistant to the effects of STI571 in combination with chemotherapeutic 
agents than MDA-MB-468 cells (Figure 2.12A). 
 
2.4 Discussion 
In this chapter, we demonstrate for the first time that STI571 sensitizes breast 
cancer cells containing highly active Abl family kinases to several conventional 
chemotherapeutic agents. Interestingly, sensitization is cell type-specific in that STI571 
synergizes with paclitaxel, cisplatin, and 5-FU in MDA-MB-468 cells, while STI571 only 
synergizes with cisplatin in BT-549 cells, and with camptothecin in MDA-MB-231 cells. 
These data indicate that there are intrinsic differences between the three cell lines, 
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Figure 2.11. STI571 and mechloroethamine are antagonistic in all breast cancer 
cell lines. Cells were plated, treated, and viability assessed as in Fig. 2.3A. Experiments 
were repeated three times, and representative experiments are shown. Mean±SEM. IC50 
values are mean±SEM for three independent experiments. (A-C) Done in collaboration 
with C. Holler. 
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Figure 2.12. Abl kinases are preferentially activated and reside primarily in the 
cytoplasm. (A, B) Cells were fractionated using NE-PER (Pierce; Rockford, IL) into 
cytoplasmic/membrane and nuclear fractions. Equal percentages of the fractions were 
loaded on an SDS-PAGE gel, and blotted with c-Abl antibody (A, B) or analyzed by in 
vitro kinase assay (B). Lysates also were blotted with antibodies to α-tubulin to assess 
the purity of the cytoplasmic fractions, and lamin A/C to assess nuclear fraction purity. 
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which govern their susceptibility to STI571/conventional chemotherapy combination 
regimens. Interestingly, the three cell lines all have fairly equal sensitivities to the effect 
of STI571 alone on viability (data not shown). When tritiated thymidine incorporation and 
growth kinetic assays are used to measure the sensitivity of the cell lines to STI571, BT-
549 and MDA-MB-468 cells are equally sensitive, while STI571 takes more time to 
inhibit the growth of MDA-MB-231 cells [39]. However, the overall effect after 4–5 days 
of STI571 treatment is similar between the three cell lines [39]. Activation of particular 
signaling pathways or increased expression of drug transporters may explain the 
differential sensitivity of the cell lines to different STI571/chemotherapeutic combination 
regimens. However, regardless of the mechanism, our data are significant because they 
indicate that STI571 may be effective in certain combination regimens.  
Tetrazolium salt assays (MTT, MTS, XTT) are often used to screen cell lines for 
sensitivity to drugs, due to the fact that they are relatively inexpensive, are quick, easy, 
and quantitative. However, our data clearly show that STI571 cannot reliably be used in 
MTT assays when utilizing doses of 1−10µM (Figure 2.2; data not shown), as it 
interferes with the assay. MTT assays have frequently been used to study the effects of 
STI571. In leukemic cells, BCR-Abl is much more sensitive to STI571, and doses of 
0.1−1µM inhibit BCR-Abl phosphorylation and/activity [32]. At these doses, STI571 may 
not affect the MTT assay or may not affect it to as great an extent as when higher doses 
are used. However, we and others have shown that higher doses of STI571 (5−10µM) 
are required to inhibit the activity of endogenous Abl family kinases in nontransformed 
cells and in solid tumor cell lines [38, 165]. Therefore, MTT assays cannot reliably be 
utilized to determine the effect of STI571 on the viability of solid tumor cells if doses >1 
µM are utilized, as STI571 interferes with the assay, which may lead to erroneous 
conclusions.  
Previously, we showed that the effects of STI571 on proliferation, survival, 
anchorage-independent growth, and invasion of breast cancer cells containing highly 
active Abl family kinases were c-Abl/Arg-dependent as siRNA produced similar results 
[38, 39]. In addition, except for MDA-MB-468 cells, cell lines containing high c-Abl/Arg 
activities were sensitive to STI571 even though they did not express other STI571 
targets (c-Kit or PDGF (platelet-derived-growth factor) receptors) [38]. To determine 
whether STI571 synergizes with chemotherapeutic agents specifically by inhibiting Abl 
family kinases, we attempted to test whether silencing Abl family kinases sensitizes cells 
to the chemotherapeutic drugs. Since cells must be transfected with siRNAs or shRNAs 
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prior to being treated with chemotherapeutic agents, these experiments were 
unsuccessful, as silencing Abl family kinases significantly slowed cell growth, thereby 
decreasing the effectiveness of the chemotherapeutic drugs, which act on highly 
proliferating cells (data not shown). These data highlight the importance of inhibiting Abl 
family kinases at the same time or after chemotherapeutic drug administration. In order 
to inhibit Abl family kinases during this time frame, cell lines expressing inducible 
shRNAs must be obtained; a laborious process which often results in inefficient 
silencing. Regardless of whether or not STI571 targets Abl family kinases to sensitize 
breast cancer cells to chemotherapeutic agents, the data we obtained are still significant, 
as they indicate that use of STI571 with some chemotherapeutic agents may be a viable 
treatment option for some STI571-sensitive breast cancers. Clearly, the treatment 
combinations will require individualization since some cells are responsive to certain 
combinations and others are not. STI571 also has been shown to synergize with 
camptothecin in small cell lung cancer cells [166], cisplatin in head and neck cancer 
[167] and lung cancer cells [168], carboplatin in ovarian [169], paclitaxel in ovarian [169], 
and 5-FU in colon cancer cells [170]. The target of STI571 in these cell lines also has not 
been proven, most likely due to the difficulty in using siRNA/shRNA approaches.  
Interestingly, although STI571 synergizes with both cisplatin and 5-FU in MDA-
MB-468 cells, it does so by different mechanisms. STI571 sensitizes MDA-MB-468 cells 
to cisplatin by increasing its ability to inhibit proliferation. In contrast, STI571 sensitizes 
MDA-MB-468 cells to high doses of 5-FU by dramatically increasing its ability to induce 
apoptosis, and by targeting cells that are resistant to high doses of 5-FU. These data 
demonstrate that STI571 acts not only as a cytostatic agent but also as a cytotoxic agent 
in breast cancer cells. The different mechanisms of action of the chemotherapeutic 
drugs are likely to affect the ability of STI571 to synergize with the chemotherapeutic 
agents. Previously, we showed that STI571 slows serum-induced G1S progression of 
breast cancer cells containing highly active Abl family kinases [38, 39]. Thus, by slowing 
S-phase progression, STI571 may prevent incorporation of 5-FU into DNA in S-phase 
resulting in drug antagonism at low 5-FU doses. Such an effect may not be observed at 
high doses, as STI571 may specifically target cells that are resistant to high doses of 5-
FU, perhaps by inhibiting a drug transporter which effluxes 5-FU. Indeed, STI571 inhibits 
and/or is a substrate for ABCB1 and ABCG2/BCRP [148, 171-175], and 5-FU is a 
substrate of ABCG2 [176] and ABCC5 [177].  
Significantly, STI571 synergizes with cisplatin in both MDA-MB-468 and BT-549 
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cells. In MDA-MB-468 cells, STI571 increases the ability of cisplatin to inhibit 
proliferation, whereas in BT-549 cells, STI571 enhances both the anti-proliferative and 
pro-apoptotic effects of cisplatin. These data are interesting because previous data 
indicated that cisplatin induces apoptosis of non-transformed fibroblasts by activating the 
nuclear pool of c-Abl [161]. Clearly, cisplatin does not induce apoptosis of BT-549 breast 
cancer cells via this mechanism, as STI571 would be predicted to prevent cisplatin-
induced apoptosis. However, unlike fibroblasts, breast cancer cells have highly active 
Abl family kinases. Preliminary data in another solid tumor cell line, 435s/M14, which 
also contains highly active Abl family kinases [38, 39], show that the pool of c-Abl that is 
highly active is primarily the cytoplasmic/membrane pool and not the nuclear pool 
(Figure 2.12B). These data are not particularly surprising given that activation of nuclear 
c-Abl is associated with apoptosis rather than proliferation, and that c-Abl is activated by 
cytoplasmic/membrane receptor tyrosine kinases and Src kinases in breast cancer cells 
[38, 39]. Thus, STI571 treatment of breast cancer cells may preferentially inhibit the 
highly active cytoplasmic/membrane c-Abl pool as opposed to the smaller, less-active 
nuclear pool. In addition, Arg is not located in the nucleus, Arg is the only Abl family 
kinase that is highly active in MDA-MB-468 cells, and in BT-549 cells, although both c-
Abl and Arg have elevated activities, Arg activity is much higher than c-Abl [38, 39]. 
Therefore, it is possible that STI571 synergizes with cisplatin in these two cell lines by 
targeting Arg. In contrast, cisplatin has less of an effect in MDA-MB-231 cells, which 
have more highly active c-Abl than Arg. MDA-MB-231 cells, in general, are more 
resistant to STI571/chemotherapeutic combination regimens, and this could be due to 
the fact that c-Abl, rather than Arg, is the main Abl family kinase activated in these cells 
[38, 39].  
Although STI571 has cytotoxic effects in combination with cisplatin in BT-549 
cells and 5-FU in MDA-MB-468 cells, the molecular mechanisms are different. In BT-549 
cells, STI571 increases the ability of cisplatin to inhibit constitutive Akt phosphorylation, 
while in MDA-MB-468 cells treated with 5-FU, STI571 does not alter Akt 
phosphorylation. As mentioned earlier, STI571 may inhibit a 5-FU transporter in MDA-
MB-468 cells, thereby sensitizing resistant cells to 5-FU. Future experiments will address 
this possibility. In MDA-MB-231 cells, STI571 sensitizes cells to camptothecin most likely 
by increasing the stability of IκB, thereby inhibiting NF-κB signaling which promotes 
proliferation. In MDA-MB-468 cells, STI571 treatment causes increased phosphorylation 
of STAT3, and treatment with paclitaxel, cisplatin, camptothecin or 5-FU inhibits the 
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STI571-dependent STAT3 activation. Since STAT3 induces proliferation of breast 
cancer cells, MDA-MB-468 cells may resist the effects of STI571 by activating STAT3, 
and treatment with conventional chemotherapeutic agents, which prevents this 
upregulation, may prevent resistance. Thus, inhibition of STAT3 activation may be a 
common mechanism by which STI571 synergizes with chemotherapeutic agents to 
inhibit the proliferation of MDA-MB-468 cells. Taken together, these data indicate that 
the mechanisms by which STI571 potentiates the effects of chemotherapeutic agents 
are not only cell type-specific but also are specific for particular 
STI571/chemotherapeutic combinations.  
In summary, our data demonstrate that STI571 cooperates with several 
conventional chemotherapeutic agents to inhibit viability by decreasing proliferation 
and/or increasing apoptosis. These data indicate that STI571 may be an effective agent 
in combination chemotherapy for treating breast cancer patients with ER−, PR− tumors 
that have active Abl family kinases. However, our data indicate that the cellular milieu 
dictates which cells will be sensitive to particular therapeutic combinations, which 
emphasizes the need to determine empirically, which patients will respond to particular 
STI571/chemotherapeutic combinations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Jonathan T. Sims 2012 
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CHAPTER THREE 
ABL FAMILY KINASES PROMOTE CHEMORESISTANCE TO DOXORUBICIN 
3.1 Introduction 
The Abl family of non-receptor tyrosine kinases (c-Abl/Arg) has been indicted as 
a causative force in leukemia for more than three decades; however, their role in solid 
tumors has only recently been described. We previously demonstrated that activated Abl 
family kinases drive the proliferation, invasion, cell survival, and anchorage-independent 
growth of aggressive breast cancer cells [38, 39]. Breast cancer is responsible for 26% 
of newly diagnosed cancer cases for women each year, and is the most common fatal 
cancer for women age 20-59 [88]. Treatment options for the most aggressive forms of 
breast cancer, labeled as “triple negative” status (ER- (estrogen receptor), PR- 
(progesterone receptor), and Her2-), are limited due to a lack of efficacious targets and 
development of chemoresistance [178, 179]. We demonstrated in chapter 2 that 
inhibitors of Abl family kinases abrogate resistance to a number of commonly used 
chemotherapeutics (i.e., 5-fluoruracil, cisplatin, paclitaxel, camptothecin) in a panel of 
breast cancer cells [180]; however, the anthracycline, doxorubicin, which is considered 
front-line therapy for breast cancer, was not tested in that study. Though doxorubicin is 
initially highly effective in a majority of patients, resistance arises in advanced, 
metastatic cases [179, 181]; therefore, it is imperative to identify new therapeutic targets 
in these difficult to treat patients.  
Recently, we also provided the first evidence that Abl family non-receptor 
tyrosine kinases (c-Abl, Arg) are activated in a subset of primary melanomas and in 
some melanoma cell lines, and promote many processes involved in melanoma 
progression such as proliferation, invasion, survival, and metastasis [50]. There has 
been virtually no change in one-year survival rates for patients with metastatic 
melanoma, and the number of newly diagnosed cases is increasing faster than with any 
other cancer [88]. Melanomas are highly resistant to all known chemotherapeutic agents; 
complete responses are observed in less than 5% of patients; and cells refractory to 
treatment are highly metastatic [182]. Chemotherapeutic agents spanning almost every 
class have been tested in clinical trials; however, none of these agents significantly 
impacts patient survival [116, 183]. Anthracyclines (i.e., doxorubicin, daunorubicin) are 
not routinely used to treat metastatic melanoma due to intrinsic resistance [142]. 
However, current treatment regimens (dacarbazine-DTIC or temozolamide-TMZ) are 
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also ineffective [182]. Chemotherapeutic resistance occurs via expression of multi-drug 
resistance transporters and by upregulation of anti-apoptotic signaling pathways [133, 
182]. Therapeutic strategies tailored to individuals and targeting multiple signaling 
pathways are likely to provide maximal therapeutic efficacy. 
Recurrent, metastatic disease occurs due to aberrant proliferation, invasion, and 
survival of cells at secondary sites. Melanoma progression is driven by transcription 
factors such as NF-κB and STAT3, which have major roles in melanoma survival and 
chemoresistance [114], and inhibiting expression of the anti-apoptotic proteins, XIAP 
and cIAP1, targets of NF-κB, promotes chemotherapy-induced cell death [84, 130]. 
Intrinsic resistance of malignant melanomas to DNA damage-inducing therapies also 
has been tied to activation of PI3K/Akt and B-Raf/ERK signaling pathways [68, 117], and 
co-targeting these pathways has been a major therapeutic focus for melanoma 
treatment [72]. This is especially important since Akt is a key promoter of melanoma 
progression [184].  
Based on our data in both breast cancer and melanoma cells, demonstrating that 
activated c-Abl/Arg promote proliferation, invasion, and survival [38, 39, 50], we focused 
this chapter on testing whether c-Abl/Arg promote resistance to doxorubicin. 
Understanding the mechanisms underlying melanoma and breast cancer drug 
resistance is critical for developing new therapies to treat resistant/disseminated 
disease. We demonstrate that c-Abl/Arg inhibitors dramatically sensitize breast cancer 
and melanoma cells to doxorubicin, halting cell proliferation and dramatically inducing 
apoptosis. These data indicate that, in addition to inhibiting metastatic disease [50], c-
Abl/Arg inhibitors also are likely to prevent chemotherapeutic resistance.  
 
3.2 Materials and Methods 
3.2.1 Cell Lines and Reagents 
MDA-MB-435s cells were obtained from the University of North Carolina Tissue 
Culture Facility, and are a spindle-shaped, highly metastatic variant of MDA-MB-435 
cells (Chapel Hill, NC). Genetic analysis confirmed that these cells are identical to 
melanoma M14, and therefore, are referred to as 435s/M14 [50, 157]. A drug-resistant 
variant of 435s/M14 (435s/M14-DR) was created via step-wise treatment with increasing 
concentrations of doxorubicin (using a maximum dose of 100nM) [185].  435s/M14 and 
435s/M14-DR cells were cultured in DMEM/10% FBS (fetal bovine serum), + insulin 
(10µg/ml). WM3248 cells were obtained from Dr. Meenhard Herlyn (Wistar Institute, 
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Philadephia, PA). WM3248 cells were cultured in MCDB153 + L-15 (80:20 mixture, 
respectively)/2% FBS, + insulin (5µg/ml) + calcium chloride (1.68mM). BT-549 cells were 
cultured in DMEM/10% FBS. MDA-MB-468 cells were cultured in MEM/10% FBS, + 
sodium pyruvate (10µg/ml). STI571-resistant c-Abl/Arg constructs, in which the 
Threonine 315 residue was mutated to Isoleucine (AblT/ArgT; T315I) [186, 187], were 
purchased from GenScript. 
STI571 (Gleevec; imatinib mesylate) and nilotinib were obtained from Novartis 
(Basal, Switzerland). STI571 was dissolved in water (10mM) and stored at -80oC, while 
nilotinib (10mM) was dissolved in DMSO, and stored at 4oC. Doxorubicin was purchased 
from Sigma (St. Louis, MO). PARP (poly(ADP-ribose) polymerase; sc-8007) and α-
tubulin antibodies were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA); 
phospho-Crk/CrkL (Y221/Y207) was purchased from Cell Signaling Technology 
(Danvers, MA); and GAPDH antibody was obtained from BD Biosciences (Chicago, IL). 
Western blots were performed as described in the manufacturers’ protocols.  
 
3.2.2 CellTiter-Glo Viability Assay (Promega; Madison, WI) [180] 
Cells were plated in 96-well plates in triplicate in 100µl of medium, refreshed with 
media containing drugs the following day when cells were 30-40% confluent, and 
harvested 72h later. CellTiter-Glo reagent (100µl) was added to each well, the plates 
were rocked for 2’, incubated at room temperature for 10’, 100µl was removed from each 
well and transferred to an opaque 96-well plate, and luminescence  (total light emitted, 
10”/well) measured with a Synergy 2 microplate reader (Biotek; Winooski, VT). 
 
3.2.3 Proliferation Assays 
Tritiated thymidine assays [180]. Cells were plated in 24-well plates in triplicate, 
drug-treated the following day when cells were 30-40% confluent, and harvested after 
72h. Cells were pulsed with tritiated thymidine (2.5µCi; 2h), washed with PBS, incubated 
in 10% trichloroacetic acid, radioactivity was solubilized in 0.2N NaOH, and analyzed on 
a scintillation counter. Cell cycle analysis. Cells were plated in 100mm dishes, refreshed 
with media containing drugs the following day when cells were 30-40% confluent, and 
harvested after 72h. Cells were labeled with bromodeoxyuridine (BrdU, 10µM) for 1h at 
37°C, trypsinized, washed and permeabilized with ethanol (70%), stained with 
fluorescein isothiocyanate (FITC)-conjugated anti-BrdU antibody and propidium iodide 
(PI; 5µg/ml), and analyzed by fluorescence-activated cell sorting (FACS) using Cell 
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Quest software (BD Biosciences) and Modfit analysis (Verity Software House, Topsham, 
ME).  
 
3.2.4 Apoptosis Assays 
PARP cleavage [180]. Cells were plated in 60mm dishes, and treated with drugs 
the following day when cells were 30-40% confluent. After 40h, attached and detached 
cells were lysed in RIPA buffer (50mM Tris pH 7.5, 150mM NaCl, 1% Triton-X 100, 0.1% 
SDS, 1% sodium deoxycholate), protein was quantitated by Lowry DC (Bio-Rad; 
Hercules, CA), equal protein was loaded on SDS-PAGE gels, and blots were incubated 
with antibodies for PARP and GAPDH. Fluorescent Caspase-3/7 assay (Sigma; St. 
Louis, MO) [188]. Cells were plated in 6-well dishes in triplicate, drug-treated the 
following day when cells were 30-40% confluent, and attached and detached cells were 
lysed 40h later in 1X lysis buffer. Lysate (5µl) was incubated with substrate (200µl, 
diluted 1:3), and fluorescence detected at 360nm/460nm  (excitation/emission) with a 
Synergy 2 microplate reader (Biotek; Winooski, VT). Annexin-V FACS analysis.  Cells 
were plated in 100mm dishes, and treated with drugs the following day when cells were 
30-40% confluent. After 40h, cells were trypsinized, washed in DMEM (-phenol red, 
+Ca2+)/5% FBS, counted, and 1x105 cells were incubated with Annexin-V-APC (5µl) + 
propidium iodide (50µg/ml) for 15min before analysis by FACS. 
 
3.2.5 Statistics  
Statistical analyses were performed using Sigma Stat for Windows (Systat 
Software, Inc.; San Jose, CA). Combination Index (CI) values were calculated with 
CalcuSyn software (Biosoft; Cambridge, UK) using single drug and drug combination 
dose response curves. 
 
3.3 Results 
3.3.1 c-Abl/Arg promote melanoma and breast cancer cell viability in the presence 
of doxorubicin. 
We previously demonstrated that c-Abl and Arg are highly active in a wide array 
of aggressive melanoma and breast cancer cell lines, and drive proliferation, invasion, 
survival to nutrient deprivation and metastasis [38, 39, 50]. We further demonstrated that 
inhibitors of Abl family kinases abrogate resistance to a number of commonly used 
chemotherapeutics in a panel of breast cancer cells [180]. In this chapter, we wanted to 
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determine whether inhibition of Abl family kinases sensitizes invasive breast cancer and 
melanoma cells to doxorubicin and identify the mechanism by which this occurs. 
Doxorubicin acts primarily as a topoisomerase II inhibitor and induces DNA damage by 
stabilizing topoisomerase II, preventing religation of DNA following strand breakage 
[101]. Doxorubicin also induces DNA damage by intercalating into DNA, and has been 
shown to induce free radical formation [101].  
To test our hypothesis, we first treated cells with the c-Abl/Arg inhibitor, STI571, and 
doxorubicin, alone or in combination, and measured cell viability using the CellTiter-Glo 
assay, which quantitates ATP, a measure of metabolically active cells [180]. We 
observed that STI571+doxorubicin dramatically decreased viability of 435s/M14 and 
WM3248 melanoma (Figure 3.1A, C) and BT-549 and MDA-MB-468 breast cancer 
(Figure 3.1B, D) cells, all of which express highly active c-Abl/Arg [38, 50]. A dose of 
10µM STI571 was used for these studies because this physiologically relevant dose is 
required to effectively inhibit c-Abl/Arg kinase activities [38]. Of the cell lines tested, only 
MDA-MB-468 cells possess c-Kit, another target of the c-Abl inhibitors STI571 and 
nilotinib [38, 50].  This demonstrates that selective targeting of cell populations 
containing highly active c-Abl/Arg may yield dramatic clinical benefit to numerous 
aggressive cell types. Interestingly, melanoma cells were more resistant to doxorubicin 
than breast cancer cells; however, STI571 dramatically sensitized both cell types to 
doxorubicin (Figure 3.1A-435s/M14, IC50=0.41µM; Figure 3.1B-BT-549, IC50=0.066µM). 
CalcuSyn software was utilized to calculate combination indices (CI), which indicate 
whether the effect of the two drugs together is greater than either alone using the dose 
response curves for each drug and the combination (Figure 3.2A, B) [180]. A CI value 
less than one denotes drug synergism, equal to one signifies additivity, and greater than 
one indicates antagonism. Likewise, nilotinib, a second-generation c-Abl/Arg inhibitor 
that is more potent and more specific for c-Abl/Arg, sensitized 435s/M14 cells to 
doxorubicin (Figure 3.2A, C). We proceeded to demonstrate conclusively that STI571 
specifically targets c-Abl and Arg in these cells and that inhibition of these kinases is 
responsible for the observed synergism of STI571 with doxorubicin. We expressed 
STI571-resistant mutant forms of c-Abl and Arg (AblT/ArgT) in 293T cells, treated with 
STI571, and observed no decrease in phosphorylation of Crk/CrkL, a c-Abl/Arg substrate 
(Figure 3.3A). We proceeded to stably express AblT/ArgT constructs in 435s/M14 cells, 
treated with STI571+doxorubicin, and observed that AblT/ArgT expression rescued the 
synergistic decrease in cell viability observed with STI571+doxorubicin (Figure 3.3B).   
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Figure 3.1. c-Abl/Arg inhibitors sensitize breast cancer and melanoma cells to 
doxorubicin by inhibiting viability. (A) 435s/M14, (B) BT549, (C) WM3248, and (D) 
MDA-MB-468 cells were were plated in triplicate, treated with doxorubicin and STI571 
for 72h, and viability assessed by CellTiter-Glo. Mean±SEM for 3 independent 
experiments (left). Representative dose response curve (right). (C) Done in collaboration 
with J. Tepe. *0.01≤p<0.05, **0.001≤p<0.01, ***p<0.001.  
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Figure 3.2. c-Abl/Arg inhibitors dramatically sensitize breast cancer and 
melanoma cells to doxorubicin. (A, B) Graphical representation of combination 
indices obtained with CalcuSyn software (>1-antagonism; =1-additive; <1-synergism). 
Graph shown is representative of 3 independent experiments. (C) Parental (435s/M14) 
cells were treated with nilotinib and/or doxorubicin for 72h, and viability assessed by 
CellTiter-Glo (Promega). Mean±SEM for 3 independent experiments is shown (left). 
Dose response curve is representative of 3 independent experiments (right). *p<0.05. 
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Figure 3.3. c-Abl/Arg specifically promote resistance to doxorubicin. (A) 
Functionality of STI571-resistant c-Abl (AblT) and Arg (ArgT) was analyzed in 293T cells 
following 72h treatment with STI571 via Western blotting for pCrkL, a c-Abl/Arg subrate. 
(B) Cells expressing STI571-resistant mutant c-Abl (AblT) and Arg (ArgT) were treated 
with doxorubicin and/or STI571 (48h), and viability assessed. Representative experiment 
(left). Mean±SEM of 3 independent experiments: STI571 alone (right, top) and 
STI571+doxorubicin (right, bottom). (A) Performed by H. Bennett. *p<0.05, **p<0.01. 
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3.3.2 c-Abl/Arg inhibitors sensitize doxorubicin-resistant melanoma cells to 
doxorubicin.  
Although chemotherapeutic agents sometimes kill the majority of cells, residual, 
highly resistant cells often remain, which are very aggressive and metastatic. In order to 
mimic outgrowth of highly resistant, metastatic cells following treatment with 
chemotherapeutic agents, we cultured 435s/M14 melanoma cells with increasing 
concentrations of the chemotherapeutic drug, doxorubicin, over the course of 8 months 
(435s/M14-DR). 435s/M14-DR cells were highly resistant to doxorubicin (1µM reduced 
viability by 15% as compared to 80% in parental cells; Figure 3.4A). To determine 
whether c-Abl/Arg promote chemoresistance in 435s/M14-DR cells, cells were treated 
with doxorubicin and the c-Abl/Arg inhibitor, STI571, alone or in combination, and cell 
viability measured using the CellTiter-Glo assay. STI571 dramatically decreased the 
viability of highly resistant 435s/M14-DR cells treated with doxorubicin (Figure 3.4A, C). 
Nilotinib also dramatically sensitized 435s/M14-DR cells to doxorubicin, reducing cell 
viability (Figure 3.4B, C). Remarkably, the use of these two c-Abl/Arg inhibitors rendered 
acquired chemoresistant cells equally sensitive with parental cells to doxorubicin 
treatment (Figure 3.4A, data not shown).  
 
3.3.3 c-Abl/Arg promote proliferation and prevent apoptosis in melanoma and 
breast cancer cells exposed to doxorubicin.  
Since STI571+doxorubicin decreased cell viability, and viability is a balance of 
proliferation and apoptosis, we performed tritiated thymidine assays to determine the 
extent to which cell proliferation in the presence of doxorubicin was affected by Abl 
family kinase inhibition. We observed that STI571 synergized with doxorubicin to 
completely halt proliferation of melanoma (435s/M14 and WM3248; Figure 3.5A, C, E) 
and breast cancer (BT-549 and MDA-MB-468; Figure 3.5B, C, D) cell lines, as well as 
cells that had acquired advanced chemoresistance (Figure 3.5F).  We wanted to 
determine exactly how STI571 was synergizing with doxorubicin to decrease cell 
proliferation so we performed BrdU/PI cell cycle analysis on asynchronous parental 
435s/M14 cells and 435s/M14-DR cells to accurately assess the phases of the cell cycle 
in response to combination treatment. We observed a dramatic induction of G2/M arrest 
following treatment with doxorubicin and the c-Abl/Arg inhibitor, STI571 (Figure 3.6A, B). 
Notably, STI571 or low dose doxorubicin had little effect on the cell cycle of 435s/M14-
DR cells; however, STI571+doxorubicin induced a dramatic blockade of cells in G2/M, 
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Figure 3.4. c-Abl/Arg inhibitors dramatically synergize with doxorubicin to 
decrease highly resistant cell viability. (A, B) Parental (435s/M14) and doxorubicin-
resistant (435s/M14-DR) melanoma cells were plated in triplicate, treated with 
doxorubicin and STI571 (A) or nilotinib (B) for 72h, and viability assessed by CellTiter-
Glo. Mean±SEM for 3 independent experiments (left). Representative dose response 
curve is shown (right). *p<0.05, ***p<0.001. (C) Graphical representation of combination 
indices obtained with CalcuSyn software (>1-antagonism; =1-additive; <1-synergism). 
Graph shown is representative of 3 independent experiments. Some error bars are too 
small for visualization.  
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Figure 3.5. c-Abl/Arg promote proliferation of breast cancer and melanoma cells in 
the presence of doxorubicin. (A) 435s/M14 and (B) BT-549 cells were plated in 
triplicate, treated with STI571 and/or doxorubicin for 72h, and proliferation assessed by 
tritiated thymidine assay. Representative dose response curves (left) and mean±SEM for 
3 independent experiments (right) are shown. (C) Graphical representation of 
combination indices obtained with CalcuSyn software (>1-antagonism; =1-additive; <1-
synergism). Graph shown is representative of 3 independent experiments. (D) MDA-MB-
468 and (E) WM-3248 cells were plated in triplicate, treated with doxorubicin and/or 
STI571 for 72h, and proliferation assessed by tritiated thymidine assay. Graphs shown 
are representative experiments. (D) MDA-MB-468 - Dox (0.005µM)+STI571 (10µM) 
CI=1.1; Dox (0.01µM)+STI571 (10µM) CI=0.9; (E) WM3248 - Dox (0.005µM)+STI571 
(10µM) CI=0.72; Dox (0.03µM)+STI571 (10µM) CI=0.56. (F) 435s/M14-DR cells were 
plated in triplicate, treated with doxorubicin and/or STI571 for 72h, and proliferation 
assessed by tritiated thymidine assay. Representative dose response curves (left) and 
mean±SEM for 3 independent experiments (right) are shown. Some error bars are too 
small for visualization. (E) Done in collaboration with J. Tepe. **p<0.01, ***p<0.001. 
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using extremely low doxorubicin doses (30-60nM; Fig 3.6B). Next, we determined if the 
decrease in viability following doxorubicin+STI571 treatment was also due to an 
increase in apoptosis. To ascertain this, breast cancer (BT-549 and MDA-MB-468), 
melanoma (435s/M14 and WM3248), and acquired chemoresistant melanoma 
(435s/M14-DR) cells were treated with STI571+doxorubicin and assayed for caspase-
3/7 activity and PARP cleavage. STI571 alone modestly, but significantly, induced 
caspase-3/7 activity in all cell lines tested (Figure 3.7A-D). In both breast cancer and 
melanoma cells, STI571 potentiated doxorubicin-mediated caspase-3/7 activity (Figure 
3.7A, B). Whereas no significant apoptotic response to doxorubicin was observed in 
435s/M14-DR cells, STI571+doxorubicin dramatically induced caspase-3/7 activity 
(Figure 3.7C). Intriguingly, MDA-MB-468 cells underwent apoptosis in response to 
doxorubicin, but experienced no further sensitization upon co-treatment with STI571 
(Figure 3.7D), indicating that the potentiated decrease in MDA-MB-468 cell viability 
following STI571+doxorubicin treatment was primarily via inhibition of proliferation. We 
further demonstrated that STI571 enhanced doxorubicin-mediated apoptosis in 
435s/M14, WM3248, and 435s/M14-DR melanoma cells via Annexin-V FACS analysis 
(Figure 3.8A) and PARP cleavage assays (Figure 3.8B-D). In conclusion, c-Abl/Arg 
promote chemoresistance to doxorubicin across multiple cell types and in highly 
resistant melanoma cells by promoting proliferation and inhibiting apoptosis. 
 
3.4 Discussion 
In this chapter, we demonstrate that c-Abl/Arg inhibitors synergize with 
doxorubicin to inhibit proliferation, induce a G2/M block, and dramatically promote 
apoptosis of melanoma, breast cancer, and advanced chemoresistant melanoma cells. 
Currently melanoma essentially represents an untreatable disease, with little to no 
improvement having been observed in one-year survival rates. It is highly resistant to 
currently used chemotherapeutics, leaving surgery as the only viable therapeutic option 
[88, 116].  Although doxorubicin is not routinely used in treatment of melanoma, it is 
frequently used in breast cancer therapy [101], and we present evidence demonstrating 
that c-Abl/Arg inhibition sensitizes melanoma cells to a therapeutically viable dose of 
doxorubicin, giving new life to a previously unsuccessful treatment option (Figure 3.2C-
435s/M14, Dox+Nilotinib IC50=0.16µM; Figure 3.1D-MDA-MB-468, Dox alone 
IC50=0.1µM).  
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Figure 3.6. c-Abl/Arg prevent doxorubicin-induced G2/M arrest. (A, B) 
Asynchronous 435s/M14 (A) and 435s/M14-DR (B) cells were treated with STI571 
and/or doxorubicin for 72h, and analyzed by FACS. Cell cycle distribution for a 
representative experiment is shown (top). Mean±SEM of 3 independent experiments 
(bottom). *p<0.05, **p<0.01, ***p<0.001. 
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Figure 3.7. c-Abl/Arg prevent doxorubicin-induced apoptosis. Cells were treated 
with STI571 and/or doxorubicin (40h), attached and detached cells were lysed, and 
apoptosis assessed by fluorescent caspase-3/7 assay (Promega) (A-D). Data shown are 
mean±SEM of 3 experiments. Some error bars are too small for visualization. **p<0.01, 
***p<0.001. 
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Figure 3.8. STI571+doxorubicin induces apoptosis in melanoma cells. Cells were 
treated with STI571 and/or doxorubicin (40h), unless indicated otherwise, attached and 
detached cells were lysed, and apoptosis assessed by Annexin-V FACS analysis (A), 
and PARP cleavage (B-D). Data are representative of 3 independent experiments (A-D). 
Mean±SEM of 3 experiments (B, right). (D) Done in collaboration with J. Tepe. *p<0.05. 
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As mentioned in the previous chapter, silencing c-Abl and Arg in combination 
with doxorubicin is not experimentally feasible. Inhibition of c-Abl/Arg via siRNA 
dramatically inhibits cell proliferation, and since chemotherapy works by targeting rapidly 
proliferating cells and cells must be transfected prior to chemotherapeutic treatment, this 
dramatic reduction in cell proliferation prevents full activity of chemotherapeutic drugs. 
Despite this technical limitation, we confirmed that STI571 specifically inhibited c-Abl/Arg 
by overexpressing STI571-resistant mutant forms of those proteins (AblT/ArgT). In cells 
expressing STI571-resistant mutant forms of c-Abl/Arg, STI571 did not synergistically act 
with doxorubicin to potentiate further loss of cell viability.   
It is also interesting that the loss of viability observed in MDA-MB-468 cells 
following doxorubicin+STI571 treatment (Figure 3.1D) is primarily due to cytostasis, 
since doxorubicin+STI571 halted cell proliferation (Figure 3.5D) without inducing 
apoptosis (Figure 3.7D). In contrast, STI571+doxorubicin dramatically induces apoptosis 
of all melanoma cell lines tested. Intriguingly, in the previous chapter, we observed that 
combining 5-fluoruracil+STI571 synergistically induced MDA-MB-468 cell apoptosis, but 
all other classes of chemotherapeutics tested in combination with STI571 preferentially 
halted MDA-MB-468 cell proliferation [180]. In that chapter, we postulated that “inhibition 
of STAT3 activation may be a common mechanism by which STI571 synergizes with 
chemotherapeutic agents to inhibit the proliferation of MDA-MB-468 cells” [180], and we 
further address this possibility in chapter 5.  
We previously demonstrated that Abl family kinases drive G1S cell cycle 
transition in 435s/M14 melanoma cells in response to growth factor stimulation [39]. 
Moreover, we now show that c-Abl and Arg are critically important in preventing 
doxorubicin-induced blockade of cell cycle progression at the G2/M checkpoint. The 
summation of our data demonstrates the critical role of c-Abl/Arg activity in cancer cell 
proliferation via their influence at multiple phases of the cell cycle. The mechanism by 
which c-Abl and Arg promote doxorubicin resistance will be addressed in future 
chapters. In conclusion, data presented here demonstrate that c-Abl/Arg inhibitors 
dramatically sensitize melanoma, breast cancer, and advanced chemoresistant 
melanoma cells to doxorubicin, halting proliferation and inducing apoptosis. 
 
Copyright © Jonathan T. Sims 2012 
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CHAPTER FOUR 
STI571-MEDIATED CHEMOSENSITIZATION OF ACQUIRED CHEMORESISTANT 
MELANOMA IS PARTIALLY MEDIATED VIA ABCB1 
4.1 Introduction 
Significantly, we demonstrated in the previous chapter that STI571 dramatically 
sensitizes acquired chemoresistant melanoma cells to G2/M arrest and apoptosis in the 
presence of doxorubicin. The degree of sensitization that we observed is especially 
exciting when considering the degree of difficulty that clinicians experience in treating 
advanced chemoresistant metastatic melanoma. As mentioned earlier, there has been 
little improvement in one-year survival rates for patients with metastatic melanoma, while 
the number of newly diagnosed cases continues to increase faster than with any other 
cancer [88]. Melanomas possess extremely high resistance levels to all known 
chemotherapeutic agents, and cells intractable to treatment are highly metastatic [182]. 
Approximately 40% of patients will develop multidrug resistance, making this a 
tremendous hurdle for cancer therapy [189, 190]. Cells resistant to chemotherapy, such 
as doxorubicin, not only evade apoptosis, but also are more invasive than their parental 
counterparts [100]. To best treat cancer types endued with the propensity for developing 
resistance, therapeutic strategies must target multiple survival mechanisms.  
Chemotherapeutic resistance occurs via upregulation of anti-apoptotic signaling 
pathways and expression of multi-drug resistance transporters [133, 182]. The ATP 
binding cassette (ABC) transporter family, a primary mechanism for cancer cell 
resistance, effluxes a wide variety of hydrophobic chemotherapeutic compounds [128]. 
ABCB1, in particular, confers the greatest degree of resistance to the widest array of 
drugs, including those central to many chemotherapeutic regimens (e.g. anthracyclines 
and taxanes) [128]. A recent retrospective study showed that melanoma metastases 
express significantly higher levels of ABCB1 than primary tumors, indicating that ABCB1 
contributes to the aggressive nature of malignant melanoma [125], and another report 
demonstrated a functional link between ABCB1 expression and melanoma invasion 
[126]. Activation of PI3K and ERK pathways has been shown to induce ABCB1 
upregulation [191, 192].  
Understanding the mechanisms underlying melanoma drug resistance is critical 
for developing new therapies to treat resistant/disseminated disease. Herein, we 
identified a mechanism by which melanoma cells develop resistance to the 
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chemotherapeutic anthracycline, doxorubicin, by demonstrating that c-Abl/Arg mediate 
upregulation of ABCB1, and c-Abl/Arg inhibitors dramatically sensitize highly resistant 
melanoma cells to doxorubicin by inhibiting ABCB1 expression and function. These data 
indicate that, in addition to preventing metastatic disease [193], c-Abl/Arg inhibitors also 
are likely to reverse acquired chemotherapeutic resistance.  
 
4.2 Materials and Methods 
4.2.1 Reagents and Cell Lines 
MDA-MB-435s cells were obtained from the University of North Carolina Tissue 
Culture Facility, and are a spindle-shaped, highly metastatic variant of MDA-MB-435 
cells (Chapel Hill, NC). Genetic analysis confirmed that these cells are identical to 
melanoma M14, and therefore, are referred to as 435s/M14 [157, 193]. A drug-resistant 
variant of 435s/M14 (435s/M14-DR) was created via step-wise treatment with increasing 
concentrations of doxorubicin (using a maximum dose of 100nM) [185]. 435s/M14 and 
435s/M14-DR cells were cultured in DMEM/10% FBS (fetal bovine serum), + insulin 
(10µg/ml).  STI571 (Gleevec; imatinib mesylate) and nilotinib were obtained from 
Novartis (Basal, Switzerland). STI571 was dissolved in water (10mM) and stored at -
80oC, while nilotinib (10mM) was dissolved in DMSO, and stored at 4oC. Doxorubicin, 
paclitaxel, camptothecin, 5-fluorouracil (5-FU), cisplatin, and verapamil were purchased 
from Sigma (St. Louis, MO). Rhodamine 123 was purchased from Invitrogen (Carlsbad, 
CA). Luciferin was obtained from Promega (Madison, WI). Silencer select ABCB1 siRNA 
was obtained from Ambion (Carlsbad, CA). α-tubulin and Arg antibodies were purchased 
from Santa Cruz Biotechnologies (Santa Cruz, CA). GAPDH and c-Abl (8E9) were 
obtained from BD Biosciences (Chicago, IL). Lamin A/C, ABCB1, ABCG2, and ABCC1 
antibodies were from Milllipore (Temecula, CA). Western blots were performed as 
described in the manufacturers’ protocols.  
 
4.2.2 CellTiter-Glo Viability Assay (Promega; Madison, WI) 
Cells were plated in 96-well plates in triplicate in 100µl of medium, refreshed with 
media containing drugs the following day when cells were 30-40% confluent, and 
harvested 72h later. CellTiter-Glo reagent (100µl) was added to each well, the plates 
were rocked for 2’, incubated at room temperature for 10’, 100µl was removed from each 
well and transferred to an opaque 96-well plate, and luminescence  (total light emitted, 
10”/well) measured with a Synergy 2 microplate reader (Biotek; Winooski, VT). 
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4.2.3 Drug efflux assays [194] 
Subconfluent cells were incubated with either rhodamine 123 (0.5µg/ml) or 
doxorubicin (10µM) in the presence of verapamil (10µM) or STI571 (40µM) for 30’, 
washed extensively and incubated with verapamil or STI571 for an additional 45’, and 
analyzed by FACS to assess intracellular retention of rhodamine 123 or doxorubicin.  
 
4.2.4 Cell Lysis and Western Blots 
 Cells were plated in 60mm dishes, treated the following day, and detached nad 
attached cells were lysed in RIPA buffer (50mM Tris pH 7.5, 150mM NaCl, 1% triton-X 
100, 0.1% SDS, 1% sodium deoxycholate, 1mM PMSF, 1mM sodium orthovanadate, 
25mM sodium fluoride, 10µg/ml leupeptin, aprotinin, pepstatin). Total protein was 
quantitated with a Lowry DC kit (Biorad; Hercules, CA), equal protein was loaded on 
SDS-PAGE gels, and blots were incubated with specified antibodies. 
 
4.2.5 Subcellular Fractionation 
Cells were plated in 60mm dishes, and cytoplasmic/membrane and nuclear 
fractions were isolated using the NE-PER kit (Pierce; Rockford, IL) according to the 
manufacturer's protocol. 
 
4.2.6 Semi-quantitative RT-PCR 
Cells were plated in 60mm dishes, refreshed with media containing drugs the 
following day when cells were 30-40% confluent, RNA extracted 48h later (RNeasy kit; 
Qiagen; Valencia, CA), digested with DNase I (Invitrogen), reverse-transcribed with 
Superscript Reverse Transcriptase and random primers (Invitrogen; Carlsbad, CA), and 
PCR performed using primers specific for c-Abl (10nM), and Arg (10nM). β-actin primers 
(10nM) were included in the PCR reaction as an internal control. PCR cycling 
parameters involved 27 cycles of 95oC-1', 55oC-1', 72oC-1'. Aliquots were also taken at 
cycles 31 and 35 to check for linearity. Scanned photographs were quantified with 
ImageQuant (Molecular Dynamics, GE Healthcare, Piscataway, NJ) and specific bands 
normalized to β-actin internal control bands. 
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4.2.7 Statistics  
Statistical analyses were performed using Sigma Stat for Windows (Systat 
Software, Inc.; San Jose, CA). Combination Index (CI) values were calculated with 
CalcuSyn software (Biosoft; Cambridge, UK) using single drug and drug combination 
dose response curves. 
 
4.3 Results 
4.3.1 ABCB1 is dramatically upregulated in 435s/M14-DR cells.  
Chemotherapeutic resistance commonly develops due to upregulation of multi-
drug resistance transporters, which efflux the chemotherapeutic agents, and transporter 
upregulation is observed in late stage, metastatic melanomas [80, 133, 195]. To 
determine whether an ABC transporter is upregulated in 435s/M14-DR cells, we tested 
whether the cells also are resistant to other chemotherapeutic agents from a variety of 
different classes. Interestingly, 435s/M14-DR cells were highly resistant to paclitaxel, 
and this resistance was abrogated by STI571 treatment (Figure 4.1A). However, 
435s/M14-DR cells remained sensitive to camptothecin, 5-fluorouracil, and cisplatin 
(Figure 4.1A). Candidate transporters that efflux doxorubicin and paclitaxel include 
ABCB1, ABCG2, and ABCC1 [134]. 435s/M14-DR cells expressed dramatically elevated 
levels of ABCB1 protein compared to parental cells, whereas ABCC1 and ABCG2 were 
expressed at low levels in both cell lines (Figure 4.1B). Treatment of 435s/M14-DR cells 
with STI571 or transfection of cells with c-Abl but not Arg siRNA inhibited ABCB1 
expression (Figure 4.1C), indicating that active c-Abl contributes to ABCB1 upregulation 
following acquired resistance to doxorubicin. Next, we tested whether the STI571-
mediated decrease in ABCB1 expression influenced doxorubicin retention. Doxorubicin 
possesses intrinsic fluorescence, which allows for its detection by flow cytometry. Cells 
were treated with vehicle/STI571 for 72h, and then incubated with doxorubicin for 30’ in 
the absence of STI571 in a doxorubicin efflux assay, and intracellular doxorubicin 
assessed in living cells. Less intracellular doxorubicin was observed in 435s/M14-DR 
cells as compared to parental cells, which do not overexpress ABCB1 (Figure 4.1D). 
Moreover, doxorubicin efflux in 435s/M14-DR cells was partially inhibited when cells 
were treated prior to the efflux assay with STI571 (Figure 4.1D). Since STI571 was not 
present during the efflux assay (i.e. during incubation with doxorubicin), and STI571 
binding to ABC transporters is known to be a reversible process [148], these data  
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Figure 4.1. 435s/M14-DR cells are resistant to paclitaxel and doxorubicin, and 
express high levels of ABCB1. (A) Cells were plated in triplicate, treated for 72h with 
STI571 (10µM) and/or the indicated chemotherapeutic drugs, and viability assessed by 
CellTiter-Glo (Promega, Madison, WI). A representative experiment is shown. Some 
error bars are too small for visualization. PTX=paclitaxel, Cam=camptothecin, 
Cis=cisplatin, 5-FU=5-fluorouracil. (B) Lysates prepared in non-reducing conditions from 
untreated cells were analyzed by Western blot. Lysate from MCF-7 cells transfected with 
ABCC1 served as a positive control for ABCC1 expression. (C) Cells were treated with 
STI571 for 48h or transfected with siRNAs, and lysates analyzed for ABCB1 expression 
by Western blotting. Graphs are Mean±SEM from 3 independent experiments. 
*p<0.05,**p<0.01. (D) Cells were treated with STI571 for 72h, washed extensively, 
treated with doxorubicin for 30’ in the absence of STI571, and intracellular doxorubicin 
fluorescence assessed by FACS analysis.  
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indicate that c-Abl inhibits intracellular doxorubicin retention, in part, by increasing 
ABCB1 expression. 
 
4.3.2 STI571 increases intracellular doxorubicin accumulation, in part, by 
inhibiting ABCB1 function.  
STI571 has been shown to be a substrate and/or inhibitor of ABCB1 and ABCG2 
in leukemic cells [148, 171-175, 196]. Therefore, STI571 also may mediate 
chemosensitization by directly inhibiting drug efflux. To confirm that ABCB1 mediates 
doxorubicin efflux in 435s/M14-DR cells and to ascertain whether STI571 specifically 
interferes with ABCB1-mediated efflux of doxorubicin, we performed a doxorubicin efflux 
assay in the absence or presence of STI571 and ABCB1 siRNA or the ABCB1 inhibitor 
(verapamil) and measured doxorubicin intracellular fluorescence. Silencing ABCB1 
inhibited doxorubicin efflux (Figure 4.2A), and STI571 inhibited efflux of doxorubicin and 
the ABCB1 substrate, rhodamine 123, to a similar extent as verapamil (Figure 4.2B, C). 
Taken together, these studies demonstrate that STI571 directly inhibits ABCB1-
mediated doxorubicin efflux in 435s/M14-DR melanoma cells, in addition to preventing 
ABCB1 upregulation.   
Next, we assessed the functional impact of ABCB1 expression on 
chemoresistance of 435s/M14-DR cells by assessing the effect of silencing/inhibiting 
ABCB1 on cell viability. Silencing ABCB1 or verapamil treatment dramatically sensitized 
resistant cells to doxorubicin (Figure 4.3A, B). However, STI571 retained the ability to 
inhibit the viability of cells treated with verapamil/doxorubicin or ABCB1 
siRNA/doxorubicin, indicating that inhibition of ABCB1 is not the only mechanism by 
which STI571 sensitizes 435s/M14-DR cells to doxorubicin (Figure 4.3A, B). In addition, 
unlike rhodamine 123, in the absence of pump inhibitors, doxorubicin is not completely 
effluxed from 435s/M14-DR cells (Figure 4.2C vs. Figure 4.2B). Therefore, since 
435s/M14-DR cells continue to retain some doxorubicin, yet, are resistant to its effects, 
this indicates that transporter-independent pathways are likely to contribute to 
doxorubicin resistance. To test this hypothesis, we examined whether 435s/M14-DR 
cells continue to efflux doxorubicin following prolonged treatment with doxorubicin (72h; 
cell viability time point). Interestingly, doxorubicin was efficiently effluxed after 2h 
doxorubicin treatment; however, after 72h, high levels of doxorubicin were retained in 
435s/M14-DR cells (Figure 4.3C), even though >80% of cells are alive at this time point  
 
 75 
 
Figure 4.2. STI571 reverses doxorubicin-resistance, in part, by directly inhibiting 
ABCB1 function.  (A) siRNA-transfected cells were treated with doxorubicin for 30’, 
cells were washed, and intracellular doxorubicin fluorescence quantitated by FACS 
analysis. A representative Western blot demonstrating siRNA knockdown efficiency on 
the day of harvest is shown (right). (B, C) Cells were treated with either doxorubicin 
(10µM) (B) or rhodamine 123 (0.5µg/ml) (C) in the presence of the ABCB1 inhibitor, 
verapamil (10µM), or STI571 (40µM) for 30’, washed and incubated with verapamil or 
STI571 for an additional 45’, and rhodamine 123 or doxorubicin intracellular 
fluorescence assessed by FACS. Experiments shown are representative of 3 
independent experiments.  
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Figure 4.3. Resistance to doxorubicin occurs via transporter-dependent and 
independent mechanisms.  (A,B) ABCB1 was inhibited with verapamil (10µM) (A) or 
silenced with siRNA (B), cells were treated STI571 (10µM) and/or doxorubicin (0.5µM) 
for 72h, and cell viability assessed (CellTiter-Glo assay; Promega, Madison, WI). A 
representative Western blot demonstrating silencing efficiency on the day of harvest is 
shown (B, right). Dox+STI571 CI=0.66±0.19; Dox+verapamil CI=0.14±0.04; 
Dox+STI571+verapamil CI=0.47±0.5. (C) Cells were treated with doxorubicin (1µM) for 
2h or 72h, washed, and intracellular doxorubicin fluorescence assessed by FACS. 
Graphs are representative of 3 independent experiments (A-C). (C, right) Mean±SEM 
from 3 independent experiments. Some error bars are too small for visualization. 
**p<0.01.  
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(Figure 3.4A). Taken together, these data indicate that transporter-independent 
pathways also play a major role in resistance of 435s/M14-DR cells to doxorubicin.  
 
4.4 Discussion 
In this chapter, we demonstrate that STI571 directly inhibits ABCB1 function in 
melanoma cells and activated c-Abl contributes to acquired doxorubicin resistance by 
upregulating expression of ABCB1. c-Abl/Arg inhibitors have been identified as 
substrates of drug transporters in other cell types [134, 197]; however, this is the first 
demonstration that they inhibit ABCB1 in melanoma cells. In addition, we are the first to 
show that activation of c-Abl promotes expression of an ABC transporter, which 
indicates that STI571’s effects on drug transport involve not only direct inhibition but also 
indirect modulation via expression regulation. These data are significant because they 
indicate that c-Abl plays an active role in promoting ABC transporter upregulation during 
acquired chemotherapeutic resistance. Intriguingly, ABCB1 also is known to efflux 
STI571 [148]; however, doxorubicin-resistant, ABCB1-expressing cells are actually more 
sensitive to STI571 than parental cells (Figure 3.4A). This may be due to the fact that c-
Abl is more highly activated in resistant compared with parental cells (Figure 4.4A), since 
STI571 preferentially binds the active conformation of c-Abl/Arg [198]. c-Abl protein 
expression was decreased in a post-transcriptional manner, since no change was 
observed in mRNA levels (Figure 4.4A). In addition, more c-Abl was localized to the 
cytoplasm in the highly resistant cells relative to parental cells (Figure 4.4B), which is 
significant, since we previously demonstrated that activation of cytoplasmic c-Abl and 
Arg promotes cancer cell proliferation, anchorage-independent growth, invasion, and 
survival [38, 39, 193].  
The ability of c-Abl/Arg inhibitors to not only sensitize highly resistant cells to 
doxorubicin, but also paclitaxel, indicates broad spectrum application of c-Abl/Arg 
inhibitors is warranted for any therapeutic regimen targeting drug-resistant cells 
possessing highly active c-Abl/Arg.  c-Abl/Arg inhibitors have been shown to inhibit a 
number of ABC transport proteins (i.e., ABCB1, ABCG2) [174, 197], and, based on our 
data, the transporter-specific inhibitory function of drugs like STI571, coupled with 
inhibition of c-Abl/Arg signaling mechanisms, may indicate a high degree of therapeutic 
usefulness for patients whose tumors harbor highly active Abl family kinases.   
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Figure 4.4.  435s/M14–DR cells contain highly active, predominantly cytoplasmic 
Abl family kinases.  (A) c-Abl and Arg were immunoprecipitated from untreated cell 
lysates and analyzed by in vitro kinase assay using GST-Crk as a substrate (top), by 
Western blotting with indicated antibodies (middle), or RNA was extracted from 
untreated cells and semi-quantitative RT-PCR was performed with c-Abl- and Arg-
specific primers (bottom). (B) Cells were fractionated into cytoplasmic/membrane and 
nuclear fractions using NE-PER (Pierce) and analyzed by Western blotting. All 
experiments were performed three times, and representative experiments are shown.  
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Although 435s/M14-DR cells, which have acquired resistance to doxorubicin, 
express high levels of ABCB1, and ABCB1 clearly effluxes doxorubicin, unlike 
rhodamine 123, another ABCB1 substrate, doxorubicin is not fully effluxed from these 
cells (Figure 4.2). This could be due to upregulation of another transporter that effluxes 
doxorubicin. Although we did not observe upregulation of ABCC1, ABCG2, or ABCC2, 
we cannot rule out upregulation of other transporters that efflux doxorubicin (Figure 
4.1B; data not shown). However, we found that prolonged treatment (72h) with 
doxorubicin induces a significant accumulation of intracellular doxorubicin (Figure 4.3C) 
even though >80% of the cells are alive at this time point (Figure 3.4A). The enhanced 
intrinsic resistance of these cells, which allows them to thrive despite retaining drastically 
high levels of doxorubicin (in connection with our data demonstrating STI571 decreases 
cell viability to a greater degree than explained by silencing/inhibiting ABCB1), leads to 
our studies in future chapters focused on determining the c-Abl/Arg-mediated signaling 
pathway that promotes cellular resistance to chemotherapy.  
In summary, our data demonstrate that c-Abl and Arg dramatically promote 
acquired chemoresistance in melanoma cells in part by inducing expression of an efflux 
pump (ABC transporter). These data have important clinical ramifications, as they 
indicate that c-Abl/Arg inhibitors not only may be effective for treating metastatic disease 
[193], but also are likely to be effective in reversing acquired chemoresistance. 
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CHAPTER FIVE 
ABL FAMILY KINASES PROMOTE MELANOMA CHEMORESISTANCE VIA 
STAT3-MEDIATED INHIBITION OF NF-KB TRANSCRIPTIONAL REPRESSION 
AND A STAT3-MEDIATED HSP27/P38/AKT SURVIVAL PATHWAY 
5.1 Introduction 
Cancer therapy is severely limited by resistance to currently used treatments 
[116]. Tumor cells resistant to therapeutic intervention promote advanced disease and 
metastasis, which is responsible for 90% of all cancer-related deaths [199]. Slightly less 
than half of all cancers recur due to aberrant proliferation, invasion, and survival, and 
spread to secondary sites [190]. Thus, there is a great need to identify new drug 
combinations for treating patients with metastatic disease. 
Cancer progression to metastasis is driven by aberrant kinase activation (i.e., 
PI3K/Akt, MAPK, and receptor tyrosine kinases) and induction of transcription factors 
such as NF-κB and STAT3, all of which have major roles in survival and 
chemoresistance [70, 114]. Inhibiting expression of the anti-apoptotic proteins, XIAP and 
cIAP1, targets of NF-κB, promotes chemotherapy-induced cell death [84, 130]. NF-κB 
signaling is also activated by STAT3 and PI3K/Akt and promotes cancer cell survival in 
the presence of chemotherapeutic agents [79-81]; however, recent evidence indicates 
that NF-κB promotes cell death upon stimulation with chemotherapeutics such as 
doxorubicin in some cell types [86, 87]. These studies demonstrated that doxorubicin 
induces apoptosis via p65/RelA-mediated transcriptional repression of anti-apoptotic 
genes [86, 87, 200, 201]. Understanding the dual nature of NF-κB and elucidating how it 
may be possible to convert this classically pro-survival protein into a tumor suppressor is 
an especially intriguing therapeutic option. Activation of the PI3K/Akt pathway is critical 
for chemoresistance and survival [60, 70, 71]; however, the mechanism by which Akt 
activation occurs in response to chemotherapeutic agents is unclear. Therefore, it is 
important to ascertain cell type-specific activators of Akt signaling in order to design 
drugs that can prevent aberrant activation in response to therapy. 
Recently, we provided the first evidence that Abl family non-receptor tyrosine 
kinases (c-Abl, Arg) are activated in a subset of primary melanomas and in some 
melanoma cell lines, and promote many processes involved in melanoma progression 
such as proliferation, invasion, survival, and metastasis [50]. We further demonstrated 
that c-Abl promotes melanoma cell invasion in a STAT3-dependent manner [50]. Based 
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on our data in both breast cancer and melanoma cells demonstrating that activated c-
Abl/Arg promote processes including proliferation and invasion [38, 39, 50], and survival 
in response to chemotherapeutic agents (chapters 2-4), we focused this chapter on the 
signaling mechanisms by which c-Abl/Arg promote chemoresistance. Understanding the 
mechanisms underlying drug resistance is critical for developing new therapies to treat 
resistant/disseminated disease. In this chapter, we identified novel signaling pathways 
by which cells develop resistance to the chemotherapeutic anthracycline, doxorubicin, by 
demonstrating that c-Abl/Arg: 1) modulate STAT3 to prevent NF-κB-mediated repression 
of anti-apoptotic targets, and 2) act via STAT3 to promote HSP27/p38/Akt activation. 
These data demonstrate not only that c-Abl/Arg inhibitors are likely to prevent 
chemotherapeutic resistance, but also outline the specific mechanism by which c-Abl 
and Arg promote survival in the presence of doxorubicin. 
 
5.2 Materials and Methods 
5.2.1 Cell Lines and Reagents 
Cell lineage and culturing procedures were described in chapters 3 and 4. 
STAT3 cDNA (pRc/CMV-STAT3C; Addgene, Cambridge, MA) was donated by Dr. 
James Darnell. Vector and STAT3C-expressing cells were obtained by transfection, 
G418 selection (900µg/ml), and pooling clones. The 3X-NF-κB reporter construct was 
provided by Dr. Denis Guttridge (Ohio State University; Columbus, OH) [202]. Cells 
expressing GFP-tagged PI3K(E545K) (Addgene, Cambridge, MA) were obtained by 
transfection/G418+Puromycin selection, and flow sorting GFP-positive cells (University 
of Kentucky Flow Cytometry Facility). STI571 (Gleevec; imatinib mesylate) and nilotinib 
were obtained from Novartis (Basal, Switzerland). STI571 was dissolved in water 
(10mM) and stored at -80oC. Doxorubicin was purchased from Sigma (St. Louis, MO). 
LY294002 was obtained from Cell Signaling Technology (Danvers, MA). Silencer select 
STAT3 and p65/RelA siRNAs were purchased from Ambion. PARP (poly(ADP-ribose) 
polymerase; sc-8007), α-tubulin, p65/RelA antibodies were purchased from Santa Cruz 
Biotechnologies (Santa Cruz, CA); GAPDH was obtained from BD Biosciences 
(Chicago, IL); Lamin A/C was obtained from Milllipore (Temecula, CA); β-Actin and 
FLAG (M2) antibodies from Sigma (St. Louis, MO); XIAP, cIAP1, and HSP27 antibodies 
were from R&D Systems (Minneapolis, MN); and STAT3, phospho-STAT3 (Y705), 
caspase-3 (8G10), phospho-Crk/CrkL (Y221/Y207), phospho-p38 (T180/T182), p38, Akt, 
and phospho-Akt (S473) antibodies were purchased from Cell Signaling Technology 
 82 
(Danvers, MA). Western blots were performed as described in the manufacturers’ 
protocols.  
 
5.2.2 Viability and Apoptosis Assays  
CellTiter-Glo Viability Assay (Promega; Madison, WI). Cells were plated in 96-
well plates in triplicate in 100µl of medium, refreshed with media containing drugs the 
following day when cells were 30-40% confluent, and harvested 72h later. CellTiter-Glo 
reagent (100µl) was added to each well, the plates were rocked for 2’, incubated at room 
temperature for 10’, 100µl was removed from each well and transferred to an opaque 
96-well plate, and luminescence  (total light emitted, 10”/well) measured with a Synergy 
2 microplate reader (Biotek; Winooski, VT). PARP and caspase-3 cleavage blots. Cells 
were plated in 60mm dishes, and treated with drugs the following day when cells were 
30-40% confluent. After 40h, attached and detached cells were lysed in RIPA buffer 
(50mM Tris pH 7.5, 150mM NaCl, 1% Triton-X 100, 0.1% SDS, 1% sodium 
deoxycholate), protein was quantitated by Lowry DC (Bio-Rad; Hercules, CA), equal 
protein was loaded on SDS-PAGE gels, and blots were incubated with antibodies for 
PARP, caspase-3, and GAPDH. 
 
5.2.3 Proliferation Assays 
Tritiated thymidine assays [180]. Cells were plated in 24-well plates in triplicate, 
drug-treated the following day when cells were 30-40% confluent, and harvested after 
72h. Cells were pulsed with tritiated thymidine (2.5 µCi; 2h), washed with PBS, 
incubated in 10% trichloroacetic acid, radioactivity was solubilized in 0.2N NaOH, and 
analyzed on a scintillation counter. Cell cycle analysis. Cells were plated in 100mm 
dishes, refreshed with media containing drugs the following day when cells were 30-40% 
confluent, and harvested after 72h. Cells were labeled with bromodeoxyuridine (BrdU, 
10µM) for 1h at 37°C, trypsinized, washed and permeabilized with ethanol (70%), 
stained with fluorescein isothiocyanate (FITC)-conjugated anti-BrdU antibody and 
propidium iodide (PI; 5µg/ml), and analyzed by fluorescence-activated cell sorting 
(FACS) using Cell Quest software (BD Biosciences) and Modfit analysis (Verity Software 
House, Topsham, ME).  
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5.2.4 Semi-quantitative RT-PCR 
Cells were plated in 60mm dishes, refreshed with media containing drugs the 
following day when cells were 30-40% confluent, RNA extracted 48h later (RNeasy kit; 
Qiagen; Valencia, CA), digested with DNase I (Invitrogen), reverse-transcribed with 
Superscript Reverse Transcriptase and random primers (Invitrogen; Carlsbad, CA), and 
PCR performed using primers specific for XIAP (10nM), cIAP1 (10nM). β-actin primers 
(10nM) were included in the PCR reaction as an internal control. PCR cycling 
parameters involved 27 cycles of 95oC-1', 55oC-1', 72oC-1'. Aliquots were also taken at 
cycles 31 and 35 to check for linearity. Scanned photographs were quantified with 
ImageQuant (Molecular Dynamics, GE Healthcare, Piscataway, NJ) and specific bands 
normalized to β-actin internal control bands. 
cIAP1 forward primer, 5'CAGCCTGAGCAGCTTGCAA3',  
cIAP1 reverse primer, 5'CTTCTGAAGAACTTTCTCCAG3' 
XIAP forward primer, 5'AGTGGTAGTCCTGTTTCAGCATCA3',  
XIAP reverse primer, 5'AAAGATAGTCTGCATGTGTCTCAG3' 
β-actin forward primer, 5'CCTTCCTGGGCATGGAGTCCT3',  
β-actin reverse primer 5'GGAGCAATGTCTTTGATCTTC3' 
 
5.2.5 Luciferase assays 
Cells were transfected with 3X-NF-κB luciferase reporter and pcDNA3.1 
plasmids (10:1 ratio), selected with G418 (900µg/ml), and clones were pooled. Cells 
expressing the reporter were plated in triplicate, treated with STI571 and/or doxorubicin 
for 24h, lysed in lysis buffer (Promega; Madison, WI), lysate was incubated with luciferin 
(Promega; Madison, WI) for 2”, and luminescence resulting from luciferase activity 
measured with the Synergy 2 microplate reader (total light emitted, 10”/well).  
 
5.2.6 Nuclear fractionation assays 
 Cells were plated in 60mm dishes, and nuclear fractions were isolated using the 
NE-PER kit (Pierce; Rockford, IL) as described in the manufacturer’s protocol.   
 
5.2.7 Statistics  
Statistical analyses were performed using Sigma Stat for Windows (Systat 
Software, Inc.; San Jose, CA). Combination Index (CI) values were calculated with 
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CalcuSyn software (Biosoft; Cambridge, UK) using single drug and drug combination 
dose response curves. 
 
5.3 Results 
5.3.1 c-Abl/Arg promote survival in response to doxorubicin in a STAT3-
dependent manner.  
We focused our efforts on better understanding the signaling mechanisms by 
which c-Abl/Arg promote chemoresistance in melanoma.  Progression of melanoma from 
radial growth phase to vertical growth phase depends on aberrant expression of 
transcription factors, such as STAT3 [114].  We previously showed that c-Abl/Arg 
induced STAT3 phosphorylation in melanoma and breast cancer cells [39, 50]. 
Therefore, we tested whether Abl family kinases mediated survival in the presence of 
chemotherapeutics in a STAT3-dependent manner. We demonstrated that inhibition of 
Abl family kinases induced caspase-3/7 activity in melanoma and breast cancer cells 
(Figure 2.1B) [188]; therefore, we first tested the relationship of STAT3 and c-Abl/Arg in 
absense of doxorubicin. We observed that stable expression of a constitutively active 
form of STAT3 (STAT3C) completely rescued STI571-mediated induction of caspase-3/7 
activity (Figure 5.1A).  Since c-Abl/Arg act via STAT3 to promote survival, we proceeded 
to assess the effect of doxorubicin+STI571 on STAT3 phosphorylation in parental and 
acquired chemoresistant melanoma cells. We observed a dramatic decrease in pSTAT3 
(Figure 5.1B) that corresponded with significantly decreased cell viability (Figure 3.1A; 
3.4A). Expression of STAT3C partially rescued the ability of STI571 to synergize with 
doxorubicin to decrease cell viability (Figure 5.2A) and promote G2/M arrest (Figure 
5.2B, C). This indicates that c-Abl/Arg promote cell proliferation in the presence of 
doxorubicin in a STAT3-independent manner.  
We next tested whether c-Abl/Arg promote resistance to doxorubicin-induced 
apoptosis via STAT3. We observed that STAT3C completely rescued the STI571-
mediated increase in doxorubicin-induced apoptosis as detected by cleavage of PARP 
and caspase-3 (Figure 5.3A). Cleavage of PARP and caspase-3 was assessed after 
cells were treated with doxorubicin or doxorubicin+STI571. In pcDNA cells 
doxorubicin+STI571 enhanced cleavage of PARP and caspase-3 far greater than 
doxorubicin alone (Figure 5.3A). However, in cells stably expressing a constitutively 
active form of STAT3 (STAT3C) there is no corresponding increase in apoptosis with 
STI571+doxorubicin (Figure 5.3A). Additionally, treatment of STAT3 siRNA-transfected  
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Figure 5.1. c-Abl/Arg promote survival via STAT3 and regulate pSTAT3 in 
response to doxorubicin.  (A) 435s/M14 cells, stably transfected with pcDNA or 
STAT3C, were treated with STI571 (40h), attached and detached cells were lysed, 
caspase-3/7 activation assessed. Graph represents mean±SEM from 3 independent 
experiments. Representative Western blot demonstrating STAT3C expression is shown. 
(B) Parental (435s/M14) and doxorubicin-resistant (435s/M14-DR) cells were treated 
with STI571 and/or doxorubicin (40h), attached and detached cells were lysed, and 
blotted with the indicated antibodies. *p<0.05,**p<0.01, ***p<0.001. 
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Figure 5.2. c-Abl/Arg promote proliferation in the presence of doxorubicin via a 
STAT3-independent mechanism. (A-C) pcDNA and STAT3C cells were treated with 
STI571 and/or doxorubicin for 72h, and analyzed by CellTiter-Glo viability assay (A), 
tritiated thymidine assay (B), or BrdU/PI FACS analysis (C). Graphs shown represent 
data from individual experiments (left) and mean±SEM for three independent 
experiments (right). **p<0.01.  
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Figure 5.3. c-Abl/Arg promote survival in response to doxorubicin in a STAT3-
dependent manner. (A) 435s/M14 cells transfected stably with pcDNA or STAT3C cells 
were treated with STI571 and/or doxorubicin for 40h followed by western blotting with 
indicated antibodies. (B) 435s/M14 cells were transfected with STAT3 siRNA, treated 
with doxorubicin (40h), and attached and detached cells were lysed, and blotted. Graphs 
are mean±SEM for three independent experiments. *p<0.05,**p<0.01, ***p<0.001. 
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cells with doxorubicin induced apoptosis (Figure 5.3B). These exciting data show that c-
Abl/Arg prevent doxorubicin-induced apoptosis in a STAT3-dependent manner. 
 
5.3.2 c-Abl/ArgSTAT3 prevents doxorubicin-mediated NF-κB transcriptional 
repression.  
NF-κB promotes oncogenesis, increasing proliferation, survival, invasion, and 
metastasis by promoting the transcription of pro-proliferative, pro-invasive, and anti-
apoptotic genes [203]. Recent data has shown that STAT3 promotes NF-κB 
transcriptional activity and acetylation of p65/RelA [78]. Based on our strong data 
demonstrating a link between c-Abl/Arg and STAT3, we next examined whether c-
Abl/Arg regulated NF-κB signaling in these cells. We fractionated STI571-treated cells 
and observed that STI571 decreased nuclear localization of p65/RelA (Figure 5.4A). We 
also measured p65/RelA nuclear localization following treatment of cells with c-Abl/Arg-
specific siRNAs, and we observed that c-Abl/Arg promote p65/RelA nuclear localization 
(Figure 5.4B). We tested whether c-Abl/Arg promote NF-κB transcriptional activity by 
creating a cell line that stably expressed a NF-κB promoter-regulated luciferase 
construct [202]. We demonstrated that STI571 decreased NF-κB activity both basally 
and following stimulus with TNFα (Figure 5.4C).  Importantly, these data provide the first 
demonstration that c-Abl/Arg regulate NF-κB signaling in melanoma.  
In some cell types, NF-κB promotes survival and resistance to doxorubicin; 
however, in other cells, doxorubicin kills cells by activating NF-κB and converting it into a 
repressor, which promotes apoptosis [75, 86, 87, 200]. To determeine how 
STI571+doxorubicin affected NF-κB activity, we fractionated parental 435s/M14 
melanoma cells after treatment with STI571+doxorubicin and observed a dramatic 
increase in the doxorubicin-induced nuclear localization of p65/RelA by STI571 (Figure 
5.5A). This coincided with an increase in p65/RelA phosphorylation at both 8h and 40h 
(Figure 5.5B, data not shown). In parental 435s/M14 cells, the increase in nuclear 
p65/RelA following doxorubicin+STI571 also coincided with decreased NF-κB 
transcriptional activity, as observed by a decrease in luciferase activity (Figure 5.5C, 
top). Intriguingly in contrast, doxorubicin treatment induced NF-κB transcriptional activity 
in 435s/M14-DR cells, and this was abrogated by cotreatment with STI571 (Figure 5.5C, 
bottom). This demonstrates that NF-κB signaling is regulated very differently in parental 
vs. acquired chemoresistant cells. 
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Figure 5.4. c-Abl/Arg promote NF-κB signaling in melanoma cells. (A, B) Cells were 
treated with STI571 for 40h (A), or c-Abl/Arg-specific siRNAs (B), fractionated using NE-
PER (Pierce), and nuclear fractions were analyzed by Western blotting. Graphs 
represent mean±SEM from 3 independent experiments. (C) Cells stably expressing a 
3X-NF-κB-luciferase reporter were plated in triplicate, treated with STI571 for 8h in the 
absense or presence of TNFα, and luciferase activity assessed in the lysate (Promega, 
Madison, WI). Mean±SEM for 3 independent experiments is shown. (B) Performed by 
W. Friend. *p<0.05. 
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Figure 5.5. c-Abl/Arg activation of STAT3 prevents doxorubicin-mediated NF-κB 
transcriptional repression. (A) 435s/M14 cells were treated with STI571 and/or 
doxorubicin (8h), and nuclear fractions blotted with indicated antibodies. Graph 
represents mean±SEM from 3 independent experiments. (B) 435s/M14 cells were 
treated with STI571 and/or doxorubicin (8h), attached and detached cells were lysed, 
and blotted with indicated antibodies. Graph represents mean±SEM from 3 independent 
experiments. (C) Parental (435s/M14) and doxorubicin-resistant (435s/M14-DR) cells, 
stably expressing a 3X-NF-κB-luciferase reporter, were treated with STI571 and/or 
doxorubicin (8h), and luciferase activity assessed. Mean±SEM from 3 independent 
experiments performed in triplicate. *p<0.05, **p<0.01.  
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Next, we silenced p65/RelA with siRNA and observed that inhibition of p65/RelA 
decreased the effectiveness of doxorubicin to induce apoptosis, and, significantly, 
partially inhibited the dramatic induction of apoptosis observed by cotreatment with 
STI571 (Figure 5.6). We next wanted to assess whether c-Abl/Arg prevented 
doxorubicin-induced nuclear localization of p65/RelA in a manner dependent on STAT3. 
We first tested whether STAT3 affected nuclear localization of p65/RelA by silencing 
STAT3 since this should have the same effect as inhibiting c-Abl/ArgSTAT3 signaling 
with STI571. As observed with STI571, silencing STAT3 resulted in increased nuclear 
p65/RelA following doxorubicin treatment (Figure 5.7A). Constitutively active STAT3 
(STAT3C) prevented the STI571+doxorubicin-induced nuclear localization of p65/RelA 
and, significantly, also prevented the decrease in NF-κB transcriptional activity observed 
with STI571+doxorubicin (Figure 5.7B, C). These data are significant because we are 
the first to demonstrate that c-Abl/Arg act via STAT3 to inhibit nuclear localization of 
p65/RelA and thereby relieve the doxorubicin-induced NF-κB-mediated transcriptional 
repression of anti-apoptotic genes. These data indicate that inhibition of c-
Abl/ArgSTAT3 induces doxorubicin-mediated NF-κB transcriptional repression.  
 
5.3.3 c-Abl/Arg promote cIAP1/XIAP transcription in the presence of doxorubicin 
in a STAT3-dependent manner.  
Since c-Abl/Arg inhibit doxorubicin-mediated NF-κB transcriptional repression via 
STAT3, we sought to establish whether this resulted in expression changes of anti-
apoptotic NF-κB targets. The anti-apoptotic proteins, cIAP1 and XIAP, targets of NF-κB, 
are overexpressed in melanomas, and prevent caspase activation in response to 
apoptotic stimuli [204-206]. We performed semi-quantitative RT-PCR and demonstrated 
that c-Abl/Arg promote transcription of cIAP1/XIAP in the presence of doxorubicin. 
Doxorubicin induced transcription of cIAP1/XIAP and c-Abl/Arg were required for 
cIAP1/XIAP transcription in the presence of doxorubicin, since transcript levels were 
dramatically lower following cotreatment with STI571 (Figure 5.8A, B). We confirmed this 
finding by Western blot and observed a decrease in expression of both of these anti-
apoptotic proteins following treatment with STI571+doxorubicin at both 8 and 40 hours 
(Figure 5.8A, B; data not shown). In doxorubicin-resistant cells, doxorubicin treatment 
increased transcription of cIAP1, but had little effect on XIAP transcription or cIAP1/XIAP 
protein expression (Figure 5.9A, B). However, addition of STI571 dramatically reduced  
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Figure 5.6. p65/RelA is required for doxorubicin-mediated apoptosis. 435s/M14 
cells, transfected with p65/RelA siRNA, were treated with STI571 and/or doxorubicin 
(8h), and PARP and caspase-3 cleavage assessed. Mean±SEM from 3 independent 
experiments (left). Mean±SEM of fold differences between doxorubicin+STI571 and 
doxorubicin-treated samples (right). **p<0.01, ***p<0.001.   
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Figure 5.7. c-Abl/Arg inhibit p65-mediated transcriptional repression in a STAT3-
dependent manner. (A) 435s/M14 cells, transfected with STAT3 siRNA, were treated 
with doxorubicin (8h), and nuclear fractions analyzed by Western blot. Graph represents 
mean±SEM from 3 independent experiments. (B) 435s/M14 cells stably expressing 
pcDNA or STAT3C were treated with STI571 and/or doxorubicin (8h), and nuclear 
fractions assessed by Western blot. Graph represents Mean±SEM of 3 independent 
experiments. (C) pcDNA and STAT3C-expressing cells, stably expressing a 3X-NF-κB-
luciferase reporter, were treated with STI571 and/or doxorubicin (8h), and luciferase 
activity assessed. Mean±SEM from 3 independent experiments performed in triplicate. 
*p<0.05, **p<0.01.  
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cIAP1/XIAP protein expression at 12h and 40h time points (Figure 5.9A, B; data not 
shown), and inhibited transcription of cIAP1 (Figure 5.9A, B). Moreover, expression of 
STAT3C prevents the STI571+doxorubicin-mediated decrease in cIAP1/XIAP in parental 
cells, confirming the role of c-Abl/ArgSTAT3 in mediating expression of anti-apoptotic 
factors in the presence of doxorubicin (Figure 5.10). These data are significant because 
they confirm that STI571 not only prevents NF-κB activation following doxorubicin 
treatment, but also converts NF-κB into a transcriptional repressor, thereby inhibiting 
transcription of cIAP1/XIAP. 
 
5.3.4 c-Abl/Arg promote survival to doxorubicin via HSP27/p38/Akt pathway.  
c-Abl/Arg act via STAT3 to prevent NF-κB transcriptional repression in response 
to doxorubicin, promoting survival and chemoresistance of metastatic melanoma cells. 
However, c-Abl/ArgSTAT3 promote survival in the presence of doxorubicin via more 
than one signaling pathway since expression of constitutively active STAT3 (STAT3C) 
fully rescued STI571-mediated induction of apoptosis (Figure 5.3A) and STI571’s 
potentiation of doxorubicin-mediated NF-κB transcriptional repression (Figure 5.7B, C), 
but silencing p65/RelA only partially abrogated STI571+doxorubicin-induced apoptosis 
(Figure 5.6). Therefore, we focused on the PI3K/Akt pathway, a major mediator of 
survival in melanoma cells and a signaling target of BCR-Abl in leukemic cells [70, 184, 
207]. We observed increased phosphorylation of Akt in response to doxorubicin in both 
parental and doxorubicin-resistant cells, and induction of pAkt in response to doxorubicin 
is abrogated by addition of STI571 in parental, as well as doxorubicin-resistant, cells 
(Figure 5.11A, B). Likewise, we observed that doxorubicin activated Abl family kinases, 
as demonstrated by increased phosphorylation of the c-Abl/Arg substrate, Crk/CrkL 
(Figure 5.11A). To confirm that activation of Akt promoted survival, we inhibited PI3K 
using LY294002 and observed that Akt activation indeed promotes melanoma cell 
survival in response to doxorubicin (Figure 5.11C). The PI3K/Akt pathway promotes 
survival in response to a wide array of stimuli [62]. In response to neutrophil cell stress, 
Akt activation occurs via complex formation with HSP27 and activation by p38/MAPK 
[63, 64]; however, no report has previously described Akt activation by doxorubicin via 
the cell stress response pathway.   
HSP27 expression promotes Akt activity in neutrophils in response to cell stress 
by forming a complex that brings p38/MAPK in proximity with Akt [64]. We observed that  
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Figure 5.8. c-Abl/Arg promote cIAP1/XIAP expression in melanoma cells. (A) Cells 
were treated with STI571 and/or doxorubicin (40h-top, 24h-bottom), lysate analyzed by 
Western blot (top), and RNA subjected to semi-quantitative RT-PCR (bottom). (B) 
Graphical representation of semiquantitative RT-PCR (right) and Western blots (left). 
Mean±SEM for 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 5.9. c-Abl/Arg promote cIAP1/XIAP expression in highly resistant 
melanoma cells. (A) Cells were treated with STI571 and/or doxorubicin (40h), lysate 
analyzed by Western blot (top), and RNA subjected to semi-quantitative RT-PCR 
(bottom). (B) Graphical representation of semiquantitative RT-PCR (right) and Western 
blots (left). Mean±SEM for 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 5.10. c-Abl/Arg inhibit p65-mediated repression of NF-κB targets in a 
STAT3-dependent manner. pcDNA and STAT3C-expressing cells were treated with 
STI571 and/or doxorubicin (40h), and lysate from attached and detached cells was 
assessed by Western blot. Mean±SEM from 3 independent experiments. *p<0.05. 
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Figure 5.11. c-Abl/Arg promote survival via Akt, p38, and HSP27. (A, B) 435s/M14 
(A) and 435s/M14-DR (B) cells were treated with STI571 in combination with doxorubicin 
(435s/M14-0.5µM, p38 and Akt; 1µM, HSP27 and pCrkL) for 40h, attached and 
detached cells were lysed, and assessed by Western blot with indicated antibodies. 
Graphs represent mean±SEM from 3 independent experiments. (C) 435s/M14 cells were 
treated with doxorubicin and LY294002 for 72h and viability assessed via CellTiter-Glo 
assay. Graph represents mean±SEM from 3 independent experiments. Some error bars 
are too small for visualization. *p<0.05, **p<0.01, ***p<0.001. 
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STI571+doxorubicin completely decreased HSP27 expression, correlating with 
decreased pAkt (Figure 5.11A). The same pattern of regulation that we observed with 
pAkt was also observed with p38/MAPK, in which STI571 completely prevented the 
doxorubicin-induced increase in p38/MAPK phosphorylation (Figure 5.11A). This is the 
first observation of c-Abl/Arg mediating stress-induced Akt activation in melanoma. We 
proceeded to determine the role of STAT3 in c-Abl/Arg-mediated activation of Akt. 
Constitutively active STAT3 (STAT3C) prevented the STI571-mediated decrease in 
HSP27, p38/MAPK, and Akt phosphorylation that we observed following doxorubicin 
treatment (Figure 5.12A).  The role of STAT3 in regulating expression of these pro-
survival proteins was confirmed with STAT3 siRNA.  We discovered that doxorubicin 
treatment of STAT3 siRNA-transfected cells resulted in loss of HSP27 expression and 
decreased phosphorylation of p38/MAPK and Akt (Figure 5.12B), as previously 
observed with STI571+doxorubicin (Figure 5.11A). Significantly, this is the first 
demonstration that STAT3 mediates activation of Akt. We next examined whether c-
Abl/Arg-mediated activation of Akt mediated cell survival in the presence of doxorubicin. 
Expression of a constitutively active form of the p110α catalytic subunit of PI3K (PI3K-
E545K), which activates Akt, partially rescued STI571+doxorubicin-induced apoptosis 
(Figure 5.13). These data, together with our observations on NF-κB-mediated apoptosis, 
demonstrate that c-Abl and Arg promote survival in the presence of doxorubicin by 
activating STAT3. This leads to activation of a pro-survival signaling complex containing 
HSP27/p38/Akt and prevention of doxorubicin-mediated NF-κB transcriptional 
repression of pro-survival factors XIAP and cIAP1 (Figure 5.14). 
 
5.4 Discussion 
In this chapter, we showed that c-Abl/Arg regulate multiple survival pathways 
(i.e., STAT3, NF-κB, Akt) involved in doxorubicin resistance. Foremost, we demonstrate 
that c-Abl/Arg inhibit doxorubicin-mediated apoptosis via activation of STAT3. 
Furthermore, we demonstrated in this chapter that c-Abl/ArgSTAT3 signaling prevents 
doxorubicin-induced NF-κB-mediated transcriptional repression of anti-apoptotic genes. 
We also identified a novel melanoma survival pathway, in which c-Abl/ArgSTAT3 
promotes cell survival via activation of HSP27/p38/Akt signaling. This expands on our 
previous data demonstrating that melanoma cell invasion occurs via c-Abl/ArgSTAT3 
signaling [50], and illustrates the critical nature of these proteins in melanoma 
progression.  
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Figure 5.12. c-Abl/Arg promote chemoresistance by activating a 
STAT3/HSP27/p38/Akt survival pathway. (A) pcDNA and STAT3C-expressing cells 
were treated with STI571 and treated with doxorubicin for 40h, and lysate from attached 
and detached cells blotted with the indicated antibodies. Graphs represent mean±SEM 
from 3 independent experiments. (B) STAT3 was silenced with siRNA in combination 
with doxorubicin (0.5µM, p38 and Akt; 1µM, HSP27) for 40h, attached and detached 
cells were lysed, and assessed by Western blot with indicated antibodies. Graphs 
represent mean±SEM from 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 5.13. Constitutive activation of Akt partially rescues STI571+doxorubicin-
induced apoptosis. 435s/M14 cells expressing vector or constitutively active 
PI3K(E545K) were treated with STI571 and/or doxorubicin (8h) and PARP cleavage 
assessed. Graph represents mean±SEM from 3 independent experiments. A 
representative Western blot demonstrating Akt activation in cells expressing 
PI3K(E545K) is shown. *p<0.05, **p<0.01. 
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Figure. 5.14. Mechanisms by which c-Abl/Arg drive doxorubicin resistance. c-
Abl/Arg activation of STAT3 prevents doxorubicin-mediated phosphorylation and 
translocation of NF-κB into the nucleus and NF-κB-mediated transcription of anti-
apoptotic genes such as cIAP1/XIAP. c-Abl/Arg activation of STAT3 also promotes 
activation of a HSP27/p38/Akt survival pathway. Designed in collaboration with Hope 
Johnson (Markey Cancer Research Communications Office).  
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The role of NF-κB in doxorubicin-induced cell death is controversial as 
doxorubicin induces NF-κB anti-apoptotic activity in some cell types, and in others it 
inhibits NF-κB anti-apoptotic signaling by converting it into a transcriptional repressor 
[75, 86]. It is unclear why NF-κB responds differently to pro-apoptotic stimuli, such as 
doxorubicin, in different cell types, and the manner in which NF-κB transcriptionally 
represses anti-apoptotic targets is also controversial since reports differ on the 
mechanism by which this occurs [86, 87]. Some reports indicate that phophorylation and 
acetylation of p65/RelA is required for NF-κB-mediated transcriptional repression [86], 
while others report that DNA binding and transcriptional repression of anti-apoptotic 
genes occurs in the absense of p65/RelA phosphorylation and acetylation [87].  
STAT3 modulates the activity of NF-κB, and, in the absence of doxorubicin, 
STAT3 promotes phosphorylation and acetylation of NF-κB and thereby increases its 
transcriptional activity in cancer cells [78], but there is a lack of clarity regarding the 
mechanism by which NF-κB mediates transcriptional repression of anti-apoptotic genes. 
We now present evidence that the response of the NF-κB pathway to doxorubicin occurs 
in a manner dependent on the expression level of pSTAT3 and phosphorylation of 
p65/RelA coincides with enhanced transcriptional repression. A fundamental 
discrepancy in how NF-κB responds to doxorubicin between two related cell types 
(435s/M14 and 435s/M14-DR cells) corresponds with dramatic differences in pSTAT3 
expression, offering insight into the mechanism governing NF-κB activity in response to 
doxorubicin. Doxorubicin promotes phosphorylation of p65/RelA; however, in parental 
cells there is no induction of transcriptional activity. In fact, the addition of STI571 
effectively inhibits pSTAT3 (Figure 5.1B), further enhances phosphorylation of p65/RelA 
(Figure 5.5C), and dramatically enhances NF-κB-mediated transcriptional repression of 
anti-apoptotic targets in parental cells treated with doxorubicin (Figure 5.8). Expression 
of constitutively active STAT3 (STAT3C) prevents STI571-mediated nuclear localization 
of p65/RelA (Figure 5.7B), the corresponding decrease in transcriptional activity (Figure 
5.7C), and downregulation of anti-apoptotic NF-κB targets (Figure 5.10). Therefore, c-
Abl and Arg inhibit NF-κB transcriptional repression of apoptotic genes in a STAT3-
dependent manner; thereby, promoting cell survival in the presence of doxorubicin.  
In contrast with our observations in parental cells, doxorubicin dramatically 
increased NF-κB transcriptional activity in cells with acquired chemoresistance, which 
retain much higher levels of pSTAT3 than parental cells. In parental cells, doxorubicin 
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decreases pSTAT3 levels, but in 435s/M14-DR cells, doxorubicin has much less effect 
on STAT3 phosphorylation (Figure 5.1B) and, doxorubicin activates NF-κB 
transcriptional activity (Figure 5.5C). This increase in NF-κB activity in melanoma cells 
possessing acquired resistance perfectly mirrors the observed increase in NF-κB 
transcriptional activity observed when cells expressing constitutively active STAT3 
(STAT3C) are treated with doxorubicin (Figure 5.7C), indicating that STAT3 modulates 
whether NF-κB acts as a transcriptional repressor or transcriptional activator in the 
presence of doxorubicin. Interestingly, STI571 treatment not only prevented doxorubicin-
mediated upregulation of NF-κB targets, but significantly inhibited expression of NF-κB 
targets (cIAP1, XIAP) at protein and transcriptional levels, indicating that inhibition of c-
Abl/Arg converts NF-κB from a transcriptional activator to a transcriptional repressor in 
the presence of doxorubicin in resistant cells. In summary, we demonstrate that 
modulation of NF-κB by c-Abl/Arg requires STAT3, indicating that STAT3 expression 
predicates whether NF-κB will act as a transcriptional repressor or transcriptional 
activator in the presence of doxorubicin. Future experiments delineating the mechanism 
by which c-Abl/ArgSTAT3 directly modulates NF-κB transcriptional activity are 
currently in progress. These data are highly significant because they functionally 
demonstrate that inhibition of c-Abl/Arg can convert a master survival regulator, NF-κB, 
from a pro-survival into a pro-apoptotic factor, thereby making conventional 
chemotherapeutic drugs more effective for treating metastatic disease, and this 
knowledge could potentially lead to the development of agents that specifically convert 
NF-κB into a transcriptional repressor of anti-apoptotic targets in cancer cells. 
In addition to promoting activation of NF-κB, doxorubicin also increases 
phosphorylation of the survival factor, Akt, in a c-Abl/Arg-dependent manner. 
Doxorubicin induced loss of an upper phospho-Akt band, and increased expression of a 
lower phospho-Akt band. This may be due to band collapse of the upper into the lower 
form such as by dephosphorylation or deglycosylation, or doxorubicin may inhibit 
phosphorylation of a specific Akt isoform and increase phosphorylation of a different 
isoform. Future experiments are in progress to elucidate the Akt isoform or post-
translational modification responsible for promoting c-Abl/Arg-mediated doxorubicin 
resistance. 
Interestingly, induction of ABCB1 expression has been linked to activation of 
PI3K/Akt signaling [191, 192]. Thus, our observation that c-Abl/Arg upregulate Akt in 
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response to doxorubicin treatment, suggests that c-Abl may promote ABCB1 expression 
via Akt. Intriguingly, we found that prolonged treatment (72h) with doxorubicin induces a 
significant accumulation of intracellular doxorubicin (Figure 4.3C) even though >80% of 
the cells are alive at this time point (Figure 3.4A). Moreover, doxorubicin treatment, of 
acquired chemoresistant cells, induces changes in signal transduction pathways (i.e., 
Akt, NF-κB, STAT3), which indicates that these cells still respond to doxorubicin despite 
expressing high levels of ABCB1 (Figure 5.1B; 5.5C; 5.11B). Taken together, these data 
indicate that drug transport is only partially responsible for the high-level doxorubicin 
resistance observed, and c-Abl/Arg-dependent upregulation of anti-apoptotic and pro-
proliferative signaling pathways also contribute to acquired doxorubicin resistance. 
These data have important clinical ramifications, as they identify underlying resistance 
mechanisms within advanced chemoresistant cells which may be targeted by c-Abl/Arg 
inhibitors to better treat metastatic disease and reverse breast cancer and melanoma 
chemoresistance. 
We have proven that c-Abl/Arg inhibition dramatically sensitizes breast cancer 
and melanoma cells to doxorubicin, halting proliferation and inducing apoptosis. We now 
present a model outlining the signaling network by which c-Abl/ArgSTAT3 promote 
resistance to doxorubicin-induced apoptosis (Figure 5.14). As described in this chapter, 
STAT3C completely prevents STI571-mediated induction of apoptosis; however, only 
partially rescues the STI571-potentiated decrease in cell proliferation. The mechanism 
by which STI571+doxorubicin halts cell proliferation is the subject of chapter 6.  
 
 
 
 
 
 
 
Copyright © Jonathan T. Sims 2012 
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CHAPTER SIX 
ABL FAMILY KINASES PROMOTE PROLIFERATION VIA STAT3-INDEPENDENT 
MODULATION OF THE MEK/ERK PATHWAY  
6.1 Introduction 
The MAPK (mitogen-activated protein kinase) signaling pathway is made up of a 
series of serine/threonine kinases, and is critical to cancer cell progression [70]. 
Canonical activation of this pathway occurs via growth factor receptor-mediated 
stimulation, which phosphorylates adaptor proteins (i.e., Grb-2), allowing them to bind 
guanine exchange factors (i.e., SOS), and thereby activate Ras [208]. Ras/Raf-
dependent activation of MEK (mitogen-activated protein kinase kinase) and ERK 
(extracellular signal-regulated kinase) promotes cell cycle progression and survival; 
therefore, this pathway is currently under intense therapeutic scrutiny, with B-Raf 
inhibitors generating especially strong clinical data [117]. ERK signaling can promote or 
inhibit proliferation depending on the amplitude of activation and duration of the signal, 
whereas MEK/ERK inhibition sensitizes other cells to doxorubicin-induced cell death 
[209, 210].  
STI571 increases pERK1/2 in BCR-Abl+ CML cells [162], and treatment w/ a 
MEK1/2 inhibitor sensitizes CML cells to STI571-dependent apoptosis [163]. Intrinsic 
resistance of malignant melanomas to DNA damage-inducing therapies has also been 
tied to activation of PI3K/Akt and B-Raf/ERK signaling pathways [68, 117]. Co-targeting 
these pathways has been a major therapeutic focus for melanoma treatment [72]. 
Studies have demonstrated that inhibition of MEK/ERK signaling reduced melanoma cell 
growth in vitro [72]; however, mounting evidence shows that enhanced ERK activation in 
mutant B-Raf cells decreases cell proliferation [211]. In these cells, Akt3 promotes 
cancer cell proliferation by phosphorylating and negatively regulating B-Raf, slightly 
reducing its activation of MEK/ERK, since overstimulation of B-Raf/MEK/ERK induces 
cytostasis [211].   
It is critical to understand the mechanisms that promote chemoresistance so that 
new therapies can be devised to better target aggressive cancers. To this end, we have 
previously demonstrated that c-Abl/Arg promote proliferation and survival of breast 
cancer and melanoma cells [39, 50], and have specifically shown in chapter 5 that c-
Abl/Arg inhibit doxorubicin-mediated apoptosis in a STAT3-dependent manner. STI571, 
a c-Abl/Arg inhibitor, synergizes with doxorubicin to dramatically halt cell proliferation by 
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promoting G2/M arrest (Figure 3.5; 3.6); however, this occurs in a STAT3-independent 
manner (Figure 5.2). MEK/ERK signaling promotes proliferation and survival [70]; 
therefore, we sought to elucidate whether c-Abl/Arg regulate ERK signaling in response 
to doxorubicin. We show that activation of the MEK/ERK pathway occurs coordinately 
with STI571+doxorubicin-mediated inhibition of cell cycle progression and cell 
proliferation; however, inhibition of MAPK signaling dramatically sensitized cells to 
STI571 and STI571+doxorubicin.  We also postulate a model that sheds light on the role 
of MAPK signaling in chemoresistant cell growth and survival. 
 
6.2 Materials and Methods 
6.2.1 Reagents and Cell Lines   
MDA-MB-435s cells were obtained from the University of North Carolina Tissue 
Culture Facility, and are a spindle-shaped, highly metastatic variant of MDA-MB-435 
cells (Chapel Hill, NC). Genetic analysis confirmed that these cells are identical to 
melanoma M14, and therefore, are referred to as 435s/M14 [50]. A drug-resistant variant 
of 435s/M14 (435s/M14-DR) was created via step-wise treatment with increasing 
concentrations of doxorubicin (using a maximum dose of 100nM) [185].  435s/M14 and 
435s/M14-DR cells were cultured in DMEM/10% FBS (fetal bovine serum), + insulin 
(10µg/ml). BT-549 breast cancer cells were cultured in DMEM/10% FBS. MDA-MB-468 
breast cancer cells were cultured in MEM/10% FBS, + sodium pyruvate (10µg/ml). 
STI571 (Gleevec; imatinib mesylate) was obtained from Novartis (Basal, Switzerland), 
dissolved in water (10mM), and stored at -80oC. Doxorubicin was obtained from Sigma 
(St. Louis, MO) and dissolved in water. U0126 was obtained from Cell Signaling 
Technology (Danvers, MA) and dissolved in DMSO. ERK1/2 (sc-94) was purchased 
from Santa Cruz Biotechnologies (Santa Cruz, CA, USA) and phospho-ERK1/2 antibody 
was obtained from Promega (Madison, WI). Western blots were performed as described 
in the manufacturers’ protocols. 
 
6.2.2 Cell Lysis and Western Blots 
 Cells were plated in 60mm dishes, treated the following day, and detached nad 
attached cells were lysed in RIPA buffer (50mM Tris pH 7.5, 150mM NaCl, 1% triton-X 
100, 0.1% SDS, 1% sodium deoxycholate, 1mM PMSF, 1mM sodium orthovanadate, 
25mM sodium fluoride, 10µg/ml leupeptin, aprotinin, pepstatin). Total protein was 
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quantitated with a Lowry DC kit (Biorad; Hercules, CA), equal protein was loaded on 
SDS-PAGE gels, and blots were incubated with specified antibodies. 
 
6.2.3 CellTiter-Glo (CTG) assay (Promega; Madison, WI)   
Cells were plated in triplicate in 96-well plates, refreshed with media containing 
drugs the next day when cells were 30-40% confluent, and harvested 72h (for 
doxorubicin+STI571+U0126), or 96h (for STI571+U0126), later with an equal volume of 
CTG reagent. Plates were rocked for 2m, half of the volume was transferred to an 
opaque 96-well plate, and total light emitted was measured 10m later using a Synergy 2 
microplate reader (Biotek; Winooski, VT).  
 
6.3 Results 
6.3.1 Inhibition of Abl family kinases induces ERK activation.  
Aggressive tumor cells co-opt a multitude of proliferation and survival pathways 
during progression to metastasis [199]. MEK/ERK signaling is one of the most frequently 
deregulated pathways in cancer cell progression due to its ability to promote proliferation 
and survival [212]. Our previous observations indicate a role for the MAPK pathway in c-
Abl/Arg-mediated signaling within breast cancer and melanoma cells [39, 180].  We have 
demonstrated that inhibition of c-Abl/Arg by siRNA and STI571 treatment induces ERK 
activation, specifically ERK1, dramatically in 435s/M14 melanoma cells [39]. This 
occurred as early as 2-4h after STI571 treatment, indicating a direct, rather than 
compensatory, mechanism [39]. Likewise, STI571-mediated induction of ERK1/2 activity 
was observed in multiple breast cancer cell lines possessing highly active c-Abl/Arg 
[180]. Similar to our observations, treatment of BCR-Abl+ CML cells with STI571 
increases ERK1/2 activity [162]. We have previously demonstrated that Abl family 
kinases promote cell proliferation, G1S transition, and survival [39]. Therefore, to 
determine whether STI571-mediated upregulation of ERK1/2 activity is required for 
STI571-dependent inhibition of proliferation and loss of cell viability, we treated cells with 
STI571 and U0126, a MEK1/2 inhibitor, alone and in combination and observed a 
dramatic decrease in cell viability in 435s/M14 melanoma and BT-549 and MDA-MB-468 
breast cancer cells (Figure 6.1A-C). This indicates that inhibition of ERK1/2 activity 
promotes cell death and dramatically sensitizes cells to STI571.  
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Fig. 6.1. Inhibition of MEK/ERK signaling sensitizes cells to STI571 and 
doxorubicin+STI571. (A-C) Cells were plated in triplicate, treated with STI571 and/or 
U0126 for 96h, and viability assessed by CellTiter-Glo assay (Promega, Madison, WI). 
Mean±SEM for 3 independent experiments. Some error bars are too small for 
visualization. (D-F) Cells were treated with STI571 and/or doxorubicin for 40h, attached 
and detached cells were lysed, and analyzed by Western blotting with indicated 
antibodies. Experiments shown are representative of 3 independent experiments. (G,H) 
Cells were treated with STI571, U0126, and/or doxorubicin for 72h, and analyzed by 
Western blotting (G) and CellTiter-Glo assay (H). Mean±SEM for 3 independent 
experiments. Combination indices (CI) were determined for mean±SEM of 3 
independent experiments (<1=synergistic; 1=additive; >1=antagonistic). Dox+STI571 
CI=0.24±0.15; Dox+U0126 CI=0.38±0.18; U0126+STI571 CI=0.72±0.14; 
Dox+U0126+STI571 CI=0.14±0.1. (G,H) Done in collaboration with W. Friend. *p<0.05; 
**p<0.01; ***p<0.001. 
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6.3.2 Addition of STI571 and doxorubicin dramatically induces ERK activity in 
breast cancer and melanoma cells.  
We demonstrated in chapters 3 and 5 that STI571, a c-Abl/Arg inhibitor, 
synergizes with doxorubicin to dramatically halt cell proliferation by promoting G2/M 
arrest in a STAT3-independent manner (Figure 3.5; 3.6; 5.2). Therefore, we sought to 
elucidate whether the anti-proliferative effects of STI571+doxorubicin occured via 
regulation of ERK signaling. Similar to our observations with STI571 alone, we 
previously provided evidence of a potentiated induction of ERK1/2 activity in breast 
cancer cells treated with combinations of STI571 and camptothecin, 5-fluorouracil, or 
cisplatin, and this coincided with inhibition of cell proliferation [180]. Cotreatment of BT-
549 breast cancer and 435s/M14 melanoma cells with doxorubicin+STI571 dramatically 
induced ERK1/2 activity at doses that resulted in loss of cell viability, proliferation, and 
induction of apoptosis (Figure 6.1D, E; 3.1A, B), and this effect was observed as early as 
4h post-treatment (data not shown).  
 
6.3.3 Inhibition of MAPK signaling sensitizes doxorubicin-resistant cells to 
undergo apoptosis.  
ERK signaling can promote or inhibit proliferation depending on the amplitude of 
activation and duration of the signal [209, 210]. Sustained ERK activation induces cell 
cycle arrest and apoptosis in some cell types in response to doxorubicin, whereas 
MEK/ERK inhibition sensitizes other cells to doxorubicin-induced cell death [209, 210]. 
Interestingly, doxorubicin treatment of advanced chemoresistant cells only modestly 
increased ERK phosphorylation, and STI571 treatment dramatically potentiated 
doxorubicin-induced ERK2 phosphorylation at 4h and 40h time points (Figure 6.1F, data 
not shown). Based on these results, it is possible that inhibition of Abl family kinases 
may activate ERK1/2 by deregulating a negative feedback mechanism, or inducing a 
cytoprotective stress response pathway. To test whether ERK upregulation mediates 
apoptosis or survival, we inhibited ERK1/2 activation by treating cells with a MEK 
inhibitor (U0126) (Figure 6.1G). Significantly, U0126 treatment of 435s/M14-DR cells 
sensitized cells to doxorubicin, STI571, and doxorubicin+STI571 treatment (Figure 
6.1H), indicating that inhibition of ERK2 activity abrogated acquired chemoresistant 
melanoma cell survival. 
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6.4 Discussion 
The Ras/Raf/MEK/ERK pathway promotes doxorubicin resistance [80]; however, 
sustained activation of this pathway following doxorubicin treatment can lead to cell 
cycle arrest [209]. To help resolve how ERK1/2 activity promotes or inhibits cell 
proliferation we present a model of ERK1/2’s actions as a molecular rheostat (i.e., a 
resistor in a biological circuit) within the confines of Ohm’s Law. We believe this model 
harmonizes all known aspects of ERK signaling in carcinoma cells. To bypass cell 
senescence and promote tumorigenic growth, cancer cells have upregulated 
mechanisms to fine tune activation of the ERK pathway [211]. Cancer cells continue to 
proliferate under these conditions; however, disruption of these cellular regulators of 
ERK activity give rise to aberrantly high ERK activity, once again initiating the cellular 
senescence protocol [211]. Aberrantly high ERK1/2 activity promotes cytostasis; 
however, cells can overcome this stimulation and recapture control of ERK activity as we 
observed with 435s/M14-DR cells (Figure 6.1F). In summary, our data, viewed through 
the model we propose, illustrates that aberrantly high ERK1/2 activity potentially induces 
cytostasis; however, shutting off this signaling pathway seemingly shifts the fate of a cell 
toward apoptosis (Figure 6.2A; 6.1H).  
Viewed in context of Ohm’s Law, stimulation of a circuit possessing low 
resistance (moderate ERK activation) with a set amount of voltage (growth promoting 
signals) corresponds to a set output of current (proliferation); however with increased 
resistance (more ERK activation), the same amount of voltage (growth promoting 
signals) now correspond to less current output (proliferation) (Figure 6.2B) [213]. As with 
most cellular signaling events, a number of factors are likely to determine the response 
of cells to insults and/or stimuli. We have previously demonstrated in breast cancer cells 
that cell type-specific differences in signaling pathway modulation governs the response 
of cells to combination treatments of STI571 and chemotherapeutic drugs [180]. 
Complete inhibition of ERK1/2 activity trumps the cytostatic response induced by highly 
activated ERK1/2. We postulate that just as voltage flows through a circuit, with 
resistance building only slightly as the output current increases, increasing ERK activity 
promotes cell growth; however, once a threshold level of activation is reached, 
increasing ERK activity further results in cytostasis (Figure 6.2A). This corresponds to 
Ohm’s Law since dramatic increases in resistance within a circuit lead to less current 
output [213]. Moreover, inhibition of ERK activity fully sensitizes cells to undergo 
apoptosis (Figure 6.1H), just as a failed resistor prevents current flow due to the loss of  
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Fig. 6.2. Model illustrating that the extent of ERK activation determines cell 
proliferation/apoptosis. (A) As the signal intensity and/or signal duration of ERK 
activity increases, a threshold level of growth-promoting ERK activation is surpassed 
and cytostasis is induced. (B) Based on Ohm’s Law, a circuit with high resistance yields 
much lower current output than a circuit with low/moderate resistance when presented 
with the same amount of voltage. I=current; V=voltage; R=resistance.  
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conductive material, resulting in infinite resistance [213]. In line with our hypothesis, 
other reports have established that Akt regulates ERK activity to promote growth, and 
inhibition of Akt leads to increased ERK activity and cytostasis [211].   
 ERK phosphorylation can promote chemoresistance or inhibit proliferation 
depending on signal duration, amplitude, and cellular context [80]. 435s/M14 and 
435s/M14-DR melanoma cells possess mutant B-Raf and wildtype PTEN [214], and in 
this cellular context, activation of Akt results in B-Raf phosphorylation, which limits B-Raf 
activity and thereby limits overstimulation of ERK activity [211]. BT-549 and MDA-MB-
468 cells possess mutant PTEN, suggesting that activated Akt may induce ERK 
activation, irrespective of B-Raf status, in these cells as well [214, 215]. In all cell types 
tested in this chapter, ERK activity is regulated to circumvent cytostasis and drive 
proliferation and survival. Here, we show that doxorubicin induces upregulation of 
ERK1/2 in breast cancer and melanoma cells, and inhibition of c-Abl/Arg with STI571 
potentiates this upregulation. Interestingly, ERK activation is regulated differently in cells 
possessing acquired chemoresistance. Unlike ERK2, ERK1 is not further upregulated in 
response to STI571+doxorubicin. Others have demonstrated that ERK2, but not ERK1, 
promotes resistance to anti-cancer therapy [216]. Likewise, ERK1, but not ERK2, was 
shown to inhibit Ras-dependent proliferation [217]. In order to evade anti-apoptotic 
insults, these acquired chemoresistant melanoma cells may have downregulated ERK1 
activity, which explains why only ERK2 remains sensitive to STI571+doxorubicin (Figure 
6.1F). However, the inhibition of c-Abl/Arg critically sensitizes these acquired 
chemoresistant cells to doxorubicin-mediated decrease in cell viability, and coordinately 
overstimulates ERK2 activity (Figure 3.4A; 6.1F).  
 Based on current literature, and the model we propose, one cannot differentiate 
the effect that ERK activation has on proliferation vs. apoptosis based on data derived 
from use of MEK/ERK inhibitors. ERK activation results in two completely opposite 
physiological outcomes depending on the intensity and duration of activation [209, 210] 
(Figure 6.2A). Our model reconciles seemingly conflicting data regarding ERK activation, 
and explains how STI571+doxorubicin treatment halts cell proliferation. Moreover, our 
data are particularly exciting since we demonstrate that despite the benefit of arresting 
cancer cell growth, if the desired outcome is inhibition of cancer cell viability, then ERK 
inhibitors combined with doxorubicin and c-Abl/Arg inhibitors may be a highly effective 
combination for treating acquired resistance.        
Copyright © Jonathan T. Sims 2012 
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CHAPTER SEVEN 
SUMMARY AND FUTURE DIRECTIONS 
7.1 Summary 
Chemoresistance presents a tremendous hurdle in cancer therapy and the 
discovery of novel therapeutic targets that specifically impinge on the viability of resistant 
cells is cancer type and cell type-specific in nearly all cases. Highly refractory cells are 
typically the most aggressive and invasive forms of disease [80, 195]. Receptor and non-
receptor tyrosine kinases are overwhelmingly involved across all cancer types in the 
dissemination and amplification of growth promoting signals [218]. Our data demonstrate 
that the non-receptor tyrosine kinases, c-Abl and Arg, are highly active in response to 
growth factors (i.e., EGFR, Her2, IGF-1R), and c-Abl and Arg are integrally involved in 
promoting proliferation, survival to nutrient deprivation, invasion, and metastasis, 
properties indicative of highly advanced, metastatic disease [38, 39, 50].  
Our current work has identified Abl family kinases as critical mediators of 
chemoresistance in breast cancer and melanoma cells. Inhibition of c-Abl/Arg sensitizes 
a panel of breast cancer cell lines to halt proliferation and undergo apoptosis in response 
to a variety of chemotherapeutic agents. c-Abl/Arg inhibitors, likewise, dramatically 
synergize with doxorubicin to arrest melanoma cells in G2/M phase of the cell cycle, and 
induce apoptosis in melanoma and breast cancer cells; therefore, c-Abl and Arg promote 
proliferation and survival in the presence of chemotherapy in both breast cancer and 
melanoma cells. We also discovered that c-Abl promotes ABCB1 expression in acquired 
chemoresistant melanoma cells, and inhibitors of c-Abl/Arg dramatically sensitize 
advanced chemoresistant cells to doxorubicin via inhibition of ABCB1 transporter activity 
and c-Abl and Arg-mediated signaling pathways. In the presence of doxorubicin, c-Abl 
and Arg act via STAT3 to prevent NF-κB-mediated transcriptional repression of anti-
apoptotic genes, and upregulate an HSP27/p38/Akt pro-survival signaling pathway in 
melanoma cells leading to enhanced survival. These data are of particular importance 
due to the highly resistant nature of melanoma and the clinical frustration resulting from 
the inability to halt advanced disease progression.       
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7.2 Future Directions 
7.2.1 CHAPTER TWO: ABL FAMILY KINASES PROMOTE BREAST CANCER 
CHEMORESISTANCE 
We demonstrated that the c-Abl/Arg inhibitor, STI571, was highly effective at 
sensitizing breast cancer cells to a variety of chemotherapeutic drugs. Our data illustrate 
the cell type-specific nature wherein these combinations are most effective. We 
observed that STI571 synergizes with camptothecin in MDA-MB-231 cells, cisplatin in 
BT-549 cells, and paclitaxel, 5-FU, and cisplatin in MDA-MB-468 cells. The significance 
of these studies would be greatly enhanced by extension of our in vitro data to xenograft 
mouse studies. We have observed markedly enhanced efficacy in vivo with use of 
nilotinib rather than STI571 [50], so future in vivo studies will focus on combining nilotinib 
with chemotherapy. Mammary fat pad injections in nude mice would allow us to monitor 
primary tumor regression in chemotherapy-treated mice vs. mice cotreated with nilotinib 
and chemotherapy. Combinations that would be especially interesting to test are 
cisplatin and nilotinib in BT-549 xenografts and 5-FU and nilotinib in MDA-MB-468 
xenografts due to the dramatic induction of apoptosis observed in vitro in these cells with 
these drug combinations. Considering our recent evidence demonstrating that c-Abl/Arg 
promote melanoma metastasis [50], the data presented in chapter 2 suggest that 
inhibition of c-Abl/Arg could synergize with chemotherapeutics to significantly prevent 
the metastatic spread of breast cancer as well; therefore, separate studies within this 
aim will be carried out in which treatment with nilotinib and/or chemotherapy will be 
administered upon removal of primary tumors and lungs of all animals will be monitored 
using IVIS imaging (University of Kentucky DLAR).   
Potential biomarkers identified from our signaling studies could help identify 
which therapy may yield the best prognosis in specific subsets of patients. We identified 
Akt, NF-κB, and ERK signaling pathways as major downstream targets of c-Abl/Arg in 
breast cancer cells. Future experiments will confirm these signaling molecules as 
potential mediators of c-Abl/Arg signaling. First, silencing these genes with siRNAs will 
confirm that inhibition of these pathways promotes cell death in the presence of 
chemotherapeutics. Second, BT-549 cells were sensitized to STI571+cisplatin via 
inhibition of Akt signaling; therefore, a constitutively active form of PI3K (PI3K(E545K)) 
will be expressed in these cells, resulting in dramatic activation of Akt signaling, which 
should prevent synergism of STI571 and cisplatin if cells are sensitized to this therapy 
due to Akt inhibition. Also, increased levels of the NF-κB inhibitory molecule, IκB, were 
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observed following STI571+camptothecin treatment in MDA-MB-231 cells. We will 
silence IκB, which should activate NF-κB signaling, and determine whether this prevents 
the dramatic decrease in cell proliferation observed with STI571+camptothecin 
treatment. We also found in MDA-MB-468 cells that low concentrations of 5-FU were 
antagonistic with STI571; however, cells were sensitized to higher concentrations of 5-
FU when combined with STI571. STI571 has been shown to interact with certain ABC 
transporters [148]; therefore, we could identify if STI571 sensitizes MDA-MB-468 cells to 
5-FU by inhibiting efflux of 5-FU via a drug transporter (i.e., ABCG2).  
We present evidence that Abl family kinases are functionally involved in 
promoting breast cancer cell proliferation in the presence of chemotherapeutics from a 
variety of different classes. Cell proliferation is promoted via complex regulation of cell 
cycle components allowing for aberrant progression through the cell cycle [219, 220]. 
We demonstrated that Abl kinases promote G1S progression in breast cancer cells, 
and activate STAT3 [39]. STAT3 activates c-Myc, which inhibits p27 and activates cyclin 
D1/cyclin dependent kinase 4 (cdk4) complexes [54, 55, 221]. These steps are critical 
for cell cycle transition, and can promote cell cycle reentry after DNA repair processes 
halt cycling cells [3, 222]. To determine if c-Abl/Arg promote proliferation via cyclin D1 
and c-Myc, protein expression of cyclin D1 and c-Myc will be measured following 
treatment with STI571 and various chemotherapeutics. Since we observed that c-
Abl/ArgSTAT3 regulate chemoresistance, we will elucidate whether cyclin D1 and c-
Myc are regulated in a STAT3-dependent manner by treating STAT3 siRNA-transfected 
cells with anti-proliferative chemotherapeutics described in chapter 2 and monitoring 
expression changes of these proteins. Further studies focused on testing the mechanism 
by which Abl family kinases promote proliferation and survival in the presence of breast 
cancer chemotherapeutics will test whether constitutive activation of cyclin D1 and c-Myc 
rescues the inhibition of proliferation observed with STI571+chemotherapy treatment. 
These data could lead to insights regarding the mechanism by which c-Abl/Arg promote 
breast cancer cell proliferation in response to chemotherapeutic agents.  
 
7.2.2 CHAPTER THREE: ABL FAMILY KINASES PROMOTE CHEMORESISTANCE 
TO DOXORUBICIN 
We definitively demonstrated that c-Abl and Arg promote doxorubicin resistance 
in invasive melanoma and breast cancer cells. c-Abl and Arg are specifically targeted by 
STI571, and inhibition of these kinases sensitizes cells to doxorubicin-mediated cell 
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cycle arrest in G2/M phase and induction of apoptosis. As noted in the discussion 
regarding chapter 2, we are likewise focused on transitioning our exciting data 
describing synergistic interactions of c-Abl/Arg inhibitors and doxorubicin to in vivo 
studies. We observed that STI571 synergizes with doxorubicin to kill BT-549, WM-3248, 
435s/M14, and 435s/M14-DR cells and the significance of these data would be 
strengthened further by xenograft mouse studies. As mentioned in the discussion 
regarding chapter 2, we have observed greater efficacy in vivo with use of nilotinib rather 
than STI571 [50], so future in vivo studies will focus on combining nilotinib with 
doxorubicin. Subcutaneous injections to the flanks of nude mice will be done to form 
primary melanoma tumors so that tumor regression in doxorubicin-treated mice vs. mice 
cotreated with nilotinib and doxorubicin can be studied. We previously demonstrated that 
c-Abl/Arg promote melanoma metastasis [50]; therefore, future studies will focus on 
whether inhibition of c-Abl/Arg synergizes with doxorubicin to significantly prevent 
metastatic spread of melanoma. Extended use of doxorubicin is restricted due to cardiac 
toxicity [223]. The c-Abl/Arg inhibitor, STI571, may induce cardiomyopathy; however, this 
remains controversial [224]. We have demonstrated that STI571 sensitizes melanoma 
cells to doxorubicin, dramatically lowering its IC50. Since STI571 allows for lower levels 
of doxorubicin to be used for therapy, as compared to doxorubicin alone, we will 
determine whether STI571+doxorubicin decreases cardiomyopathy as compared to 
relative high dose treatment of doxorubicin.  This will be quantitated by monitoring the 
weights of the animals during the course of the experiment and H/E (hematoxylin/eosin) 
staining sections of the hearts of euthanized mice. Further analysis of ventricular 
hypertrophy markers (i.e., ANP, BNP) will be assessed via semi-quantitative RT-PCR.    
We demonstrated that c-Abl/Arg prevent doxorubicin-induced apoptosis, and that 
c-Abl/Arg inhibitors dramatically sensitize cells to undergo apoptosis. Apoptosis, whether 
mediated by the intrinsic or extrinsic pathway, is initiated via a plethora of stimuli [204]. 
Future experiments will determine if STI571 sensitizes cells to doxorubicin by inducing 
an ER (endoplasmic reticulum) stress response. ER stress occurs via increased Ca2+ 
signaling and accumulation of misfolded proteins [225]. We have demonstrated c-
Abl/Arg-mediated induction of HSP27, a chaperone responsible for the correct folding of 
misfolded proteins [226], in the presence of doxorubicin (Figure 5.11A) and preliminary 
data from an R&D Apoptosis Array showed that STI571 dramatically decreased 
cytochrome c expression (J.T. Sims, unpublished observation), indicating potential 
deregulation of mitochondria and Ca2+ repositories. Abl family kinases have been shown 
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to modulate Ca2+ levels in cells, and STI571-mediated apoptosis of CML cells occurs via 
ER stress [225, 227]. This evidence suggests a role for STI571 in cellular regulation of 
Ca2+ and modulation of ER stress. We will determine if STI571+doxorubicin-mediated 
apoptosis results from an ER stress response by first characterizing cellular levels of 
GRP78 and CHOP, which are known ER stress-regulated proteins [228, 229]. CHOP 
promotes apoptosis via ER stress response [228]; therefore, we will determine whether 
silencing this gene prevents synergistic induction of apoptosis following 
STI571+doxorubicin. In addition, we will quantify the effects that c-Abl/Arg have on 
cellular Ca2+ homeostasis in the presence of doxorubicin using a fluorescent dye, Fura-
2, which binds free intracellular calcium [230]. These data will be critical as we seek a 
fuller understanding of how c-Abl and Arg promote survival and chemoresistance.  
 
7.2.3 CHAPTER FOUR: STI571-MEDIATED CHEMOSENSITIZATION OF DRUG-
RESISTANT MELANOMA PARTIALLY MEDIATED VIA ABCB1 
We have shown that Abl family kinases promote chemoresistance. One 
mechanism by which this occurs is via c-Abl-mediated induction of ABCB1 expression. 
c-Abl/Arg inhibitors, such as STI571, inhibit ABCB1-mediated efflux of doxorubicin and 
thereby dramatically sensitize advanced chemoresistant cells to undergo apoptosis and 
halt proliferation. Therefore, STI571-mediated inhibition of drug transport involves not 
only direct inhibition of transporter activity, but also indirect modulation via regulation of 
transporter expression. These data are significant because they indicate that c-Abl plays 
an active role in promoting ABC transporter upregulation during acquired 
chemotherapeutic resistance. Interestingly, ABCB1 expression and efflux activity is 
induced in leukemic cells via PI3K/Akt/FOXO3a signaling [231]. Thus, our observation 
that c-Abl/Arg activate Akt in response to doxorubicin treatment, suggests that c-Abl may 
promote ABCB1 expression via Akt. We will determine if c-Abl/ArgAkt activates 
FOXO3a and determine whether doxorubicin-induced upregulation of ABCB1 occurs via 
this mechanism. Future experiments will also address whether decreased expression of 
ABCB1 observed in response to silencing c-Abl expression with siRNA specifically 
decreases the cells’ ability to efflux doxorubicin.  
Interestingly, Ejlertesen and colleagues found that sensitivity to 
doxorubicin/anthracyclines depends on Her2, Top2A, and TIMP1 expression [232]. 
Top2A (topoisomerase 2A) is a direct target of doxorubicin and therefore is recognized 
as a determinant of cellular response to doxorubicin [232]. We have demonstrated that 
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Her2 activates Abl family kinases and that activation of Abl family kinases in these cells 
promotes chemoresistance [38, 180].  Significantly, we recently discovered that 
435s/M14-DR cells highly express TIMP1 as compared to parental cells, and STI571-
mediated inhibition of c-Abl/Arg dramatically decreases TIMP1 transcription in these 
cells (J.T. Sims and S. Ganguly, unpublished observations). These data could lead to a 
greater understanding of c-Abl/Arg-mediated resistance mechanisms in solid tumor cells 
in light of the recently recognized role for TIMP1-mediated survival via PI3K/Akt 
signaling [233].  
Drugs that regulate reactive oxygen species (ROS) formation have been shown 
to induce melanoma cell apoptosis [234], and the ability of cells to combat this insult 
correlates with disease progression [235]. Upregulation of survival pathways, like those 
regulated by NF-κB, promote cell survival in the presence of increased ROS [236, 237]. 
ROS are eliminated from cells via controlled elimination processes by peroxiredoxin, 
glutathione peroxidase, and catalase [238], and doxorubicin, which produces ROS, 
induces catalase expression [239]. In other cell types, c-Abl/Arg operate as part of the 
oxidative stress response to phosphorylate and activate catalase [238, 240]. Using the 
R&D Apoptosis Array, we found that 435s/M14-DR cells, which contain increased c-
Abl/Arg activity (Figure 4.4), possess dramatically elevated levels of catalase as 
compared with parental cells, and STI571+doxorubicin dramatically decreases catalase 
expression in these cells (J.T. Sims, unpublished observation). 435s/M14-DR cells 
initially efflux doxorubicin efficiently; however, with prolonged treatment, doxorubicin 
accumulates within these cells. Despite enhanced levels of intracellular doxorubicin, 
which is known to induce ROS, these acquired chemoresistant cells remain viable. A 
potential mechanism of resistance to the ROS-inducing effects of doxorubicin may be via 
c-Abl/Arg-mediated upregulation of catalase. Catalase expression and activity in 
response to Abl family kinases will be tested [241]. The identification of a potential 
connection between c-Abl/Arg and catalase in acquired chemoresistant cells could yield 
significant insights for the cancer field regarding potential mechanisms of resistance.   
Future studies are focused on understanding the molecular mechanisms by 
which this acquired chemoresistant cell population, containing very highly active c-
Abl/Arg, promotes cell survival and resistance. Studies aimed at characterizing the 
435s/M14-DR cells show that these doxorubicin-resistant cells proliferate at a higher rate 
than parental cells in serum-deprived conditions (J.T. Sims, unpublished observation). 
Cancer stem cells (CSCs) are highly resistant to chemotherapeutic agents [242]. CSCs 
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make up a small subset of dedifferentiated, highly refractory cells within a tumor that are 
able to survive commonly used chemotherapeutics and result in residual disease [243-
245]. We demonstrated that a small subset of highly resistant cells derived from serial 
treatment of 435s/M14 melanoma cells with doxorubicin is exquisitely sensitive to 
STI571, and we hypothesize that these cells may possess CSC qualities allowing for the 
outgrowth of a highly refractory cell population. Preliminary data demonstrate no 
alteration of the CSC markers, CD24/CD44, relative to parental cells (J.W. Friend, 
unpublished observation), but the melanoma stem cell markers CD133 and ALDH were 
not tested [244]. If 435s/M14-DR cells possess a stem cell phenotype then our discovery 
that these highly resistant cells preferentially express a greater degree of highly active, 
cytoplasmically localized c-Abl/Arg as compared to parental cells will be extremely 
important for therapeutically targeting this highly refractory subset of cancer cells and 
provide rationale for new CSC-based therapies.  
 
7.2.4 CHAPTER FIVE: ABL FAMILY KINASES PROMOTE MELANOMA 
CHEMORESISTANCE VIA STAT3-MEDIATED INHIBITION OF NF-KB 
TRANSCRIPTIONAL REPRESSION AND A STAT3-MEDIATED HSP27/P38/AKT 
SURVIVAL PATHWAY 
We previously showed that c-Abl promotes melanoma invasion via a STAT3-
dependent mechanism [50]. Moreover, we now demonstrate that c-Abl and Arg promote 
resistance to apoptosis via activation of STAT3. Understanding the c-Abl/ArgSTAT3-
mediated regulation of IAP molecules is imperative for combating chemoresistance. One 
mechanism by which cIAP1/XIAP are negatively regulated is via interaction with 
Smac/DIABLO [83]. Other reports have shown that high IAP expression and low 
Smac/DIABLO expression could lead to doxorubicin resistance in multiple myeloma cells 
[83]. Preliminary data from an R&D Apoptosis Array demonstrate a strong correlation 
between increased Smac/DIABLO and decreased cIAP1 protein expression in cells 
treated with STI571+doxorubicin (J.T. Sims, unpublished observation). Thus, a possible 
mechanism by which c-Abl and Arg enhance IAP protein expression and prevent 
caspase-dependent apoptosis may involve downregulation of Smac/DIABLO.  
Mounting evidence has recently demonstrated a clear pro-apoptotic role for the 
NF-κB pathway [246]; however, the mechanism by which NF-κB mediates apoptosis is 
unclear and perhaps could differ based on cell type and/or stimuli [86, 87]. We have 
demonstrated that inhibition of c-Abl/ArgSTAT3 signaling promotes doxorubicin-
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mediated conversion of p65/RelA into a transcriptional repressor of anti-apoptotic genes. 
We confirm previous reports suggesting that post-translational modification of p65/RelA 
in response to chemotherapeutic agents promotes transcriptional repression by means 
of our observation that phosphorylation of p65/RelA coincides with decreased 
transcriptional activity and loss of cIAP1 and XIAP expression (Figure 5.5B,C; 5.8) [247]. 
We provide further clarity regarding the conversion of NF-κB into a transcriptional 
repressor by demonstrating that c-Abl/Arg act via STAT3 to prevent doxorubicin-induced 
transcriptional repression of NF-κB targets, and propose that STAT3 expression levels 
dictate whether p65/RelA will respond to doxorubicin in a pro- or anti-apoptotic manner. 
The interaction of p65/RelA with HDACs has been shown in other cell types to be 
dependent on p65/RelA phosphorylation [86, 247]. We hypothesize that c-
Abl/ArgSTAT3 prevents the binding of histone deacetylases (HDACs) to p65/RelA by 
modulating the phosphorylation status of p65/RelA. Therefore, our observation that c-
Abl/ArgSTAT3 decreases phosphorylation and promotes cytoplasmic retention of 
p65/RelA in response to doxorubicin provides insight into mechanism of NF-κB 
regulation in these cells (Figure 5.7B).  
We will test whether the phosphorylation and acetylation of NF-κB is dependent 
on STAT3. We also will extend our findings regarding the STI571-mediated conversion 
of NF-κB from a pro-survival factor to a transcriptional repressor to other melanoma and 
breast cancer cell lines. We will first test whether silencing p65/RelA decreases 
doxorubicin-mediated cell death and prevents STI571+doxorubicin potentiation of 
apoptosis in a number of melanoma and breast cancer cell lines. Following these 
studies, assessment of transcriptional activity will be done using our stable luciferase-
based promoter system as described in chapter 5.  
Akt is activated in ~70% of melanomas [184], which makes our observation of c-
Abl/ArgAkt signaling critical to understanding and preventing melanoma 
chemoresistance. We have demonstrated that Abl family kinases are activated by 
doxorubicin to promote HSP27/p38/Akt activation. The mechanism by which c-Abl/Arg 
are activated by doxorubicin is unknown. Intriguingly, in certain cell types, DNA-PK is 
activated by DNA damage and acts in a PDK2-like manner to activate Akt via 
phosphorylation on S473 [68]. Studies have demonstrated that DNA-PK directly 
phosphorylates c-Abl and that stimulation of DNA-PK via incubation with sonicated DNA 
resulted in enhanced c-Abl-dependent phosphorylation of the Abl substrate, GST-Crk 
[248]. Moreover, it would also be interesting to test whether DNA-PK may activate c-Abl 
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in melanoma cells in response to doxorubicin, resulting in activation of Akt via complex 
formation with p38 and HSP27. Our observations that c-Abl/Arg promote HSP27/p38/Akt 
signaling in a STAT3-dependent manner provides evidence of novel c-Abl/Arg-mediated 
signaling pathways in solid tumor cells, and also demonstrates that doxorubicin-induced 
Akt activation via HSP27/p38 occurs not only in neutrophils, but also in solid tumor cells. 
To confirm direct regulation of Akt via p38 and HSP27, siRNA-mediated inhibition of both 
p38 and HSP27 will be performed and the decrease in doxorubin-induced Akt 
phosphorylation will be assessed. To verify that c-Abl/Arg promote complex formation of 
HSP27/p38/Akt in response to doxorubicin, Akt, p38, and HSP27 will be 
immunoprecipitated in lysates from untreated, doxorubicin-treated, and 
STI571+doxorubicin-treated samples. The interaction of these proteins in response to 
these various treatments will offer insight into the c-Abl/Arg-mediated resistance 
mechanism. 
The identification of signaling molecules modulated by c-Abl/Arg provides a 
number of therapeutic targets that can be used as biomarkers to determine if tumors are 
likely to respond to c-Abl/Arg inhibitors in combination with chemotherapeutic drug 
treatment. Since c-Abl/Arg are integral to advanced melanoma progression and 
metastasis [50], we will also determine if c-Abl/Arg regulate melanoma specific 
biomarkers. One such marker of particular interest is GRIN2A, the gene that encodes 
NMDA receptors, which is mutated in 33% of melanomas [249]. GRIN2A can activate 
Akt [250], and associates with Src family kinases, PTK2B [251, 252], and, intriguingly, 
Abl family kinases interact with NMDA receptors (i.e., glutamate receptor) in neurons 
[253]. This work is of particular significance if we determine that c-Abl/Arg regulate 
biomarkers such as GRIN2A, since this would aid in the selection of patient populations 
who may be good candidates for c-Abl/Arg inhibitor therapy. The proper identification of 
advanced chemoresistant tumors that possess elevated levels of these tumor-promoting 
signaling molecules will lead to effective use of targeted agents in treatment regimen 
possibly rendered ineffective in the past. Our current work has identified potential 
biomarkers (STAT3, Akt, p38, HSP27) that could provide rationale for the selection of 
patients who may be candidates for combination treatment with c-Abl/Arg inhibitors. The 
extension of our findings to established biomarkers, such as GRIN2A, would aid in this 
effort as well.  
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7.2.5 CHAPTER SIX: ABL FAMILY KINASES PROMOTE PROLIFERATION VIA 
STAT3-INDEPENDENT MODULATION OF THE MEK/ERK PATHWAY  
Inhibition of MEK/ERK signaling sensitizes acquired chemoresistant cells to 
STI571/doxorubicin treatment. To better understand the mechanism by which U0126 
synergizes with STI571 and doxorubicin to kill resistant cells, we will express activated 
ERK and determine whether this limits STI571+doxorubicin-induced G2/M arrest and 
apoptosis in 435s/M14-DR cells.  There are potential issues related to this experiment 
since enhanced activation of ERK can also stimulate cytostasis of cancer cells [211]. We 
will modulate expression of ERK1/2 via siRNA and tet-inducible expression vectors, and 
determine whether expression of either isoform is more responsible for the observed 
effects in resistant cells.  This is of particular importance because we observed 
downregulated ERK1 activation in STI571+doxorubicin-treated 435s/M14-DR cells as 
compared to parental cells. Others have demonstrated that MAPK signaling is 
downregulated in doxorubicin-resistant cells [254].  
Preliminary data indicate that STI571 prevents ERK1/2 activation in WM3248 
cells grown in serum-deprived conditions (S. Ganguly, unpublished observation). 
WM3248 cells possess wildtype B-Raf and mutant PTEN; therefore, regulation of ERK 
signaling in these cells may be via another mechanism rather than c-Abl/ArgAkt 
signaling since these cells possess activated Akt. To further test the reason for this 
discrepancy, we will use a tet-inducible system to regulate expression of activated 
ERK1/2 and thereby determine whether activation of ERK1/2 prevents the 
STI571+doxorubicin-mediated decrease in WM3248 cell proliferation. Understanding the 
mechanism by which STI571 prevents breast cancer and melanoma cell proliferation is 
especially important in relation to inhibition of disease progression, and these studies will 
shed light on that potential mechanism. 
 
7.3 Studies in Progress 
Our work has identified Abl family kinases as causative agents in solid tumor 
progression (i.e., breast cancer, melanoma, glioblastoma) [38, 44, 50]. Others have also 
demonstrated a role of c-Abl and Arg in breast cancer [41-43, 255], gastric carcinomas 
[45], hepatocellular carcinoma [256], and lung cancer [19, 257]. Some recent evidence 
has demonstrated a potential role of c-Abl in prostate cancer motility [48]. We propose 
future experiments that will elucidate whether c-Abl/Arg are activated in 
invasive/metastatic prostate cancer and promote prostate cancer progression and 
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survival. We have discovered that Abl family kinases are indeed highly activated in 
invasive/metastatic prostate cancer cells, and their activation strongly correlates with the 
invasive/metastatic capability of each cell line (Figure 7.1A). Prostate cancer, the most 
frequently diagnosed noncutaneous form of cancer, is difficult to treat if not detected 
early, and refinement of biomarkers for this cancer can potentially result in dramatically 
improved patient prognosis [258]. Recent evidence by Kyprianou and colleagues 
suggests that Talin, a high molecular weight cytoskeletal protein overexpressed in 
prostate cancer, is a causative prognostic marker of disease progression to metastasis 
[259]. Talin promotes proliferation, survival, invasion through the endothelial cell layer, 
and metastasis via activation of integrin and Akt signaling pathways [260]. Talin is critical 
for focal adhesion formation and cell motility, and is a known substrate of c-Abl [261]. It 
was recently shown in PC3 cells that HSP90 stabilizes c-Abl, thereby promoting 
WASF3-mediated cell motility, and that PDGF-stimulated nuclear localization of β-
catenin occurs via c-Abl [48, 49]. Others have shown that STI571 sensitized PC3, but 
not LNCAP, cells to UV, but the mechanism and reason for the discrepancy between cell 
types is unknown [262]. PC3 cells are more aggressive and are androgen-independent, 
whereas LNCAP cells are androgen-dependent and much less aggressive [263], and we 
have previously demonstrated that Abl family kinase activation is enhanced in the most 
aggressive/invasive breast cancer cell lines [38]. 
Here we present novel data demonstrating that Abl family kinases are 
dramatically activated in invasive/metastatic prostate cancer cells (Figure 7.1A). 
Importantly, DU145 cells, which are highly invasive and hormone-insensitive, also 
possessed dramatically enhanced c-Abl/Arg activities (Figure 7.1A). Talin expression, 
similar to our observation with Abl family kinase activity, also increases with disease 
stage [259]. We also observed that overexpression of Talin in PC3 cells markedly 
increased c-Abl/Arg activity (Figure 7.1B); however, silencing Talin expression in DU145 
cells did not dramatically alter c-Abl/Arg activities (Figure 7.2A). Studies focused on the 
functional interplay of these two proteins could potentially reveal critical information 
regarding prostate cancer progression and motility.  
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Figure 7.1. Expression and activation of Abl kinases in prostate cancer cell lines. 
(A) c-Abl and Arg kinase activities were assessed in serum-starved prostate cancer cell 
lines by in vitro kinase assay (top).  Western blotting was performed for Abl protein 
expression or using a phospho-specific antibody to CrkL. (B) c-Abl and Arg kinase 
activities were assessed in serum-starved prostate cancer cell lines by in vitro kinase 
assay and Abl protein expression determined by Western blotting. Blots are 
representative of 3 independent experiments. Relative protein levels were quantitated by 
analyzing blots with ImageQuant software. 
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Figure 7.2. Silencing Talin does not inhibit the activity of Abl family kinases. (A) c-
Abl and Arg kinase activities were assessed in serum-starved DU145 shVector and 
shTalin cells by in vitro kinase assay.  (B) Expression of PDGFRα and β in prostate 
cancer cell lines. Lysates from serum-starved prostate cancer cell lines were probed with 
antibodies to both PDGFRα and β. Blots are representative of 3 independent 
experiments. 
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Future experiments will focus on elucidating the functional relationship between 
Abl family kinases and Talin in prostate cancer cells and how these proteins regulate 
diverse signaling pathways to promote cell migration/motility and prostate cancer 
progression to metastasis. Experiments are currently underway focused on whether c-
Abl/Arg and Talin interact to promote prostate cell viability and motility, and preliminary 
results indicate that co-inhibition of Abl family kinases and Talin synergistically prevents 
prostate cell motility and dramatically decreases cell viability (data not shown). 
Importantly, two other primary potential targets of c-Abl/Arg inhibitors (i.e., c-Kit, 
PDGFR) are not expressed in these cells (Figure 7.2B). These preliminary studies 
represent a potentially exciting foray into the study of c-Abl and Arg in prostate cancer 
progression. 
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